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SUMMARY OF THE THESIS 
Koalas are an iconic Australian marsupial species that attract much public sympathy and 
support. Despite several thousand koalas being presented to wildlife rehabilitation facilities 
annually for treatment of traumatic injuries (primarily motor vehicle strikes and dog 
predation) and disease (principally chlamydiosis), little information exists regarding the 
success of treatments or whether rehabilitated animals survive in the wild after release. 
This thesis examines several aspects of the diagnosis, treatment and management of the 
most important infectious disease of koalas, chlamydiosis, and provides an evidence base 
for rational diagnostic and treatment decisions in the rehabilitation setting. 
Experimental work commences in Chapter 2 with a study of the admission records of a 
large koala rehabilitation facility (the Koala Hospital of the Koala Preservation Society of 
NSW) showing that traumatic presentations and those relating to clinical chlamydiosis 
were most common, with motor vehicle collisions apparently a significant and increasing 
threat to survival of the local koala population. The implications of these findings are 
discussed with reference to measures aimed at maintaining a viable population of wild 
koalas in Port Macquarie and for logistic planning at the Koala Hospital.  
Initial studies in this thesis confirmed that koalas with chlamydiosis are frequently treated 
at wildlife rehabilitation facilities. Despite the commonness of this disease, there is a lack 
of rigorous scientific studies examining frequently used treatments. Chapter 3, a 
retrospective review of medical records of a cohort of koalas admitted for treatment for 
chlamydiosis, revealed that diagnostic and treatment decisions were frequently based on 
clinical signs alone and treatment choices and durations were inconsistent with those used 
to successfully treat chlamydiosis in other species. Despite this, treated animals were 
frequently released and many survived in the wild. 
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Chapter 4 outlines general methods common to the clinical work undertaken in Chapters 5, 
7 and 9.  
Antibiotic treatment with drugs commonly used to treat chlamydiosis in other species 
(erythromycin, oxytetracycline) has led to wasting and death in koalas. A pilot study, 
presented in Chapter 5, found that, similarly, more modern forms of these drugs 
(doxycycline and azithromycin) cannot be used safely in koalas, leading to the author‟s 
decision to investigate, in detail, the efficacy of the less conventional anti-chlamydial 
drugs, the fluoroquinolones. 
Studies of marsupial pharmacokinetics are uncommon and, prior to this thesis, there were 
no published studies of pharmacokinetics in koalas. The author‟s investigations, using a 
modified agar diffusion assay (Chapter 6) and high performance liquid chromatography 
(Chapter 7), found the absorption of enrofloxacin and marbofloxacin by the oral route in 
koalas was extremely poor and suggested absorption rate limited disposition 
pharmacokinetics. In combination with plasma protein binding of approximately 50%, the 
concentrations of enrofloxacin and marbofloxacin achieved in plasma were not considered 
likely to inhibit the growth of chlamydial pathogens in vivo. 
In Chapter 8 the author explored the apparent contradiction between the failure to achieve 
appropriate plasma concentrations of fluoroquinolones to treat chlamydiosis and the 
apparent efficacy of these drugs reported in historical medical records. Methods to monitor 
clinical signs by clinical scoring and chlamydial load using real-time polymerase chain 
reaction were developed during the study. The results of these studies showed that clinical 
signs were poorly sensitive in determining the presence of chlamydial organisms in koalas; 
all fluoroquinolone treatment regimes led to a dramatic reduction in Chlamydophila 
pecorum load during treatment; and clinical signs improved in many animals. Importantly, 
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however, pathogen load rebounded after withdrawal of treatment, indicating that most 
animals failed to clear infections. These findings have implications for the diagnosis, and 
treatment of chlamydial disease in koalas and for the subsequent return of fluoroquinolone 
treated animals to the wild. 
The findings and limitations of these studies are presented in general terms in Chapter 9 
and recommendations for future studies are proposed. 
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GLOSSARY 
ALKP   alkaline phosphatase 
ALT   alanine transaminase 
ANOVA  analysis of variance 
AST    aspartate aminotransferase 
ATP   adenosine triphosphate 
AUC   area under the curve 
BID   twice daily 
BIW   twice weekly 
bp   base pairs 
BSP   bromosulphalein 
cAMP   cyclic adenosine monophosphate 
chi-sq   chi-square test for goodness of fit 
CI   confidence interval 
CK   creatinine kinase 
Cmax   maximum plasma concentration 
CT   cycle threshold (real-time polymerase chain reaction) 
Ct last measurable concentration above level of quantification (high 
performance liquid chromatography) 
d.f.   degrees of freedom 
 x 
EDTA   ethylene diamine tetra-acetic acid 
ELISA   enzyme linked immunosorbent assay 
HPLC   high performance liquid chromatography 
i.m.   intramuscular injection 
Kel   elimination constant 
Koala Hospital Koala Preservation Society of New South Wale‟s Koala Hospital in 
Port Macquarie, New South Wales, Australia 
LOD   limit of detection 
LOQ   limit of quantification 
MVA   motor vehicle accident 
NSW   New South Wales, Australia 
OR   odds ratio 
PCR    polymerase chain reaction 
p.o.   per os 
Qld   Queensland, Australia 
qPCR    real-time polymerase chain reaction 
REML   restricted maximum likelihood procedure 
s.c.   subcutaneous injection 
SD   standard deviation  
SEM   standard error of the mean 
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SID   once daily 
SIW   once weekly 
Tmax   maximal plasma concentration 
t½    half life 
TWC    tooth wear class 
Vic   Victoria, Australia 
vs.   versus 
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CHAPTER 1 - GENERAL INTRODUCTION, LITERATURE 
REVIEW AND AIMS OF THE STUDY 
The koala (Phascolarctos cinereus), a popular and iconic animal in Australia, faces many 
threats to survival (Department of the Environment, Water, Heritage and the Arts, 2009). 
One effort to mitigate threats to wildlife is rehabilitation of injured, diseased, displaced and 
orphaned wildlife; and such efforts may contribute to maintenance of some wildlife 
populations (Tribe & Brown, 2000). Koalas appear particularly suitable for rehabilitation. 
In studies to date post-release survival of rehabilitated animals appears to be high: 70 - 
100% of rehabilitated koalas survived over 2 - 11 months monitoring (Ellis, White et al., 
1990; Tribe, Hanger et al., 2005; Jones, 2008) and survival rates were no different to that 
of wild controls (Lunney, Gresser et al., 2004). In contrast, post-release survival of other 
rehabilitated wildlife in Australia and overseas is often poor
1
. 
                                                 
1
 Hand-reared ringtail possums (Pseudocheirus peregrinus) survived a median 31 days c.f. median 169 days 
of wild controls (Augee, M.L., Smith, B. & Rose, S. (1996) Survival of wild and hand-reared ringtail 
possums (Pseudocheirus peregrinus) in bushland near Sydney. Wildlife Research, 23(1), 99-108.); 
70% of healthy translocated wild brushtail possums (Trichosurus vulpecula) died within a week (Pietsch, R. 
(1994) The fate of urban common brushtail possums translocated to sclerophyll forest. In Reintroduction 
biology of Australian and New Zealand fauna. Ed Serena, M., Surrey Beatty, Chipping Norton, NSW. pp 
236–246.); 
44-59% survival of rehabilitated little penguins (Eudyptula minor) c.f. 50-77% of wild controls at 20 months 
(Goldsworthy, S., Giese, M., Gales, R., Brothers, N. & Hamill, J. (2000) Effects of the Iron Baron oil spill on 
little penguins (Eudyptula minor). II. Post-release survival of rehabilitated oiled birds. Wildlife Research, 
27(6), 573-582.); 
Rehabilitated barn owls (Tyto alba) survived mean 77.9 days c.f. 365.7 days survival of wild controls 
(Fajardo, I., Babiloni, G. & Miranda, Y. (2000) Rehabilitated and wild barn owls (Tyto alba) dispersal, life 
expectancy and mortality in Spain. Biological Conservation, 94(3), 287-295.); 
Hand-reared fox cubs (Vulpes vulpes) survived a mean 94 days c.f. 466 days of wild controls (Robertson, 
C.P.J. & Harris, S. (1995) The condition and survival after release of captive-reared fox cubs. Animal 
Welfare, 4(4), 281-294.); 
 55% of river otters (Lontra canadensis) were alive at 100 days compared to 80% of wild controls (Ben-
David, M., Blundell, G. & Blake, J. (2002) Post-release survival of river otters: effects of exposure to crude 
oil and captivity. Journal of Wildlife Management, 66(4), 1208-1223.); 
52% of hand-reared white tailed deer fawns (Odocoileus virginianus) died within 30 days of release 
(Beringer, J., Mabry, P., Meyer, T., Wallendorf, M. & Eddleman, W. (2004) Post-release survival of 
rehabilitated white-tailed deer fawns in Missouri. Wildlife Society Bulletin, 32(3), 732-738.). 
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Despite the treatment of many thousands of koalas annually in wildlife rehabilitation 
facilities, little information exists regarding which treatments are most successful in 
returning koalas to the wild (Blanshard, 1994). Chlamydiosis is the most common 
infectious disease of koalas with up to 85% of some populations affected (Jackson, White 
et al., 1999), and treatment of this disease in the wildlife rehabilitation setting is common 
despite equivocal results as to its success (Cockram & Jackson, 1976; Bodetti, Johnston et 
al., 2002; Markey, Wan et al., 2007) and the unknown effect of rehabilitated animals on 
wild populations.  
This introductory chapter first examines the popularity and uniqueness of koalas as a 
motivation for their preservation and as a driving force for wildlife carers. Threats to the 
survival of koalas are considered, with particular reference to disease caused by chlamydial 
organisms. The ethics and success of wildlife rehabilitation, in particular the ethics of 
treating infectious disease, are discussed. The clinical signs and pathology of chlamydiosis 
in koalas are summarised, and literature describing diagnostic tests and past treatments 
examined. The background literature suggesting the potential for unusual pharmacokinetics 
in koalas is discussed. Finally, the key gaps in the body of knowledge are highlighted to 
identify future directions of research and the aims of the thesis are outlined.  
1.1 WHY CARE FOR KOALAS? 
Koalas elicit enormous public interest and sympathy, and feature frequently in the media 
around the world. Their annual economic contribution to the tourist industry has been 
estimated to be worth several billion dollars (Hundloe & Hamilton, 1997). They are one of 
few wild Australian animals with multiple rehabilitation centres solely dedicated to their 
care and a number of non- governmental organisations dedicated to preservation of the 
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species
2
. Clearly, there is huge concern as to the plight of this iconic and charismatic 
animal.  
Although the public may be interested in preserving the koala for its own sake, the loss of 
koalas as a species would be a tragedy on a number of levels. Koalas, the only living 
representative of the family Phascolarctidae, have unique anatomical (Snipes, Snipes et al., 
1993), physiological (Cork & Dawson, 1983) and behavioural (Nagy & Martin, 1985) 
adaptions to life as an obligate eucalypt folivore and occupy an unusual ecological niche, 
most analogous to that of the neotropical sloth, Bradypus variegates (Nagy & Martin, 
1985) of Central and South America. Thus, study of these animals provides unique 
opportunities to learn about Australian evolutionary history and adaption of marsupials to 
difficult environments. Secondly, koalas may be useful to medical research by providing a 
naturally occurring biological model for diseases such as cryptococcosis and chlamydiosis 
in other species, including people (Krockenberger, Canfield et al., 2002; Higgins, Hemsley 
et al., 2005b). Finally, loss of biodiversity may have wide reaching effects including 
changes to the balance of ecosystems, and wider social, political and economic effects 
(Clark, Schuyler et al., 2002). Current proposed threats to the survival of koalas include 
loss of habitat (Melzer, Carrick et al., 2000), predation by dogs (Caneris & Jones, 2004; 
Lunney, Gresser et al., 2007), collision with motor vehicles (Dique, Thompson et al., 
2003; Caneris & Jones, 2004), loss of genetic diversity (Sherwin, Timms et al., 2000), 
bushfire (Lunney, Gresser et al., 2004; Lunney, Gresser et al., 2007), climate change 
                                                 
2
 Friends of the Koala, Lismore NSW; Friends of the Koalas Inc, Cowes, Vic; Hunter Koala Preservation 
Society, Hunter Valley, NSW; Ipswich Koala Protection Society, Ipswich, Qld; The Koala Preservation 
Society of NSW (the Koala Hospital), Port Macquarie, NSW; Koala Squad, Eumundi, Qld; Koalas In Care 
Inc, Taree, NSW; Moggill Koala Hospital Association, Toowoomba, Qld; Moreton Bay Koala Rescue Inc, 
Moreton Bay, Qld; Pine Rivers Koala Care Association Inc, Strathpine, Qld; Australian Koala Foundation, 
Brisbane, Qld; Friends of Local Koalas, Land and Wildlife, Somers, Vic; Koala Action Pine Rivers Inc, 
Warner, Qld. 
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(Clifton, Ellis et al., 2007; Department of the Environment, Water, Heritage and the Arts, 
2009) and diseases (Canfield, 1987; Tarlinton, Meers et al., 2005; Department of the 
Environment, Water, Heritage and the Arts, 2009), the most prevalent and important of 
which is chlamydiosis (Obendorf, 1983; Canfield, 1987; Weigler, Girjes et al., 1988; 
Canfield, 1989; Jackson, White et al., 1999; McLean, 2003; Stalder, 2003). The 
significance of these threats to the population of koalas living within and in the surrounds 
of the Port Macquarie is investigated in Chapter 2 through analysis of admission data from 
the Koala Hospital of the Koala Preservation Society of NSW. 
1.2 THE CHLAMYDIACEAE AND CHLAMYDIOSIS IN 
 KOALAS 
The Chlamydiaceae are a group of obligate intracellular bacterial parasites of eukaryotic 
cells characterised by a biphasic replication cycle illustrated in Figure 1-1. The lifecycle 
involves an infectious, extracellular, metabolically inert “spore-like” stage (the elementary 
body) that becomes attached to host cells, is endocytosed, and then differentiates into the 
metabolically active form (the reticulate body) within the phagocytic vacuole 
(phagosome), avoiding lysis by inhibiting lysosome fusion. Reticulate bodies multiply by 
binary fission using host cell ATP, glucose, and nucleotides and eventually differentiate 
back into elementary bodies. The life cycle begins again after the vacuole ruptures, killing 
the host cell and allowing infective elementary bodies to disperse (Brooks, Butel et al., 
2007). An important factor in the pathogenesis of chlamydial disease is the ability of 
chlamydial organisms to exist perpetually within host cells in an atypical metabolically 
inert state in response to stressors such as nutrient deficiency; host cytokines (principally 
interferonϒ); antimicrobial agents, particularly in sub-inhibitory concentrations; and 
various inhibitors of normal cellular metabolism (cAMP, calcium antagonists, inhibitors of 
peptidyl-prolyl isomerase) (Beatty, Morrison et al., 1994). This form is difficult to 
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eliminate by normal immunological mechanisms and, as organisms are metabolically inert, 
by antibiosis; thus disease may recur after stressors are removed (Mpiga & Ravaoarinoro, 
2006). 
 
Figure 1-1. Chlamydial life cycle.  
N: nucleus; EB: elementary body; RB: reticulate body (Mpiga & Ravaoarinoro, 2006). 
 
Chlamydiaceae parasitise a wide range of hosts including humans, mammals, birds, 
reptiles, amphibians, fish, invertebrates and amoebae and generally cause a spectrum of 
inflammatory disease of the conjunctiva, urinary, reproductive, gastrointestinal and 
respiratory systems (Nigg, 1942; Kazdan, Schachter et al., 1967; Storz, 1971; Gaillard, 
Hargis et al., 1984; Grimes & Clark, 1986; Storz, 1988; Harrison, 1989; Fukushi & Hirai, 
1992; Fox, Stills et al., 1993; Grimes, 1994; Mare, 1994; Carrasco, Segales et al., 2000; 
Donati, Piva et al., 2005). Marsupial species in which Chlamydiales (C. pecorum, C. 
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pneumoniae and novel uncultured Chlamydiales strains) have been detected in the ocular, 
urogenital or respiratory tract include the greater glider (Petauroides volans), mountain 
brushtail possum (Trichosurus caninus), western barred bandicoot (Perameles 
bouganville), greater bilby (Macrotis lagotis) and Gilbert‟s potoroo (Potorous gilbertii 
(Bodetti, Viggers et al., 2003; Warren, Swan et al. 2005; Kutlin, Roblin et al., 2007). Both 
clinical disease (commonly conjunctivitis) and subclinical disease have been reported in 
these species (Bodetti, Viggers et al., 2003; Warren, Swan et al. 2005; Kutlin, Roblin et 
al., 2007) with a particularly strong association between ocular Chlamydiales infection and 
clinical disease observed in bandicoots and gliders in one study (Bodetti, Viggers et al., 
2003). In koalas, Chlamydiaceae have been detected in conjunctivae and throughout the 
urogenital tract (Brown & Grice, 1984; McColl, Martin et al., 1984; Obendorf & 
Handasyde, 1990; Girjes, Hugall et al., 1993; Hemsley & Canfield, 1997; Jackson, White 
et al., 1999; Devereaux, Polkinghorne et al., 2003), in the rectum (Brown & Grice, 1986; 
Hemsley & Canfield, 1996), pulmonary alveolar macrophages or epithelial cells, and 
hepatic and splenic macrophages (Higgins, Hemsley et al., 2005b) and peripheral blood 
mononuclear cells (Bodetti & Timms, 2000). 
The pioneering work of Girjes et al. (1988) demonstrated that chlamydial infection in 
koalas is caused by two species, now reclassified as Chlamydophila pneumoniae and 
Chlamydophila pecorum (Everett, Bush et al., 1999). Prior to this work, chlamydial 
infections in koalas were considered to be one species (Chlamydia psittaci) (Cockram & 
Jackson, 1976; McColl, Martin et al., 1984; Brown & Grice, 1986; Brown, 1986; Weigler, 
Girjes et al., 1988; Canfield, Love et al., 1991a). Even more modern studies have failed to 
speciate infections, possibly due to a lack of species-specific diagnostic tools (White & 
Timms, 1994; Hemsley & Canfield, 1996; Kempster, Hall et al., 1996; Martin, 1996; 
Higgins, Hemsley et al., 2005a; Higgins, Hemsley et al., 2005b; Markey, Wan et al., 
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2007). The lack of speciation in these works limits interpretation with regard to 
pathogenesis of chlamydiosis in koalas. In people and swine, infections by multiple 
Chlamydiaceae species have been associated with more severe clinical signs of ocular 
disease and abortion, respectively, but the role of mixed infections in pathogenesis is 
poorly understood (Schiller, Koesters et al., 1997; Dean, Kandel et al., 2008). In koalas, 
the situation is potentially complicated further by the possible co-infection by at least nine 
“Chlamydia-like” bacteria, although they have not yet been identified as primary 
aetiological agents of clinical disease (Devereaux, Polkinghorne et al., 2003). Based on 
field studies of wild animals, Jackson et al. (1999) suggested C. pecorum is more 
pathogenic than C. pneumoniae and that C. pneumoniae has a predilection for ocular sites. 
This last assertion has more recently been disputed (Timms, 2001). Little work has been 
done to expand the original findings of Jackson et al. (1999), with the exception of a study 
in five animals that demonstrated C. pecorum was present more commonly than C. 
pneumoniae within diseased tissues (Devereaux, Polkinghorne et al., 2003). In particular, 
detailed studies describing clinical disease in relation to the presence of specific 
chlamydial organisms are lacking and further clarification of the possible site bias of 
chlamydial species is required.  
There is strong evidence supporting venereal transmission as the most frequent mode of 
chlamydial transmission in koalas (Handasyde, 1986; Girjes, Hugall et al., 1988; Martin & 
Handasyde, 1999), but the common finding of chlamydial infection of prepubertal 
subadults (up to 58% of some populations) is supportive of a second, non-venereal 
mechanism of transmission (Weigler, Girjes et al., 1988; Jackson, White et al., 1999; 
Santamaria, 2001). The process of koala joeys ingesting caecal contents directly from the 
mother‟s cloaca (Thompson, 1987; Osawa, Blanshard et al., 1993) could provide a non-
venereal route of transmission, as the rectum may be infected with Chlamydiaceae in 
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koalas (Brown & Grice, 1986; Hemsley & Canfield, 1996; Hemsley & Canfield, 1997) and 
intestinal infections and faecal shedding are common in other species (ruminants, birds) 
(Shewen, 1980). Alternatively, neonates could be infected during parturition, as the 
urogenital sinus may be infected with Chlamydiaceae (Hemsley & Canfield, 1997) and 
infection during parturition occurs in people (Schachter, Grossman et al., 1979) and cats 
(Shewen, Povey et al., 1978).  
Clinical signs of chlamydial urogenital tract disease in koalas include dysuria, haematuria, 
incontinence, cloacal eversion and the secondary effects of urine scald, such as ulceration 
and cutaneous myasis (Obendorf, 1983; Booth & Blanshard, 1999; Connolly, 1999). 
Animals are often in poor condition (Obendorf, 1983; McLean, 2003) and females are 
frequently presumed infertile due to no evidence of recent breeding (Brown, Carrick et al., 
1984; McColl, Martin et al., 1984; Handasyde, 1986; Santamaria, 2001; McLean, 2003). 
The dark brown discolouration of rump pelage as a result of chronic incontinence lends 
this syndrome its common names “wet bottom” or “dirty tail” (Blanshard, 1994) (Figure 
1-2). Clinical signs of chlamydial conjunctivitis include serous to mucopurulent ocular 
discharge, conjunctival hyperaemia, chemosis and papillary hypertrophy, corneal oedema 
and neovascularisation and periocular alopecia (Kempster, Hall et al., 1996) (Figure 1-3). 
Chlamydophila pneumoniae has also been implicated in severe respiratory disease in 
captive koalas (Wardrop, Fowler et al., 1999; Nicolson, 2002). 
Gross pathological changes to the urogenital tract include: distortions, enlargements, and 
thickening of the uteri and oviducts; accumulation of purulent material within the uterine 
lumens, cystic dilations of the oviducts and ovarian bursae; adhesions between 
reproductive tract tissues and adjacent organs; and thickening of the wall and reddening of 
the mucosa of the bladder (Figure 1-4) (Obendorf, 1981; Canfield, Oxenford et al., 1983; 
Obendorf & Handasyde, 1990). 
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Histopathological changes are consistent with varying degrees of acute, subacute and 
chronic inflammation and may occur at all levels of the female reproductive tract 
(Obendorf, 1981; Canfield, Oxenford et al., 1983; Canfield, 1989; Obendorf & Handasyde, 
1990; Hemsley & Canfield, 1997; Higgins, Hemsley et al., 2005b), the rectum (Hemsley & 
Canfield, 1996), the prostate (Canfield, 1989), the upper and lower urinary tracts (Hemsley 
& Canfield, 1997; Higgins, Hemsley et al., 2005b) and the conjunctiva (Hemsley & 
Canfield, 1997). 
 
  
 
Figure 1-2. Typical rump pelage colour change and matting of fur associated with chronic 
incontinence from urogenital tract chlamydial infection. 
 
 
    
a) b) c) d) 
Figure 1-3. Examples of clinical signs of ocular chlamydiosis. 
a) Chemosis, conjunctival hyperaemia, periocular alopecia; b) papillary conjunctival hypertrophy, 
conjunctival hyperaemia, periocular alopecia; c) copious mucopurulent discharge, periocular alopecia; d) 
moderate serous discharge, conjunctival hyperaemia, chemosis, periocular alopecia. 
 10 
   
a) b) c) 
Figure 1-4. Examples of gross pathology associated with urogenital chlamydiosis. 
a) Bilateral thickening and distension of both uteri (pyometra) (black arrows), bilateral oviduct and ovarian 
bursal cysts (white arrows); b) diffuse severe reddening of bladder mucosa and thickening of bladder wall 
(severe chronic diffuse fibrotic cystitis); c) gross distension of pus-filled ovarian bursal cyst with multiple 
areas of perforation, caecal adhesions and peritonitis.  
 
1.3 EPIDEMIOLOGY OF CHLAMYDIOSIS IN WILD KOALAS 
The ultimate expression of clinical disease is the result of a complex interaction between 
the host, pathogen and environment, so clinical disease might be expected to be variable 
between individuals and populations. In individual koalas chlamydiosis may be 
deleterious, causing infertility, blindness or death (Brown & Grice, 1986; Weigler, Booth 
et al., 1987; Canfield, 1988) or act as a co-morbidity factor, potentially making animals 
more susceptible to other disease or predation (Canfield, 1987; McLean, 2003). In others, 
infection and associated structural disease may be subclinical (Weigler, Girjes et al., 1988; 
White & Timms, 1994; Jackson, White et al., 1999; Devereaux, Polkinghorne et al., 2003; 
McLean, 2003). Such infections appear to affect animals little, as body condition, 
longevity and even fertility may be maintained (Handasyde, 1986; Santamaria, 2001; 
McLean, 2003). Similarly, both clinical and subclinical chlamydial disease are frequent in 
other species, including birds (Longbottom & Coulter, 2003), calves (Jaeger, Liebler-
Tenorio et al., 2007), cats (Sykes, 2005) and people (Solomon, Peeling et al., 2004): and 
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have been reported at low prevalence in other marsupials (the greater glider, mountain 
brushtail possum, western barred bandicoot, greater bilby and Gilbert‟s potoroo (Bodetti, 
Viggers et al., 2003). 
The threat of extinction of koalas as a direct result of chlamydial disease is considered 
unlikely by many authors (Handasyde, 1986; White & Timms, 1994; Caneris & Jones, 
2004; Department of the Environment, Water, Heritage and the Arts, 2009) and 
traditionally, disease alone has not been regarded as a major driver of extinction (de Castro 
& Bolker, 2005). This view is changing: recently documented extinctions as a direct result 
of infectious disease have included a captive species of land snail (Partula turgida) 
(Cunningham & Daszak, 1998) and a species of wild frog (Taudactylus acutirostris) 
(Schloegel, Hero et al., 2006). In koalas, a model designed to investigate the impact of 
Chlamydiaceae on population dynamics did not predict extinction of koalas by 
Chlamydiaceae under most circumstances (Augustine, 1998). A number of assumptions 
underlying this model suggest its conclusions require review, particularly given the 
changing population dynamics of koalas in recent years. The model assumed a relatively 
stable population density and thus is not applicable to populations where koalas are 
declining, such as south-eastern Queensland (Department of Environment and Resource 
Management, 2009); or over-abundant, such as some populations on mainland Victoria 
(McLean, 2003). It assumed non-clinical animals were always fertile and that a different 
species of Chlamydia (now known to be Chlamydophila) (Everett, Bush et al., 1999) 
infected the eyes to that infecting the urogenital tract. These suppositions are not supported 
by more recent large scale epidemiological studies of fertility and clinical signs (McLean, 
2003) and the demonstration of both species of Chlamydophila at ocular and urogenital 
sites (Jackson, White et al., 1999; Devereaux, Polkinghorne et al., 2003). Finally, as the 
koala‟s mating system was unknown in the 1990s, the model assumed polygyny, yet a 
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recent study of the koala mating system has suggested evidence of transitory males and 
polyandry (Ellis, Hale et al., 2002). Given the improved body of knowledge regarding 
chlamydiosis and the behavioural ecology of koalas, an updated epidemiological model 
would be useful to more accurately describe the effects of chlamydiosis on koala 
populations. This work aimed to provide baseline data that might be useful for the 
refinement of future epidemiological models examining the currently unknown impact of 
rehabilitated animals on local koala populations. 
In the field, several authors have attributed individual population decline to the effects of 
chlamydiosis (Handasyde, 1986; Martin & Handasyde, 1999), however most infected 
populations in Victoria and Queensland have fertility rates greater than that considered 
adequate to maintain numbers (Weigler, Girjes et al., 1988; Gordon, McGreevy et al., 
1990; White & Kunst, 1990; Martin & Handasyde, 1999) and have even become over-
abundant in some areas of Victoria (Department of the Environment, Water, Heritage and 
the Arts, 2009). Several authors have argued the major role of chlamydiosis in extinction 
of koalas is as a contributory factor in populations made vulnerable for other reasons 
(Weigler, Girjes et al., 1988; Martin & Handasyde, 1999). Although a stable host-pathogen 
balance may currently exist, the koala faces multiple potential threats that could alter this 
balance. For example, a recently described retrovirus in koalas (Canfield, Sabine et al., 
1988) has been hypothesised to contribute to immunosuppression and clinical expression 
of chlamydial disease (Tarlinton, Meers et al., 2005). Alternatively, increased deforestation 
and fragmentation of habitat, as is occurring in Queensland (Department of Environment 
and Resource Management, 2009), could contribute to crowding and increased 
transmission rates. Finally, koalas could potentially acquire new more pathogenic species 
or strains of Chlamydiaceae, as there is genetic evidence C. pecorum has been acquired 
multiple times by koalas from ruminants (Glassick, Giffard et al., 1996). Given the 
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difficulty of controlling an infectious disease in wildlife (Artois, Delahay et al., 2001), 
research into understanding chlamydiosis in koalas whilst a stable host-pathogen balance 
exists is prudent.  
1.4 SHOULD WE TREAT INFECTIOUS DISEASE IN WILD   
  ANIMALS? 
Given the high profile of koalas it is perhaps not surprising that a number of organisations 
are solely dedicated to the preservation of this species and many of these provide 
rehabilitation facilities for sick or injured koalas (see footnote 2, page 3). Wildlife 
rehabilitation frequently has poor outcomes (Robertson & Harris, 1995; Anderson, Gress et 
al., 1996; Augee, Smith et al., 1996; Fajardo, Babiloni et al., 2000; Tribe & Brown, 2000; 
Ben-David, Blundell et al., 2002; Beringer, Mabry et al., 2004) and the treatment of wild 
animals with infectious disease is perhaps the most controversial area (Kirkwood & 
Sainsbury, 1996). Diseased animals harbour potentially infectious organisms that may 
spread within wildlife rehabilitation facilities (Menzano, Rambozzi et al., 2008) or to 
animals in the wild (Jacobson, Gaskin et al., 1991; Cunningham, 1996; Chipman, Slate et 
al., 2008) or to wildlife carers (Allworth, Murray et al., 1996). Some authors have argued 
that rehabilitation of diseased animals could in theory deleteriously alter selection 
pressures for the development of disease resistance, but that it might be justifiable in 
individuals on grounds of welfare, where recovery will not occur without treatment and 
may be accomplished without undue stress (Kirkwood & Sainsbury, 1996). Ultimately, the 
effect of rehabilitation of animals with infectious disease on wild populations is usually 
unknown. Whilst the merits of rehabilitation of wild animals with infectious disease will 
continue to be debated (Kirkwood & Sainsbury, 1996; Estes, 1998; Tribe & Brown, 2000), 
in the absence of direct evidence of harm, the treatment of chlamydiosis in koalas is likely 
to continue. 
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Currently, hundreds of koalas per year are treated for chlamydiosis (Jones, 2008) despite 
lack of information regarding whether treatment reduces suffering or time spent in care, 
whether recovery may occur without treatment, whether animals are released still 
harbouring organisms, and the rates of post-release survival and breeding success of such 
animals. Only one small study using modern molecular diagnostics has investigated the 
presence of pathogens after treatment in four rehabilitated koalas and this only followed 
animals for two weeks after treatment end (Markey, Wan et al., 2007). Only two studies 
have examined post-release survival of animals treated for chlamydiosis (Tribe, Hanger et 
al., 2005; Jones, 2008). In all three studies numbers of animals were fewer than six. In this 
thesis, the author aims to examine survival of treated animals by a reviewing the survival 
of treated animals based on historical clinical records (Chapter 3); and by monitoring 
animals for four weeks after treatment end, identifying whether treatments result in 
microbial cure (Chapter 8). 
1.5 DIAGNOSIS AND TREATMENT OF CHLAMYDIAL 
 DISEASE IN KOALAS 
Historically, chlamydial infections in koalas have been diagnosed using cell culture, 
demonstration of organisms in cells or tissues by immunofluorescence or 
immunohistochemistry, DNA slot hybridisation, immuno-slot blot analyses and PCR, 
complement fixation tests, antibody ELISAs, clinical signs, contrast radiology and 
ultrasound imaging (reviewed in Blanshard, 1994; Blanshard & Bodley, 2008). The wide 
variety of diagnostic tests employed reflects the poor sensitivity and specificity of some 
tests (e.g. complement fixation), technical difficulty (e.g. cell culture), requirement for 
specialist equipment (e.g. immunofluorescence), poor availability outside a research 
environment, and the recent evolution of simpler more sensitive molecular biological 
techniques, such as PCR. In recent years PCR has been used widely to detect 
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Chlamydiaceae in koalas, as in other species (Ellis, Girjes et al., 1993; Girjes, Hugall et al., 
1993; Martin, Alexander et al., 1995; Bodetti & Timms, 2000; Timms, 2000; Santamaria, 
2001; Bodetti, Johnston et al., 2002; Nicolson, 2002; Amin, 2003; Bodetti, Viggers et al., 
2003; Helps, Reeves et al., 2003; Higgins, Hemsley et al., 2005a; Markey, Wan et al., 
2007). It is particularly useful in being able to distinguish between chlamydial species 
(Girjes, Hugall et al., 1993; Jackson, White et al., 1999), is regarded as more sensitive than 
other diagnostic tests (Ostergaard, Birkelund et al., 1990; Sykes, Studdert et al., 1999; 
Amin, 2003) and is the current diagnostic test of choice for chlamydial infections in people 
(Harindra, Underhill et al., 2003).  
Despite treatment of chlamydiosis in koalas since the 1970s (Cockram & Jackson, 1976; 
Dickens, 1978), few studies have systematically described symptoms throughout treatment 
or examined treatment success. Most treatment regimes have been based on “trial and 
error” or personal experience (Blanshard & Bodley, 2008). An early study, examining 
topical treatments for chlamydial conjunctivitis, stated a two week course of 
oxytetracycline ointment and powder was required to elicit a cure as determined by cell 
culture (Cockram & Jackson, 1976) and there are subsequent anecdotal reports of 
resolution of clinical signs using tetracycline or chloramphenicol eye ointments, although 
the treatment length was not reported (Robinson, 1978; Wood, 1978; Canfield, Love et al., 
1991a). The effectiveness of topical therapy in achieving microbial cure in koalas requires 
re-examination. The original study determined treatment success using chlamydial culture 
(Cockram & Jackson, 1976), which is at best approximately 75% sensitive (Harindra, 
Underhill et al., 2003) and when more sensitive molecular diagnostics (real-time PCR) 
have been utilised, topical treatment with chloramphenicol and corticosteroids has been 
ineffective in reducing pathogen load in one animal (Markey, Wan et al., 2007). 
Chlamydial infections in koalas may be systemic (Bodetti & Timms, 2000; Higgins, 
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Hemsley et al., 2005b) and, in such cases, topical therapy would be inappropriate. Such 
factors have contributed to the recommendation against use of topical monotherapy to treat 
chlamydiosis in people and cats, due to poor efficacy and the prolonged courses required to 
achieve microbial cure (Sparkes, Caney et al., 1999; Chiu & Amsden, 2002; Donati, Piva 
et al., 2005).  
Historically, systemic antibiotic treatment of chlamydiosis in koalas has proved to be 
problematic. Use of oxytetracycline or erythromycin has led to emaciation and death, 
attributed to gut flora disturbances, within two and six weeks, respectively (Brown, Wood 
et al., 1984; Brown, Woolcock et al., 1986; Handasyde, 1986; Osawa & Carrick, 1990; 
Osawa, Bird et al., 1993). The poor track record of oxytetracycline was improved through 
utilising a concurrently administered soya based infant formula nutritional supplement 
(Osawa & Carrick, 1990), but this regime has not gained wide acceptance. Although past 
treatments have included penicillins and potentiated sulpha drugs (Canfield, Love et al., 
1991a), weekly intramuscular doxycycline HCl (Blanshard, 1994) and tropospectomycin 
sulphate (Brown, Woolcock et al., 1986), systemic treatment regimes currently employed 
in the three major koala hospitals use enrofloxacin (most frequently dosed orally) or 
chloramphenicol (oral or intramuscular administration) (Blanshard & Bodley, 2008). 
Treatment of chlamydial conjunctivitis varies between facilities, but generally includes 
topical oxytetracycline HCl or chloramphenicol (Blanshard & Bodley, 2008).  
These treatment regimes are difficult to evaluate. Reports are usually anecdotal and 
resolution of clinical signs, rather than diagnostic testing, usually determines end points 
(Blanshard & Bodley, 2008). As clinical signs of chlamydial disease may resolve without 
treatment (Kempster, Hall et al., 1996), there is little evidence as to which treatments are 
effective. Only two studies have used molecular diagnostic testing to determine whether 
koalas are microbially negative during (Bodetti, Johnston et al., 2002) and after treatment 
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(Markey, Wan et al., 2007) and these are contradictory. In one study, seven of the eight 
koalas with clinical signs of cystitis were PCR-positive for Chlamydia during treatment 
with chloramphenicol or enrofloxacin (frequency and route not reported), despite treatment 
of up to six months, suggesting these treatments were not effective in curing animals of 
chlamydial infections (Bodetti, Johnston et al., 2002). In direct contrast, three koalas of 
three treated with intramuscular chloramphenicol had no chlamydial DNA detectable by 
real-time PCR by day 34 of treatment, suggesting chloramphenicol was an effective 
treatment (Markey, Wan et al., 2007). The treatment failure documented in the first study 
might be a result of poor bioavailability or inadequate dose regimes if pharmacokinetics in 
koalas differ from other species. Alternatively, the latter study may have failed to detect 
latent infections as animals were only monitored for two weeks following treatment. 
Studies in other species have found chlamydial pathogen load may be undetectable during 
treatment, and then recur after treatment withdrawal, possibly due to chlamydial 
persistence in other sites or a false negative result (Dean, Harley et al., 2005). Given this 
poor and contradictory evidence base, it is not surprising that there is no standardised 
method of examining koalas, describing clinical signs and prescribing effective treatments 
for chlamydiosis. This study sought to redress this obvious gap in the literature in Chapter 
8. 
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1.6 PHARMACOKINETICS IN KOALAS 
Pharmacokinetic studies in koalas are well overdue, and have the potential to shed light not 
only on the efficacy of treatments, but also the adaptive mechanisms associated with 
metabolism of other xenobiotics, such as eucalypt toxins. Pharmacokinetics in koalas 
might be expected to be different to eutherians: koalas have an increased hepatic excretory 
capacity as evidenced by increased bromosulphalein clearance in comparison with sheep 
and various macropods (Macropus giganteus, M. rufus, M. rufogriseus) (Pass & Brown, 
1990). Many authors have speculated that the koala must have unique metabolic pathways 
allowing survival on a diet almost exclusively of eucalypts, which would be toxic to other 
species (McLean & Foley, 1997; Stupans, Jones et al., 2001). Such adaptions may allow 
koalas to metabolise drugs faster than expected by metabolic scaling (Booth & Blanshard, 
1999). Further, the koala‟s small intestinal transit time is short (particulate matter: 6 min; 
soluble material: 60 min) (Cork & Warner, 1983), and their caecal surface area is the 
largest of any animal (Snipes, Snipes et al., 1993). Both of these could alter the absorption 
of orally administered drugs in comparison with domestic species. Given the unique 
anatomical and physiologic adaptions of koalas that might be expected to alter 
pharmacokinetics, the large number of animals treated annually, and the gap in the 
knowledge base of any pharmacokinetics in this species, a study of pharmacokinetics of 
commonly used drugs would prove extremely useful. Such work could provide guidelines 
for appropriate and timely medication, minimise wastage and reduce the potential for 
selection of resistant microbes in animals inappropriately medicated with antibiotics. This 
is addressed in Chapter 7. 
 19 
1.7 SPECIFIC AIMS OF THIS THESIS 
Despite the high public anxiety as to the plight of koalas, and the huge effort involved in 
the treatment and rehabilitation of this species, little evidence exists regarding efficacy of 
treatments, and pharmacokinetic studies remain to be done. This thesis aims to provide the 
necessary evidence base for effective treatment of chlamydiosis in koalas by addressing the 
diverse facets of diagnosis, treatment and management of koalas with chlamydiosis. 
Aim 1: Identify threats to wild koalas in the Port Macquarie area and describe 
demographics of koalas entering a rehabilitation facility. 
The study detailed in Chapter 2 adds to previous work by providing location-specific data, 
and utilises longitudinal data over an unusually long period (30 years) to identify changing 
threats to koalas in this area and help the Koala Hospital plan logistics. 
Aim 2: Describe the diagnostic and treatment regimes and determine the outcomes of 
koalas treated for chlamydiosis at the Koala Hospital between 1995 and 2005. 
This aim is addressed in Chapter 3 by analysis of medical records to identify prognostic 
indicators and treatment regimes associated with successful rehabilitation and survival in 
the wild. Several hypotheses that emerged from this study are addressed in Chapter 7 and 
Chapter 8. 
Aim 3: Determine whether the anti-chlamydial antibiotics, azithromycin and 
doxycycline, may be safely used to treat chlamydiosis in koalas. 
The aim of Chapter 5 was to identify a safe and effective treatment for chlamydiosis in 
koalas, given the history of theoretically unsuccessful treatments in common use found in 
Chapter 3. As this study did not identify such a treatment, the focus changed to examining 
the efficacy of fluoroquinolones in treating chlamydiosis - treatments that appeared to be 
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safe in koalas and had been reported as historically successful in treating this disease in 
Chapter 3. 
Aim 4: Describe the pharmacokinetics of enrofloxacin and marbofloxacin in koalas 
following oral and subcutaneous administration and report any identifiable adverse 
effects. 
As described in 1.6, pharmacokinetics of antibiotics in koalas have not been studied but 
might be expected to be unusual. Chapter 6 and Chapter 7 aimed to characterise the 
absorption of two fluoroquinolones to allow generation of pharmacokinetic indices that 
may be used to predict treatment success. Initial studies were by modified agar diffusion 
bioassay in a pilot study (Chapter 6) and then by the more sensitive method, high 
performance liquid chromatography (Chapter 7).  
Aim 5: Determine whether clinical signs reflect the presence of chlamydial organisms 
in koalas and the intensity of Chlamydophila pecorum shedding; and whether 
treatment with fluoroquinolones eliminates C. pecorum and C. pneumoniae from 
koalas. 
As discussed, clinical signs have been used frequently to diagnose chlamydiosis and as an 
end point of treatment, yet their sensitivity has been reported to be poor. Chapter 8 
examined the link between clinical signs and presence and load of chlamydial organisms 
by use of quantitative real-time PCR. The final aim of this study was to examine whether 
fluoroquinolones eliminated chlamydial infection from animals.  
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CHAPTER 2 - ADMISSION TRENDS OF KOALAS AT A 
WILDLIFE REHABILITATION FACILITY 
2.1 INTRODUCTION 
The study of wildlife disease is an area of growing interest and importance to the scientific 
community. Recent studies have demonstrated that disease may threaten wild species‟ 
survival or drive local populations or species to extinction and thus threaten biodiversity 
(Cunningham & Daszak, 1998; Schloegel, Hero et al., 2006). Wildlife may provide an 
important sylvatic reservoir, or act as sentinels, for emerging infectious diseases that may 
threaten human, domestic and wild animal health (Daszak, Cunningham et al., 2000). The 
study of wildlife health may indicate ecosystem health and provides opportunities to study 
the host-parasite interaction, changes in the ecology of which may contribute to disease 
emergence (Daszak, Cunningham et al., 2000; Daszak, Cunningham et al., 2001). Wildlife 
disease is likely to become an ever more important area of study, given rapidly changing 
ecosystems in the face of rising human populations, shrinking and fragmentation of 
wildlife habitat, introduction of exotic species and pathogens and implications of climate 
change on ecosystems. Recent initiatives such as the “One Health” project have recognised 
the importance of integrated human, domestic, wildlife and ecosystem health (Zinsstag, 
Schelling et al., 2005; King, Anderson et al., 2008; One Health Initiative Task Force, 
2008). 
Despite the recognised importance of such work, the study of disease in wild populations 
may be logistically difficult and expensive. This difficulty may be overcome, in part, 
through studies utilising the records of wildlife rehabilitation centres (Shine & Koenig, 
2001; Trocini, Pacioni et al., 2008). Although these data have strong inherent biases 
towards the type of animals entering the rehabilitation system, and extrapolating results to 
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wild populations must be done with care, study of such records has significant advantages. 
Record keeping is often a compulsory requirement of licensing for wildlife rehabilitators, 
and such records frequently comprise a significant data set. Useful information can be 
gathered regarding which animals present and why, the treatment regimes used and the 
ultimate fate of such animals (Hartup, 1996; Beckmen, Lowenstine et al., 1997; Deem, 
Terrell et al., 1998; Shine & Koenig, 2001; Koenig, Shine et al., 2002; Dique, Preece et 
al., 2003; Lander & Gulland, 2003; Mazaris, Mamakis et al., 2008; Neese, Seitz et al., 
2008; Trocini, Pacioni et al., 2008; Dau, Gilardi et al., 2009; Kalpakis, Mazaris et al., 
2009). Such information may be made available at minimal cost, extend over several 
decades and can often be the only practical method of gathering longitudinal information. 
Study of such data may identify threats to local populations and may thus prove useful to 
local planning authorities when making urban planning decisions that might facilitate 
survival of local wildlife. Within rehabilitation centres, information can be used to refine 
management and treatment protocols and identify the success rates of rehabilitation. 
There have been no detailed studies of the data collected by the Koala Preservation Society 
of NSW, which has been treating and rehabilitating koalas in the Port Macquarie district 
since 1973. This study examines the computerised records of animal signalment (age class 
based on tooth wear, and sex) and reasons for presentation to the Koala Preservation 
Society of NSW‟s Koala Hospital from January 1st 1975 to the 31st of December 2004. 
Examination of data seeks to provide useful information on which to base management 
decisions regarding deployment of volunteer time and resources, and the building of 
infrastructure within the hospital. More broadly, recommendations are made regarding the 
timing and type of seasonal educational campaigns required to reduce risk of animals 
coming into care. By relating these data to the population structure of the local wild 
population, threats to the local population are explored. Longitudinal changes in the 
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reasons animals present suggest evidence of emerging threats to the local population, and 
provide a sound basis for planning decisions by local authorities.  
2.2 AIMS 
The aims of this study were to: 
1/ describe why koalas present to the Koala Hospital, 
2/ determine the characteristics of groups of koalas presenting for different reasons to the 
Koala Hospital, 
3/ describe the effect of season and time on reasons koalas are admitted, to identify 
changes that might indicate specific threats to the survival of the local wild koala 
population and help the Koala Hospital plan logistics, publicity campaigns and allocation 
of resources on a seasonal basis and for the future. 
2.3 METHODS 
2.3.1 Admission data 
Members of the public report sick, injured and dead koalas to the Koala Hospital. 
Volunteers then retrieve koalas, if necessary using flagging methods to encourage koalas 
down from the tree (Blanshard, 1994). Koalas are then placed into canvas bags and 
transported to the Koala Hospital. Morphometric measurements, signalment (age class and 
sex) and clinical observations are determined by the Koala Hospital supervisor and/or 
visiting veterinarians and recorded in paper medical records. Age class is based on 
assessment of tooth wear (Martin, 1981) and modified by previous admission records. 
Animals are classed as joeys (< 1 year), juvenile (1 - 2 years), young adult (2 - 5 years), 
mature adult (5 - 8 years) or aged adult (8+ years), corresponding to tooth wear classes I, 
II, III, IV, V – VII, respectively (Martin, 1981). 
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Prior to release, all koalas are permanently identified with ear tags and subcutaneous 
passive transponder microchips (Microchips Australia, Keysborough, Vic, Australia). 
Thus, should an animal re-present, previous medical records are identified and up-dated. A 
reason for admission is added to the medical records based on the supervisor‟s and/or 
veterinarians‟ assessment (Appendix I). Weekly, between one and three individuals enter 
signalment (sex and age class), date and reason for admission to a computer database 
(Microsoft Access® 2003, Microsoft® Corporation, Redmond, Washington, USA).  
2.3.2 Data management 
Data were compiled on sex, age class, date of admission and reason for admission. 
Admission reasons were reclassified into 10 codes to combine analogous terms (Appendix 
I). Age class followed that described above, with the modification that joeys and juveniles 
were combined into one age class (juvenile). Admissions prior to 1975 were few (10 of 
3951), comprising 0.25% of the total admissions, and were therefore excluded from further 
analysis. Admissions after the 31
st
 of December 2004 were not included due to the 
possibility that commencement of research at the hospital confounded the data. Date of 
admission was reclassified into season (spring, summer, autumn, winter) and year, and 
then grouped into five-year intervals (1975 - 1979, 1980 - 1984, 1985 - 1989, 1990 - 1994, 
1995 - 1999 and 2000 - 2004). Tables from this database were imported into SAS® 
statistical software (release 9.1 © 2002 - 2003, SAS Institute Inc., Cary, North Carolina, 
USA) or GenStat for Windows (2008, 11
th
 ed., VSN International Ltd., Hemel Hempstead, 
Hertfordshire, UK) for further analyses. 
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2.3.3 Statistical analysis 
Variables 
The outcome with 10 categories represented different reasons for admission: motor vehicle 
accident (MVA), dog attack, healthy, wet bottom, eye disease, debilitated, fire, 
undiagnosed, joey and all other. Explanatory variables were sex, age class, season and 
five-year interval, as discussed above.  
Descriptive analyses 
A contingency table was created to assess the distribution of explanatory variables and 
their associations with the multicategory outcome (Table 2-1, Results). The percentage of 
the total data set for each explanatory variable was plotted using Graphpad Prism® 5 for 
Windows (Graphpad Software, La Jolla, California, USA).  
Statistical models examining risk factors in comparison with the hospital population  
Univariable multinomial logistic regression analyses were performed for each explanatory 
variable to examine their unadjusted association with the outcome using the SAS 
LOGISTIC procedure (Stokes, Davis et al.2000). Variables significant in the univariable 
analyses (p < 0.10) were used to build a multivariable multinomial logistic regression 
model by a manual forward stepwise approach to quantify risk factors for admission reason 
after adjusting for each other. Decision on inclusion or exclusion of a variable at each step 
was based on the individual contribution of each variable to the model using a likelihood-
ratio chi-square test retaining variables with p ≤ 0.05. Results are shown as adjusted odds 
ratios (OR) with 95% confidence intervals. Probabilities for each outcome category were 
calculated using SAS statistical program and plotted using Graphpad Prism 5 for 
Windows. Arbitrarily chosen reference groups for explanatory variables were: female, 
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aged adults, autumn and 1975 - 1979 and the arbitrarily chosen reference group for the 
outcome variable was eye disease. 
Identification of at-risk cohorts in comparison with the wild population 
A population structure of a 1:1 sex ratio and age class percentages of 6.3% juveniles, 
43.8% young adults, 40.6% mature adults and 9.4% aged adults were assumed for normal 
wild koala populations of Port Macquarie. This assumption was based on combined results 
from two field studies of wild koalas (n = 33) conducted in Thrumpster (Biolink, 2008) 
and the Innes Peninsula (Biolink, 2005) prior to their development as new suburbs of Port 
Macquarie. Chi-square goodness of fit tests were used to determine whether the population 
structure of hospital admissions approximated that of the wild population in each 
admission category. Statistical significance was concluded at p ≤ 0.05.  
2.4 RESULTS 
2.4.1 Descriptive statistics of koalas admitted to the Koala Hospital 
There were 3781 individual admissions from 2674 individual koalas between 1
st
 January 
1975 and 31
st
 December 2004. Table 2-1 outlines the explanatory variables for cohorts 
according to admission category. The mean number of admissions per individual was 1.41 
± 1.04 (SD). Forty-one per cent of admissions were for trauma (MVA, dog attack), 20.5% 
of koalas were admitted with clinical signs associated with chlamydial disease (wet 
bottom, eye disease), and 15.8% were admitted healthy (Figure 2-1). Animals were most 
frequently admitted in spring and least likely to be admitted in autumn (chi-sq = 264.3, d.f. 
= 3, p < 0.0001; Figure 2-2). Admissions per five-year interval increased significantly 
between 1980 and 1994 (1980 - 1984 versus 1985 - 1989: chi-sq = 52.3, d.f. = 1, p < 
0.0001; 1985 - 1989 versus 1990 - 1994: chi-sq = 34.2, d.f. = 1, p < 0.0001) but have not 
changed significantly since 1995 (Figure 2-3). 
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Table 2-1. Contingency table of explanatory variables (number (%)) for cohorts according to admission category for koalas admitted to the Koala 
Hospital from 1
st
 January 1975 to 31
st
 December 2004. 
 
  Dog attack 
 
MVA 
 
Fire 
 
Eye disease 
 
Wet bottom 
 
Debilitated 
 
Healthy 
 
Joey 
 
Undiagnosed 
 
All other 
 
Total 
Age  Juvenile  138 (3.5) 138 (3.5) 44 (1.1) 15 (0.4) 21 (0.5) 41 (1.0) 116 (2.9) 64 (1.6) 44 (1.1) 14 (0.4) 579 (14.7) 
  Young 327 (8.3) 327 (8.3) 44 (1.1) 85 (2.2) 137 (3.5) 50 (1.3) 215 (5.5) 6 (0.2) 82 (2.1) 16 (0.4) 1248 (31.7) 
  Mature  201 (5.1) 201 (5.1) 62 (1.6) 182 (4.6) 184 (4.7) 90 (2.3) 179 (4.5) 2 (0.1) 117 (3.0) 28 (0.7) 1380 (35.0) 
  Aged  79 (2.0) 79 (2.0) 7 (0.2) 66 (1.7) 78 (2.0) 72 (1.8) 77 (2.0) 0 (0.0) 54 (1.4) 3 (0.1) 512 (13.0) 
Sex  F  373 (9.5) 373 (9.5) 90 (2.3) 121 (3.1) 289 (7.3) 132 (3.4) 278 (7.1) 28 (0.7) 127 (3.2) 26 (0.7) 1752 (44.5) 
Season 
  
  
  
Autumn  88 (2.2) 88 (2.2) 2 (0.1) 52 (1.3) 96 (2.4) 53 (1.3) 49 (1.2) 6 (0.2) 53 (1.3) 5 (0.1) 524 (13.3) 
Winter  170 (4.3) 170 (4.3) 6 (0.2) 64 (1.6) 100 (2.5) 48 (1.2) 130 (3.3) 13 (0.3) 76 (1.9) 16 (0.4) 903 (22.9) 
Summer  124 (3.2) 124 (3.2) 43 (1.1) 113 (2.9) 132 (3.4) 87 (2.2) 130 (3.3) 32 (0.8) 75 (1.9) 17 (0.4) 1523 (38.7) 
Spring  367 (9.3) 367 (9.3) 108 (2.7) 121 (3.1) 94 (2.4) 71 (1.8) 289 (7.3) 21 (0.5) 103 (2.6) 25 (0.6) 831 (21.1) 
5-year  
interval 
  
  
  
  
  
1974 - 1979 45 (1.1) 45 (1.1) 4 (0.1) 26 (0.7) 23 (0.6) 24 (0.6) 54 (1.4) 7 (0.2) 27 (0.7) 1 (0.0) 235 (6.0) 
1980 - 1984 50 (1.3) 50 (1.3) 2 (0.1) 26 (0.7) 28 (0.7) 25 (0.6) 65 (1.7) 7 (0.2) 26 (0.7) 1 (0.0) 270 (6.9) 
1985 - 1989 113 (2.9) 113 (2.9) 12 (0.3) 49 (1.2) 92 (2.3) 29 (0.7) 85 (2.2) 9 (0.2) 64 (1.6) 3 (0.1) 560 (14.2) 
1990 - 1994 157 (4.0) 157 (4.0) 106 (2.7) 75 (1.9) 90 (2.3) 51 (1.3) 150 (3.8) 9 (0.2) 69 (1.8) 6 (0.2) 871 (22.1) 
1995 - 1999 219 (5.6) 219 (5.56) 1 (0.03) 80 (2.03) 85 (2.16) 51 (1.29) 144 (3.65) 8 (0.20) 55 (1.40) 14 (0.36) 869 (22.1) 
2000 - 2004 165 (4.2) 165 (4.19) 34 (0.86) 94 (2.39) 104 (2.6) 79 (2.00) 100 (2.54) 32(0.81) 66 (1.67) 38 (0.96) 976 (24.8) 
Total  749 (19.8) 802 (21.2) 159 (4.2) 350 (9.2) 422 (11.2) 259 (6.9) 598 (15.8) 72 (1.9) 307 (8.1) 63 (1.7)  3781 (100) 
F: female, M: male, MVA: motor vehicle accident. Age classed using tooth wear class (TWC) (Martin, 1981) where Juvenile: TWC I - II; Young: TWC III; Mature: TWC IV; 
Aged: TWC V-VII. Data missing from 14 (0.4%) records of gender; 62 (1.6%) records of age class.  
E
x
p
la
n
at
o
ry
 v
ar
ia
b
le
s 
 
Outcome variables 
 28 
D
og
 a
tta
ck
M
V
A
Fi
re
E
ye
 d
is
ea
se
W
et
 b
ot
to
m
D
eb
ili
ta
te
d
H
ea
lth
y
Jo
ey
U
nd
ia
gn
os
ed
A
ll 
ot
he
rs
0
5
10
15
20
25
P
e
rc
e
n
ta
g
e
 o
f 
a
d
m
is
s
io
n
s
 
Figure 2-1. Percentage of 3781 admissions to the Koala Hospital from 1
st
 January 1975 to 31
st
 
December 2004 in each re-coded admission category. 
MVA: motor vehicle accident. 
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Figure 2-2. Percentage of admissions by season for 3781 admissions to the Koala Hospital 
from 1
st
 January 1975 to 31
st
 December 2004. 
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Figure 2-3. Total number of 4728 admissions per five-year interval to the Koala Hospital 
from 1
st
 January 1975 to 31
st
 December 2009. 
Data from 1st January 2005 to 31st December 2009 not included in statistical analyses. 
 
 
2.4.2 At-risk cohorts in comparison with the wild population 
Analysis of all admissions in comparison with the assumed wild population structure found 
that males were at higher risk of presenting than females, aged and juvenile animals were 
over-represented and young and mature animals were under-represented in presentations 
(Table 2-2). Important findings were that young age groups were over-represented in 
categories associated with trauma, predation or misadventure (dog attack, fire, motor 
vehicle accidents, all other) and as healthy admissions; and older age groups were over-
represented in admission categories associated with disease (eye disease, wet bottom, 
debilitated). Finally, females were over-represented for wet bottom and males for 
admission as motor vehicle accident or eye disease.  
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Table 2-2. Comparison of admissions between the Koala Hospital population and the wild reference population (chi-sq analysis). 
 
 Age     Sex    
 Juvenile Young Mature Aged Chi-sq d.f. p  Female Male Chi-sq d.f. p 
Dog attack O (22.5) P (0.002) O (10.3) P (0.3) 65.9 3 < 0.0001  P (0) P (0) 0 1 1 
MVA O (4.2) U (2.4) P (0.3) P (0.03) 13.8 3 0.003  U (8.9) O (6.8) 31.5 1 < 0.0001 
Fire O (10.8) O (2.7) P (0.01) P (1.4) 29.9 3 < 0.0001  P (0.4) P (0.4) 1.5 1 0.215 
Eye disease P (0.7) U (9.5) P (2.6) O (5.5) 36.5 3 < 0.0001  U (4.9) O (3.6) 16.8 1 < 0.0001 
Wet bottom P (0.3) U (3.4) P (0.2) O (6.5) 20.9 3 < 0.0001  O (6.1) U (8.8) 29.9 1 < 0.0001 
Debilitated O (5.5) U (11.5) P (0.4) O (12.1) 58.9 3 < 0.0001  P (0.01) P (0.01) 0.05 1 0.826 
Healthy O (20.4) P (1.9) U (4.1) P (1.8) 56.5 3 < 0.0001  P (0.3) P (0.3) 1.3 1 0.246 
Joey O (31.8) U (7.7) U (15.3) U (3.3) 108.4 3 < 0.0001  P (0.5) P (0.4) 1.8 1 0.180 
Undiagnosed O (5.0) U (5.4) P (0.02) O (4.2) 29.1 3 < 0.0001  U (1.2) O (0.9) 4.3 1 0.038 
All other O (2.9) O (1.3) P (0.1) P (0.5) 9.5 3 0.023  P (0.2) P (0.2) 0.8 1 0.368 
Total O (74.2) U (25.0) U (3.0) O (15.4) 235.2 3 < 0.0001  U (2.4) O (2.2) 9.2 1 0.002 
Figures in brackets are contribution of each explanatory variable to the chi-square. d.f: degrees of freedom. O: over-represented, U: under represented, P: on par; compared 
with wild reference population assumed to have a 1:1 sex ratio, and age class percentages of: 6.3% juveniles, 43.75% young adults, 40.63% mature adults and 9.4% aged 
adults (Biolink, 2005; Biolink, 2008). Age classes based on tooth wear class (TWC) according to Martin (1981), where Juvenile: TWC I - II; Young: TWC III; Mature: TWC 
IV; Aged: TWC V - VII. MVA: motor vehicle accident. 
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2.4.3 Statistical models of the Koala Hospital population 
Findings from the multivariable multinomial logistic regression model are presented as 
probabilities in Figure 2-4 through Figure 2-6 and as odds ratios and 95% confidence 
intervals in Table 2-3 through Table 2-6. All the explanatory variables were significant 
(age class, p = 0.0001; sex, p = 0.0066; season, p < 0.0001; five-year interval, p < 0.0001). 
In addition, an interaction between season and sex was significant, meaning that the effect 
of sex on admission categories varied by season (p = 0.0361) and data, presented as 
probabilities, are thus presented for both sex and season in one figure (Figure 2-5). 
 
Table 2-3. The odds ratios (95% confidence intervals) calculated using logistic regression for 
the relationships between age class and the reason for admission. 
 
Outcome Juvenile p Young p Mature p 
Eye disease 1  1  1  
Dog attack 7.43 (3.95 - 14.0) < 0.0001 3.09 (2.05 - 4.66) < 0.0001 1.12 (0.75 - 1.67) 0.584 
MVA 4.8 (2.6 - 9.3) < 0.0001 2.73 (1.81 - 4.14) < 0.0001 0.46 (0.3 - 0.71) 0.0004 
Fire 21.9 (8.1 - 59.1) < 0.0001 4.56 (1.90 - 10.9) 0.0007 1.59 (1.08 - 2.33) 0.019 
Wet bottom 1.3 (0.6 - 2.8) 0.4896 1.47 (0.95 - 2.27) 0.0837 0.98 (0.67 - 1.46) 0.937 
Debilitated 2.62 (1.32 - 5.19) 0.0058 0.56 (0.34 - 0.9) 0.0181 3.49 (1.49 - 8.16) 0.0039 
Healthy 6.1 (3.2 - 11.5) < 0.0001 2.14 (1.4 - 3.26) 0.0004 0.87 (0.59 - 1.3) 0.507 
Joey > 999.99 
(<0.001 - > 999.9) 
0.9175 > 999.99  
(<0.001 - >999.9) 
0.9398 > 999.99  
(<0.001 - > 999.9) 
0.950 
Undiagnosed 3.81 (1.9 - 7.6) 0.0002 1.24 (0.77 - 2.0) 0.3672 0.86 (0.55 - 1.33) 0.489 
All other 22.4 (5.7 - 88.8) < 0.0001 3.45 (0.96 - 12.4) 0.0585 2.8 (0.82 - 9.66) 0.100 
Age estimated according to tooth wear class (TWC) (Martin, 1981): Juvenile: TWC I – II; Young: TWC III; 
Mature: TWC IV. MVA: motor vehicle accident. Reference groups: Aged (TWC V- VII) and eye disease. 
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Table 2-4. The odds ratios (95% confidence intervals) calculated using logistic regression for 
the relationship between sex and the reason for admission. 
 
Outcome Male p 
Eye disease (ref) 1  
Dog attack  0.48 (0.23 - 1.03) 0.059 
MVA  0.49 (0.24 - 1.01) 0.054 
Fire 0.47 (0.027 - 8.12) 0.60 
Wet bottom  0.2 (0.09 - 0.43) < 0.001 
Debilitated 0.44 (0.19 - 1.0) 0.049 
Healthy  0.72 (0.3 - 1.69) 0.443 
Joey 0.57 (0.09 - 3.5) 0.551 
Undiagnosed 0.44 (0.19 - 1.01) 0.053 
All other  0.26 (0.038 - 1.74) 0.164 
MVA: motor vehicle accident. Reference groups: female and eye disease.  
 
Table 2-5. The odds ratios (95% confidence intervals) calculated using logistic regression for 
the relationships between season and the reason for admission.  
 
 Winter p Spring p Summer p 
Eye disease 1  1  1  
Dog attack 1.55 (0.67 - 3.6) 0.3086 1.44 (0.72 - 2.89) 0.3025 0.42 (0.2 - 0.86) 0.018 
MVA 1.43 (0.62 - 3.25) 0.4000 0.59 (0.29 - 1.18) 0.1392 0.27 (0.13 - 0.56) 0.0004 
Fire 3.81 (0.37 - 39.0) 0.2588 16.7 (2.1 - 132.9) 0.0079 7.3 (0.90 - 59.8) 0.063 
Wet bottom 0.93 (0.41 - 2.12) 0.8625 0.32 (0.16 - 6.4) 0.0013 0.49 (0.25 - 0.95) 0.036 
Debilitated 0.911 (0.36 - 2.34) 0.8463 0.44 (0.199 - 0.98) 0.0433 0.48 (0.22 - 1.1) 0.067 
Healthy 2.71 (1.08 - 6.85) 0.0340 2.45 (1.12 - 5.35) 0.0248 0.91 (0.41 - 2.02) 0.812 
Joey 2.4 (0.47 - 12.67) 0.2928 0.68 (0.15 - 3.19) 0.6262 0.61 (0.14 - 2.8) 0.531 
Undiagnosed 1.17 (0.47 - 2.96) 0.7329 0.47 (0.21 - 1.03) 0.0603 0.39 (0.17 - 0.87) 0.021 
All other 1.6 (0.32 - 8.22) 0.5620 0.87 (0.2 - 3.73) 0.8554 0.61 (0.14 - 2.67) 0.519 
MVA: motor vehicle accident. Reference groups: autumn and eye disease.
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Table 2-6. The odds ratios (95% confidence intervals) calculated using logistic regression for the relationships between five-year interval and the 
reasons for admission. 
 
Outcome 1980 - 1984 p 1985 - 1989 p 1990 - 1994 p 1995 - 1999 p 2000 - 2004 p 
Eye disease (ref) 1  1  1  1  1  
Dog attack 1.09 (0.55 - 2.2) 0.79 1.13 (0.61 - 2.08) 0.69 0.99 (0.56 - 1.76) 0.97 1.42 (0.80 - 2.51) 0.23 1.03 (0.59 - 1.8) 0.91 
MVA 1.55 (0.7 - 3.3) 0.25 2.14 (1.1 - 4.16) 0.02 1.95 (1.04 - 3.66) 0.04 2.58 (1.38 - 4.82) 0.0029 2.75 (1.49 - 5.1) 0.0012 
Fire 0.488 (0.08 - 2.94) 0.43 1.57 (0.45 - 5.46) 0.48 8.08 (2.67 - 24.48) 0.0002 0.08 (0.01 - 0.76) 0.03 2.43 (0.78 - 7.6) 0.13 
Wet bottom 1.19 (0.54 - 2.6) 0.67 1.9 (0.96 - 3.75) 0.06 1.19 (0.6 - 2.29) 0.61 1.17 (0.6 - 2.26) 0.64 1.21 (0.64 - 2.3) 0.56 
Debilitated 0.96 (0.43 - 2.11) 0.91 0.53 (0.25 - 1.10) 0.09 0.65 (0.33 - 1.27) 0.21 0.63 (0.32 - 1.23) 0.17 0.89 (0.47 - 1.7) 0.73 
Healthy 1.16 (0.59 - 2.28) 0.66 0.74 (0.4 - 1.35) 0.33 0.825 (0.47 - 1.45) 0.50 0.79 (0.45 - 1.39) 0.43 0.49 (0.28 - 0.88) 0.02 
Joey 0.88 (0.24 - 3.19) 0.84 0.6 (0.19 - 2.06) 0.44 0.38 (0.12 - 1.25) 0.11 0.33 (0.10 - 1.10) 0.07 2.29 (0.81 - 6.48) 0.12 
Undiagnosed 0.89 (0.411 - 1.94) 0.78 1.12 (0.57 - 2.18) 0.74 0.77 (0.41 - 1.47) 0.43 0.58 (0.30 - 1.11) 0.10 0.62 (0.33 - 1.17) 0.14 
All other 0.93 (0.054 - 15.7) 0.96 1.58 (0.16 - 16.1) 0.70 1.89 (0.21 - 16.23) 0.58 4.04 (0.50 - 32.6) 0.19 11.04 (1.4 - 84.9) 0.02 
MVA: motor vehicle accident. Reference groups: 1975 - 1979 and eye disease. 
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Figure 2-4. Relative probabilities of admission outcomes where age class was a significant risk factor. 
Calculated by multivariable multinomial logistic regression. Age estimated according to tooth wear class (TWC) (Martin, 1981): Juvenile: TWC I – II; Young: TWC III; 
Mature: TWC IV. MVA: motor vehicle accident. Reference groups: Aged (TWC V- VII) and eye disease. 
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Figure 2-5. Relative probabilities of admission outcomes where sex or season was a significant risk factor.  
Calculated by multivariable multinomial logistic regression. M: male; F: female; MVA: Motor vehicle accident. The only significant interaction (p < 0.05) between sex and 
season was for MVA. Reference groups: autumn, female and eye disease. 
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Figure 2-6. Relative probabilities of admission outcomes where five-year interval was a significant risk factor. 
Calculated by multivariable multinomial logistic regression. Reference groups: eye disease and 1975 - 1979. MVA: Motor vehicle accident.  
 
 37 
Findings of these analyses were broadly in agreement with that of the previous analysis 
considering hospital and wild populations (see 2.4.2). There was an increased risk of 
younger animals presenting for traumatic reasons (dog attacks, fire) or healthy; and older 
animals presenting as admissions associated with disease (eye disease, wet bottom, 
debilitated or undiagnosed) (Figure 2-4). Females were more likely to present with wet 
bottom, debilitated or undiagnosed; and males with eye disease or as motor vehicle 
accidents (Figure 2-5). Warmer months increased risk of presentation as a result of fire 
(Figure 2-5). The only significant interaction between explanatory variables in the 
multivariable multinomial model was between sex and season. Males were at increased 
risk of motor vehicle accidents compared to references in spring (OR: 2.4; CI: 1.04 - 5.66; 
p = 0.039) and summer (OR: 2.8; CI 1.8 - 6.9; p = 0.019) but females were at decreased 
risk in these seasons (Figure 2-5). Diseased animals (wet bottom, debilitated or 
undiagnosed) were more likely to present in autumn (Figure 2-5). Risk of motor vehicle 
accidents increased after 1985 in comparison with the reference group (Figure 2-6). 
Admission as a result of fires was more likely from 1990 - 1994 and decreased 
immediately following 1995 (Figure 2-6). Admission in the category “all other” 
significantly increased between 2000 and 2004 (Figure 2-6).  
2.5 DISCUSSION 
This study examined a large data-set comprising of records kept by the Koala Hospital 
over a 30-year period. Analysis revealed important differences in the type of animals 
presenting as trauma cases (younger age groups, male), or because of disease (older age 
groups). This information may be useful in predicting the likely effect of these threats on 
the local koala populations. Seasonal differences were evident for many admission 
categories and can be used to target public educational campaigns, efficiently deploy 
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resources within the Koala Hospital and may be useful in planning future scientific field-
studies. Finally, changes over time revealed an increasing trend for animals presenting as 
motor vehicle accidents, which may be a result of fragmentation of habitat. Such evidence 
suggests a renewed effort should be made in preventing koala - motor vehicle accidents. 
Studies of coded medical records are common, as medical data are frequently organised in 
this manner and are simpler to analyse than original clinical data. In this study, the large 
size of the database allowed statistical analyses with high power. Further, data collection 
began in the 1970s, meaning temporal analysis was possible. Such studies may be difficult 
in wildlife research where baseline data do not often exist. Finally, the dataset was made 
freely available to the author and, as it was already computerised, analysis was simpler and 
less labour intensive than using paper medical records. Such inherent advantages make the 
study of medical records a frequent and attractive area of research in human and veterinary 
literature and their use in wildlife research is increasingly being recognised (Nattrass, 
1992; Shine & Koenig, 2001; Koenig, Shine et al., 2002; Dique, Preece et al., 2003; 
Dique, Thompson et al., 2003; Ramp, Caldwell et al., 2005; Pettett, Bird et al., 2006; 
Trocini, Pacioni et al., 2008).  
The limitations of such studies are commonly recognised as data entry error, inadequate 
and/or inflexible coding rules, coders‟ interpretation of medical records leading to observer 
variation, and under-reporting of co-morbidities (Safran, 1991; Barrie & Marsh, 1992; 
Pollari, Bonnett et al., 1996). In this work, the two major areas of potential inaccuracy 
were attribution of coding and errors relating to data entry. Code attribution by the Koala 
Hospital staff remains broadly incident focussed rather than diagnostically oriented and is 
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based on historical classification codes (C. Flanagan, pers. comm.)
1
. Co-morbidities are not 
recognised in admission codes, despite their acknowledged role in reasons animals present 
to wildlife care institutes (Canfield, 1987; Trocini, Pacioni et al., 2008). Although 
definitions of codes may seem obvious to rehabilitators, the implementation of objective 
case descriptions would improve rigour of data by reducing subjectivity and intra- and 
inter-observer variation. The addition of co-morbidities would allow more in-depth 
analysis of incident related admissions. In this study, rare admission codes were grouped as 
“all other”. The relative risk of animals presenting in this category increased between 2000 
and 2004, and that of “healthy” decreased (Figure 2-6), possibly indicating a change in the 
way animals have been coded rather than a real change in admissions. The current 
supervisor started working at the Koala Hospital in 2000 and may have influenced such 
coding decisions. Provision of case descriptions and associated pull-down menu options 
would improve objectivity and remove the temptation to invent new codes. A provision for 
notes in each medical record could record unusual events so that information is not lost. 
The establishment of purposeful scientifically rigorous data collection methods, including 
these suggestions, would improve the validity of future studies. Despite these limitations, 
there is still much to be gained by analysing such data, as long as conclusions are limited to 
causes of admission, and not extrapolated to presume definitive diagnosis. 
The second potential limitation - accuracy of translation of paper medical records to 
computer database - was examined by studying ages coded for joeys and, in Chapter 3 of 
this thesis, by examining cohorts of paper medical records relating to wet bottom or eye 
disease. Error rates were found to be low (11% and < 2%, respectively) in comparison to 
studies of medical records in other institutes (error rates up to 44%) (Safran, 1991). With 
                                                 
1
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, March, 2010. 
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the exception of admission codes, this study explored objective data only (signalment and 
date), thus subjective interpretation by coders and inter-observer variation, acknowledged 
as weaknesses in other studies (Safran, 1991) were likely to have had minimal influence. 
Greater exploration of other aspects of the computer database may demonstrate greater 
inaccuracies, in particular where coders have been required to interpret medical records, an 
area they occasionally find challenging (E. Gabriel, pers. comm.)
2
. 
Therefore, although this dataset is limited by the incident-based subjective coding of 
animals and the lack of information regarding co-morbidity, the size of the database, the 
access to rare longitudinal information, the high accuracy of data input from paper records, 
and the objectivity of much of the data examined suggest useful conclusions can be made 
using this dataset. 
The strength of conclusions based on comparison of the population dynamics of the 
hospital and wild populations are dependent on the accuracy of assumptions of the wild 
population structure. The reference wild population used in this study was drawn from 
bush habitat (the Innes Peninsula and Thrumpster) (Biolink, 2005; Biolink, 2008) within 
the catchment area serviced by the Koala Hospital. Surveys of koala population 
demographics are unusual outside of Victoria where koalas are intensively managed due to 
over-abundance (McLean, 2003). The interplay between selection pressures and population 
demographics may be complex and each play a role in determining final population 
structure (Byholm, Ranta et al., 2002; Cockburn, Osmond et al., 2008). Selection pressures 
in Victoria, where koalas are over-abundant (McLean, 2003), may be different to those in 
south-east Queensland, where koalas are declining (Department of Environment and 
                                                 
2
 Personal communication: E. Gabriel, Secretary, Koala Preservation Society of NSW, Port Macquarie, 
NSW, January 2010. 
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Resource Management, 2009), thus Victorian populations alone may not be a useful 
comparison population to that of Port Macquarie. Consequently, the demographics chosen 
were based on populations from within the catchment of the Koala Hospital. Although a 
larger sample size of wild koalas from Port Macquarie would be useful to confirm the 
validity of this assumption, other surveys of urban koala populations in south-east 
Queensland, likely to be under similar selection pressures to those of Port Macquarie due 
to climatic and geographic similarity, have found similar population demographics (Dique, 
Preece et al., 2003; Biolink, 2007). 
Interpretation of the odds ratios from the multivariable multinomial model must be done 
with care, as results are always relative to potentially biased reference groups. For 
example, the arbitrary reference admission reason (eye disease) in the multivariable 
multinomial model has a male sex bias, meaning that the odds ratio of a similarly biased 
group (MVA) may not be significantly different. To avoid misinterpretation, results were 
presented as probabilities, which are intuitively easier to understand and take into account 
bias in the reference group.  
Results of analyses comparing the hospital population to that of the wild are more likely to 
identify threats to the survival of wild koalas in Port Macquarie and these data are 
discussed first. Although results from the statistical models often identified similar trends, 
these data are biased to that of the hospital population and are thus most useful for 
planning hospital logistics. In discussion of potential threats to the local koala population, 
where specific components of analyses do not agree, more weight is placed on the analysis 
comparing hospital demographics to that of the wild population than that utilising hospital 
data alone. 
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The over-representation of juveniles, aged adults and males among koalas admitted to the 
Koala Hospital might be expected if juvenile animals, in particular males, are more prone 
to misadventure, trauma or predation (Martin & Handasyde, 1999), and aged animals to 
debilitation and disease (McLean, 2003). In fact, the most frequent reasons for which 
koalas presented to the Koala Hospital were trauma (motor vehicle accident, or dog attack) 
or signs consistent with chlamydial disease (eye disease, wet bottom), and the patterns of 
age and sex did fit this hypothesis. These findings are in agreement with past studies 
identifying significant threats to survival of koala populations (Obendorf, 1983; Canfield, 
1987; Weigler, Booth et al., 1987; Lunney, O'Neill et al., 2002; Department of 
Environment and Climate Change - NSW, 2008; Department of Environment and 
Resource Management, 2009; Department of the Environment, Water, Heritage and the 
Arts, 2009) and trauma is a frequent reason other species of Australian wildlife enter into 
rehabilitation organisations (Tribe & Brown, 2000; Trocini, Pacioni et al., 2008).  
Over-representation of males among motor vehicle accidents suggests that these are a 
potentially important factor limiting gene flow, and the loss of juveniles in this manner 
could contribute to decline of local populations. Male dominance in motor vehicle 
accidents has been observed before in koalas (Obendorf, 1983; Weigler, Booth et al., 1987; 
Canfield, 1991; Lunney, O'Neill et al., 2002; Dique, Preece et al., 2003; Dique, Thompson 
et al., 2003; Stalder, 2003; Department of the Environment, Water, Heritage and the Arts, 
2009) and other species, such as macropods and bandicoots, and has been attributed to 
differences in the behaviour of males in comparison with females (Dufty, 1994; Coulson, 
1997). Prior to the establishment of a home range, young koalas, particularly males, 
disperse and spend more time travelling than older animals (Mitchell, 1990; Logan & 
Sanson, 2002b) and may thus be at higher risk of motor vehicle collision (Canfield, 1991). 
Home ranges are established by about three years of age (Mitchell, 1990; Martin & 
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Handasyde, 1999), presumably reducing risks of motor vehicle accidents. This hypothesis 
is supported by the results of the study comparing hospital demographics with the wild 
population, in which young adults (approximately 3 - 5 years old) did have decreased risk 
of presenting as motor vehicle accidents. Transient males can contribute approximately 
equal numbers of offspring as resident males (Ellis, Hale et al., 2002) so loss of significant 
numbers of these animals may have implications for inbreeding of local populations.  
Young animals have higher fecundity than older animals in chlamydial affected 
populations (McLean, 2003) and loss of significant numbers of breeding animals is of 
obvious potential significance to population viability. Motor vehicle collisions have been 
identified as a serious threat to the survival of some koala populations (Martin & 
Handasyde, 1999; Caneris & Jones, 2004), and other species of Australian native animals 
(Dufty, 1994; Jones, 2000; Ramp & Ben-Ami, 2006; Roger, Laffan et al., 2007). The 
current impact of motor vehicle accidents on the Port Macquarie koala population is 
unknown but is likely to be important given the types of animals affected, and that animals 
hit by vehicles in Port Macquarie are usually otherwise healthy (Canfield, 1987; Canfield, 
1991).  
Behavioural reasons, likely to be responsible for the sex and age bias of motor vehicle 
accident admissions, did not contribute in the same way to the risk of presentation as a 
result of dog attack, as both juveniles and mature adults were over-represented as a dog 
attack victims in comparison with wild populations and there was no sex bias. This finding 
confirms observations made by other authors (Dique, Preece et al., 2003). The smaller size 
of juveniles might predispose them to dog attack; however, this does not explain why 
mature adults were over-represented. Older animals may be more prone to predation due to 
underlying disease (Canfield, 1987), but if this was the only explanation, one would expect 
aged adults to be similarly over-represented. There is little information in the literature 
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concerning the age structure of dog attack victims in other areas (Lunney, Gresser et al., 
2004) and only nine animals have been examined after death to ascertain rate of co-
morbidities (Canfield, 1987). Examination of other care groups‟ records would verify 
whether this observation exists outside of Port Macquarie. If confirmed, larger post 
mortem surveys and/or behavioural studies might help explain the underlying causes.  
In line with other traumatic reasons for admission, animals admitted as a consequence of 
fire were more likely to be juveniles and young adults than expected by chance from the 
wild. Dead animals are left in the field after fires to provide sustenance to scavengers such 
as monitors and birds of prey (C. Flanagan, pers. comm.)
3
, thus animals in the fire 
admission group reflect survivors requiring medical aid or hand-rearing, rather than the 
whole population affected. There is little information regarding the immediate effect of 
bushfires on larger marsupials, with most studies in small marsupials or native rodents 
(Russell, Smith et al., 2003; Ecological Associates Ltd, 2006; Claridge, Seebeck et al., 
2007; Lunney, Lunney et al., 2008). Juvenile koalas might have improved survival if, as 
back young, they are shielded from fire by being clasped to their mother‟s bellies. In 
addition, differences in tree use by younger, smaller animals, or anatomical factors such as 
body surface area may be responsible. It is not known how many of this group would 
survive in the wild without medical attention; however, given the extent of the injuries 
inflicted and lack of feed immediately post-fire, survival is likely to be low (Lunney, 
Gresser et al., 2004). Analysis of koala behaviour and population structures post-fire 
would provide useful information in assessing whether wild populations can recover 
without intervention. 
                                                 
3
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, March, 2010. 
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An over-representation of young animals in the “all other” and “healthy” categories are 
most likely reflective of the same behavioural factor (dispersal) that makes this group 
prone to motor vehicle accidents and dog predation. Descriptors making up the “all other” 
category commonly concern misadventure (e.g. fall, drowned) or predation by animals 
other than dogs (e.g. cat attack, crow attack) (Appendix I). “Healthy” is mostly made up of 
animals in the vicinity of danger as perceived by people (e.g. dangerous area, relocation, 
koala seeking territory, habitat loss) (Appendix I). Although the underlying behavioural 
reasons that koalas present in these categories may not be different to that of trauma, 
detailed and non-prompted information as to why animals have been thus coded should be 
easily accessible in the database in future (e.g. in a notes section) to identify emerging 
threats, describe new syndromes and identify areas for habitat rehabilitation. 
From these data it is obvious that the greatest threats to younger animals are admission 
categories associated with trauma or misadventure, probably as a result of behaviour 
unique to this group. Young animals are potentially more fecund than older age groups 
(McLean, 2003) and therefore adequate survival of this demographic is likely to be crucial 
to maintenance of viable populations. Detailed surveys including population size and 
demographics, and estimates of fertility are urgently needed to allow accurate modelling 
estimating the long-term viability of koalas in Port Macquarie, given the rate of apparent 
higher probability of attrition of young animals because of trauma. 
Due to the high frequency of trauma admissions, the ability of all rehabilitation staff 
involved in the first aid of koalas to effectively and rapidly triage trauma cases, and apply 
or seek appropriate treatment as soon as possible if required, is crucial for improved 
survival of these animals, and on grounds of welfare. At the Koala Hospital, koala 
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retrievals, particularly for trauma, are often conducted outside of normal working hours (C. 
Flanagan, pers. comm.)
4
. Such animals may not have immediate access to veterinary 
attention due to the inconvenience and expense of out-of-hours veterinary attention. There 
is a high frequency of head, thoracic and jaw injuries in cases of koala motor vehicle 
collision (Canfield, 1991), resulting ultimately in death in the majority of cases (Dique, 
Thompson et al., 2003) and severe soft tissue injuries may be inflicted by dogs (Flanagan, 
2009). Intensive treatments, opioid analgesia or euthanasia are likely to be required in 
many cases, and effective triage to determine when such veterinary attention is required, 
particularly at night when veterinarians may be less accessible, is important. Conversely, 
other diseases encountered are typically chronic in nature and so are less likely to require 
emergency treatment. Delays of a few hours until more experienced staff or veterinarians 
are available are unlikely to affect outcomes in these cases.  
Older animals were more likely to present with signs of disease or debilitation and loss of 
animals from these age groups are likely to have less impact on long-term population 
viability. Clinical chlamydiosis might be expected to be more prevalent in older, sexually 
active animals, as the main route of transmission is sexual (White & Timms, 1994; Martin 
& Handasyde, 1999). In addition, repeated infections may result in more overt clinical 
signs, as occurs in people (Grayston, Wang et al., 1985), and nutritional stress as a result of 
worn teeth (Lanyon & Sanson, 1986) may result in clinical expression of previously 
subclinical infections. The demise of such animals is unlikely to have significant effects on 
population viability: aged females in Chlamydiaceae positive populations generally have a 
fecundity of < 20% (McLean, 2003) and older males have behavioural changes that could 
reduce breeding success (Logan & Sanson, 2002a; Logan & Sanson, 2002b). Removal of 
                                                 
4
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, March, 2010. 
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older animals may even be advantageous by freeing up home ranges for other animals 
(Mitchell, 1990). Population modelling has indicated that the demise of aged animals had 
little impact on the survival of one population of koalas (Caneris & Jones, 2004), and it is 
possible that the same occurs in Port Macquarie. Where resources are limited, these 
animals should be given a lower priority than younger animals. A prospective study 
examining survival post-release using radiotelemetry or a retrospective case controlled 
study of medical records held at the Koala Hospital examining frequency of representation 
of this age group would better characterise rehabilitation and breeding success in this 
group post-release. 
Significant differences exist between the sexes that suggest both anatomical and 
behavioural factors are important in expression of clinical signs associated with 
chlamydiosis. In line with the findings of other researchers (Obendorf, 1983; White & 
Timms, 1994; McLean, 2003; Stalder, 2003), this study found females were over-
represented as wet bottom admissions, and males as eye disease admissions. Although the 
female predisposition to clinical wet bottom can be explained by anatomical differences 
(Obendorf, 1981), the over-representation of males as presenting with clinical eye disease 
is more difficult to understand. Traumatic injuries sustained whilst fighting might 
contribute to expression of ocular chlamydiosis and in addition to presentation as direct 
result of traumatic eye disease in male koalas (McLean, 2003). Dust, a contributory factor 
to trachoma in people (Alene & Abebe, 2000), may also contribute to clinical 
conjunctivitis in male koalas, if they are exposed to more dust than females: for example as 
a result of the increased travelling by males observed during breeding season (Mitchell, 
1990). The exact cause of this phenomenon is yet to be elucidated. 
A study examining animals classified as “undiagnosed” or “debilitated” in more detail 
would be useful. Debilitated and undiagnosed are vague descriptions and these categories 
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would benefit from a tighter clinical description, as it is possible that there is significant 
cross-over within these groups. Further, emerging diseases or threats might initially be 
classified within this group, thus analysis of these animals might warrant specific attention. 
The busiest season for admissions to the Koala Hospital was spring and total admissions 
have increased substantially since the 1970s. The onset of the breeding season of koalas 
coincides with early spring (Martin & Handasyde, 1999) and male koalas older than four 
years have increased frequency of movement during this time (Mitchell, 1990). The 
dispersal of juveniles may also contribute to the increase in admissions. Staff deployment 
should be maximal during this period.  
Presentations in autumn were more frequently associated with disease (eye disease, wet 
bottom, debilitated and undiagnosed) than in other seasons. During the breeding season 
animals may lose condition as a result of breeding efforts, be displaced from territory or be 
subject to sexually transmitted diseases (e.g. chlamydiosis). As the ambient temperature 
declines in autumn such stressors may present as clinical disease. This influx may reflect 
natural attrition of non-viable animals during this season. 
Although temporal population data of wild populations are unavailable, analysis of the 
hospital data reveals interesting trends. Substantial fires occurred in the Port Macquarie 
area in 1994 and 2002, causing anomalous increases in koala admissions during these 
years. When admissions as a result of fire are excluded from the data set, mean ± SD 
annual admissions have remained stable between 1990 and 2009 (Figure 2-3; ANOVA, p = 
0.47). Without knowledge of the temporal dynamics of the local koala population, it is 
difficult to draw conclusions as to why koala admissions change. The human population of 
the Port Macquarie - Hastings local government area has approximately tripled over the 
period examined, from 25,323 (Australian Bureau of Statistics, 1976) to 68,430 (Australian 
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Bureau of Statistics, 2006). Although human population increase and associated 
development may increase risks of anthropogenic admissions to the hospital, it may also 
increase risks of koalas being admitted simply because more people are looking for sick or 
“endangered” animals. Alternatively, if the risk of koalas presenting to the hospital has 
remained stable, the population of koalas themselves may have increased during the 1980s 
and plateaued over the past 20 years. For meaningful extrapolation of these data to the 
health of the wild population, regular accurate local wild koala population surveys are 
vital.  
Despite these limitations, changes in relative risk of animals presenting within each five-
year period may indicate changing risk factors for koalas, and suggest developing threats. 
The significantly increased relative risk of koalas presenting as motor vehicle accident 
since 1985 is alarming (Figure 2-6). Presumably, the increase in the human population of 
Port Macquarie has also increased the number of motor vehicles, dogs and the 
fragmentation of habitat. At first glance it would seem that increased motor vehicles in the 
area probably account for the increase in koalas presenting as result of motor vehicle 
accidents, as has been found in studies in south-east Queensland (Dique, Thompson et al., 
2003). However, analysis of the seasonal data does not support this simple hypothesis. 
Tourist numbers (and presumably associated cars and traffic), approximately double the 
population of Port Macquarie during summer (W. Beverley, pers. comm.)
5
, yet only males 
are at increased risk of presenting as a result of motor vehicle accident in summer in 
comparison with cooler seasons, and in summer and spring in comparison with females 
(Figure 2-5). The combination of seasonal male behavioural factors and seasonal increased 
numbers of vehicles most likely explains patterns of motor vehicle accidents. Vehicle 
                                                 
5
 Personal communication: W. Beverley, Project support officer, Corporate & Business Services, Port 
Macquarie-Hastings Council, Port Macquarie, NSW, December, 2008. 
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collisions in other species (deer, macropods and bandicoots) have also been associated 
with animal behavioural factors (Dufty, 1994; Coulson, 1997; Sudharsan, Riley et al., 
2006). If the risk of motor vehicle accident is related to koalas spending more time 
travelling on the ground, as well as absolute vehicle numbers, risk factors related to 
increased travelling, such as time of year (breeding in spring and summer), age (juvenile) 
and sex (male), and interactions (male and summer, male and spring) might be expected to 
be connected with increased risk of motor vehicle accident in these groups.  
The most logical reason that koalas might be spending more time on the ground in recent 
years is fragmentation of bush habitat and reduction of the number of suitable trees within 
urban habitat as a result of development. Radio-tracking of koalas in urban areas has 
demonstrated that provision of habitat corridors and patches are less important than total 
area and connectivity of habitat, and koalas may make frequent, quite long range 
movements (> 2 km) between patches of suitable habitat (White, 1999). Thus, efforts to 
mitigate koala motor vehicle collisions around Port Macquarie need to concentrate on 
providing a mosaic of more viable habitat, including trees within urban areas to reduce 
koala movement, rather than relying on funnelling koalas into habitat corridors or on traffic 
calming efforts alone. 
Mitigation efforts aimed at reducing motor vehicle/wild animal collisions broadly 
concentrate on deterring animals from road sides and/or reducing speed of vehicles 
(Magnus, Kriwoken et al,.2004) but to be effective, some authors propose they must take 
into account habitat use by the target species (Roger & Ramp, 2009), a suggestion 
supported by the findings of this work. Trials using differential speed zones at night did not 
reduce vehicle speed or reduce the number of koala-vehicle collisions (Dique, Thompson 
et al., 2003). Studies overseas using temporary signage incorporating flashing lights have 
been effective in reducing deer collisions with vehicles (Sullivan, Williams et al., 2004), 
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although this area requires further study. Night travel by vehicles has been identified as a 
risk factor for wildlife-vehicle collisions (Rowden, Steinhardt et al., 2008) and should be 
discouraged using educational campaigns. Practical and cost-effective mitigation regimes 
that the Koala Hospital might implement could include mosaic habitat maintenance and 
expansion, and identification of koala-motor vehicle collision hotspots (Preece, 2007). 
Educational campaigns targeting driving behaviour should be timed to be maximal in 
anticipation of the spring breeding season, highlight collision hotspots, recommend 
daytime travel and reduced speed, and importantly, must also educate non-local tourists in 
summer. More broadly, new urban development planning should consider habitat 
maintenance in new suburbs, and koala fencing and underpasses for new roads. 
Fortunately, recent development in an area of koala habitat in the vicinity of Port 
Macquarie (Thrumpster) has led the Port Macquarie-Hastings council to adopt a koala plan 
of management, incorporating many of these measures (Biolink, 2008). 
Interestingly, the relative risk of presenting as a dog attack has not significantly changed 
since the 1970s. The change in numbers of dogs in Port Macquarie is not known, as many 
animals are not routinely registered, but presumably has increased along with the human 
population. It is possible that the increasing practice of responsible pet ownership and the 
legal requirements to do so (The New South Wales Companion Animals Act of 1998) may 
have contributed to this situation. Continued vigilance in this area is important, as dogs 
may be a significant threat to koala populations (Lunney, Gresser et al., 2007; Department 
of the Environment, Water, Heritage and the Arts, 2009). 
Risk of admissions as a result of eye disease or wet bottom have not changed. Such data 
suggest a stable host-parasite relationship, however, subclinical chlamydiosis is a frequent 
occurrence in koalas (Jackson, White et al., 1999; McLean, 2003) and analysis of these 
data based on external clinical signs runs the risk of under-estimating prevalence. A study 
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examining chlamydial prevalence in the wild population over time would be extremely 
useful in studying the evolving host-pathogen-environment relationship. 
Outcomes of this study that predict when animals present may be useful in making 
management decisions regarding resource allocation at the Koala Hospital for each season. 
Predictably, animals were more likely to present because of fire in spring and summer, and 
training of staff in anticipation of fires must be taken in advance of these seasons. Seasonal 
risk factors for animals presenting in different admission categories may provide targets for 
educational campaigns or research efforts. For example, probability of presentation as a 
result of dog attack was increased in autumn and winter, thus educational campaigns and 
dog “curfews” could target this season. Scientists wishing to investigate potentially 
emerging diseases might target autumn, when animals are at increased risk of presenting as 
diseased, debilitated or undiagnosed.  
This study is the first of its kind in a koala hospital. It has the advantages of a large data 
set, both in terms of total numbers and in the time span covered. This study highlights the 
potential of research using wildlife rehabilitation databases to identify risks to wild 
populations, and provides information that may be useful for rehabilitation centres to plan 
logistics and allocate resources. In most cases, differences in the likely behaviour between 
the cohorts examined was considered the most important contributor to risk in each 
admission category and effective mitigation of threat must take this into account. A 
significant and increasing threat to survival of the Port Macquarie koala population was 
identified as an increasing risk of motor vehicle accidents since 1985. A regular 
scientifically rigorous ecological survey of the koala population in Port Macquarie is vital 
to assess whether the significant efforts of rehabilitators, the local council, and Port 
Macquarie residents aimed at preserving the wild koala population are effective. 
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CHAPTER 3 - ANALYSIS OF DIAGNOSIS AND 
TREATMENT REGIMES FOR CHLAMYDIOSIS AND THEIR 
IMPACT ON THE RECOVERY AND RELEASE OF KOALAS 
HELD AT THE KOALA HOSPITAL BETWEEN 1995 AND 
2005  
3.1 INTRODUCTION 
Rehabilitation of wildlife in Australia is a high profile activity involving thousands of 
people and tens of thousands of wildlife cases annually (Tribe & Brown, 2000; Shine & 
Koenig, 2001). Despite its popularity, few studies exist concerning the success of 
rehabilitation and hand-rearing of wildlife in Australia. These are limited to findings of 
rapid and high mortality of ringtail and brushtail possums (Augee, Smith et al., 1996; 
Tribe, Hanger et al., 2005) and high mortality and poor breeding success of penguins 
rehabilitated following oil immersion (Giese, Goldsworthy et al., 2000; Goldsworthy, 
Giese et al., 2000). Translocated animals, which might be expected to have lower mortality 
than rehabilitated animals, also have poor survival. For example, 70% of healthy wild 
brushtail possums died within a week of translocation (Pietsch, 1994) and relocated ringtail 
possums survived approximately 55% the length of time of wild controls (Augee, Smith et 
al., 1996). Studies from overseas have found similarly high mortality rates of rehabilitated 
and hand-reared wildlife shortly after release (Robertson & Harris, 1995; Anderson, Gress 
et al., 1996; Fajardo, Babiloni et al., 2000; Ben-David, Blundell et al., 2002; Beringer, 
Mabry et al., 2004) and extremely low three-month survival rates of many translocated 
species (McCullough, Jennings et al., 1997; Adams, Hadidian et al., 2004; Calvete, 
Angulo et al., 2005). It seems paradoxical that although large investments of time, effort 
and money are made in the rehabilitation of wildlife, there are very few studies examining 
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aspects of the disease, host or rehabilitation efforts associated with successful release 
(Gage, Gerber et al., 1993; Mignucci-Giannoni, 1999; Mowbray, 2009) and post-release 
survival (Fajardo, Babiloni et al., 2000; Goldsworthy, Giese et al., 2000; Molony, 
Dowding et al., 2006).  
This information hiatus probably reflects a difference in conservation philosophy between 
wildlife rehabilitators who usually focus on individuals, and scientists who focus on 
populations (Shine & Koenig, 2001). Wildlife rehabilitation undoubtedly provides benefit 
to individual animals, may replenish local populations, allows development of 
rehabilitation and husbandry techniques, provides the opportunity to study wild animals, 
and raises public awareness of conservation issues (Siemer, Brown et al., 1991; Tribe & 
Brown, 2000; Turnbull, 2005). Undeniably, rehabilitation of wildlife will persist whilst 
debate continues as to its ultimate worth (Estes, 1991; Estes, 1998; Tribe & Brown, 2000), 
thus it is important that methods of rehabilitation and treatments for specific disease are 
studied to minimise wastage, improve animal welfare and enable the best possible outcome 
for rehabilitated wild animals and the populations to which they return.  
Interestingly, rehabilitation of koalas for a number of different conditions appears to be 
relatively successful (Ellis, White et al., 1990; Starr, 1990; Lunney, Gresser et al., 2004; 
Tribe, Hanger et al., 2005; Jones, 2008). Furthermore, successful breeding post-release, 
perhaps the most important marker of success, has also been demonstrated: in one study 
breeding rates in nine koalas rehabilitated after bushfire matched that of the control group 
(80% and 73%, respectively) (Lunney, Gresser et al., 2004). Chlamydiosis, a common 
infectious disease in koalas, appears to be a particularly important factor determining 
successful breeding after translocation or rehabilitation of koalas. In Victoria the fertility of 
Chlamydia (now known as Chlamydophila) (Everett, Bush et al., 1999) naïve animals 
declined after translocation into a Chlamydia positive population (Handasyde, 1986). 
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Koalas admitted with clinical signs consistent with chlamydial disease, such as 
conjunctivitis (Cockram & Jackson, 1976) or reproductive tract disease (Obendorf, 1981) 
(colloquially termed “wet bottom”) (Blanshard, 1994), account for approximately 20% of 
all admissions to the Koala Preservation Society of NSW‟s Koala Hospital in Port 
Macquarie, NSW, making admissions as a result of clinical chlamydiosis second only to 
trauma (Chapter 2). Despite the acknowledged importance of this disease and the necessity 
of developing a reliable treatment, regimes differ between the three main koala 
rehabilitation centres in Australia (Blanshard & Bodley, 2008). Few studies exist regarding 
their effectiveness (Cockram & Jackson, 1976; Markey, Wan et al., 2007; Blanshard & 
Bodley, 2008) and little is known about the prognosis, particularly for breeding success of 
such animals after release. 
Medical records have been collected at the Koala Hospital since the 1970s and comprise a 
significant data set (Chapter 2). Although limited in some respects, analysis of these types 
of data may identify prognostic indicators and treatment regimes associated with 
successful rehabilitation and may be used to generate hypotheses for further study 
(Cockcroft & Holmes, 2003). It is imperative that treatments administered at the Koala 
Hospital have a sound evidence base, as wildlife rehabilitation groups and veterinarians 
frequently seek advice from staff of the Koala Hospital. 
Given the longitudinal nature of these data, it might be possible to use the medical records 
as an indicator of survival and breeding success of treated animals, similar to passive 
resight methods used with owls (rings) (Fajardo, Babiloni et al., 2000) and hump backed 
whales (photographs of tail flukes) (Mizroch, Herman et al., 2004). Although this method 
is limited by the probability of animals re-presenting, other advantages are apparent. 
Prospective survival trials undertaken by tracking radio-collared animals are usually 
limited to small numbers and relatively short monitoring times, as they are labour intensive 
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and costly (Lunney, Gresser et al., 2004; Radford, McKee et al., 2006). In addition, 
animals may be affected by the collars both in terms of behaviour (Cypher, 1997; Tuyttens, 
Macdonald et al., 2002) and as a result of collar injuries (Krausman, Bleich et al., 2004), 
although these problems appear uncommon in koalas (Radford, McKee et al., 2006). Use 
of records of a long-established wildlife rehabilitation centre allows for re-presentations of 
permanently identified animals over many years, a period of time rare in other studies. As 
koalas are relatively long lived (Martin & Handasyde, 1999), long-term passive monitoring 
of permanently identified animals is a relatively cheap and potentially useful way of 
assessing their survival. Further, it is possible to assess the breeding success of females 
through examination of records of evidence of breeding (presence of young, elongated 
nipples). 
3.2 AIMS 
This study examined a cohort of animals with external clinical signs consistent with 
chlamydial disease admitted to the Koala Preservation Society of NSW‟s Koala Hospital 
between 1995 and 2005, with the aim of describing the most recent methods of diagnosis 
and treatment at the Koala Hospital and assessing their impact on animal recovery and 
post-release survival. It was anticipated that the analysis would assist in providing 
invaluable background information for establishing treatment protocols for further 
investigation. 
The specific aims of the study were to describe: 
1/ how the diagnosis of chlamydial disease was made, 
2/ which treatments were used, the route of administration and length of medication 
courses, 
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3/ what the outcomes were, and whether a treatment regime associated with successful 
release and post-release survival could be identified. 
3.3 METHODS 
3.3.1 Data collection and storage 
Archived data available for this study incorporated information on koalas admitted to the 
Koala Hospital between 1
st
 March 1995 and 28
th
 February 2005. Paper medical records, 
amended only by veterinarians or trained para-veterinary supervisors (C. Flanagan, pers. 
comm.)
1
, included an admission reason based on methods of examination and 
classification outlined previously (see Chapter 2); diagnostic tests performed in-house or at 
a veterinary diagnostic laboratory (Symbion Vetnostics, North Ryde, NSW, Australia); and 
treatments prescribed by visiting veterinarians, or supervisors according to treatment 
protocols. Before commencement of this study, admissions data had been entered into a 
database (Microsoft Access® 2003, Microsoft® Corporation, Redmond, Washington, 
USA) using defined codes (Appendix I). 
3.3.2 Data retrieval 
Database admission codes relating to chlamydial disease were “wet”, “eye” and “wee”, 
described in Appendix I. The Koala Hospital computer database was used to identify all 
records of animals admitted under these codes during the months of March, June, 
September and December, between 1
st
 March 1995 and 28
th
 February 2005. Paper medical 
records corresponding to these admissions were retrieved from storage and formed the 
basis of the study. Exclusion criteria included: animals whose records did not mention one 
of the words “conjunctivitis”, “diseased” or “discharge” for eye admissions, or “wet 
                                                 
1
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, March, 2010. 
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bottom” or “Chlamydia” for “wet” admissions (n = 8); animals from Taree, NSW, whose 
records were unavailable for study (n = 21); animals presenting in the “wee” category (n = 
2) as this category contained too few animals for meaningful analysis; and animals whose 
paper medical records could not be located (n = 8).  
3.3.3 Statistical analysis 
Data, collected from paper medical records under the categories outlined in Table 3-1 were 
entered into a spreadsheet using Microsoft® Office Excel® 2003 (Microsoft® 
Corporation, Redmond, Washington, USA). Histograms were prepared for each categorical 
explanatory variable and box and whisker plots of the continuous data.  
The independence of categorical data was assessed using chi-square analysis in Minitab
®
 
Statistical Software (Minitab Pty Ltd, Sydney, NSW, Australia). Continuous variables 
(Table 3-1) were compared between the groups released/not released using a Mann 
Whitney test. Calculation of the odds ratios for explanatory variables, and their 95% 
confidence intervals, was conducted using binomial logistic regression (Hosmer & 
Lemeshow, 2000) in GenStat for Windows (2008, 11
th
 ed., VSN International Ltd., Hemel 
Hempstead, Hertfordshire, UK). Explanatory variables are outlined in Table 3-1 and 
outcome variables were released, or not released (i.e. euthanased, transferred or died). 
Models were constructed by a manual forward stepwise approach. Statistical significance 
was concluded at p ≤ 0.05.  
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Table 3-1. Variables used in statistical analyses of treatment data. 
  
Variable (units/ categories) Comments 
Admission code
*
 (Wet /Eye)  
Koala name  
Sex
*
 (M/F)  
Age class
* 
(juvenile/young/mature/aged) Corresponding to tooth wear class I - II/III/ IV/ V - VII 
(Martin, 1981) 
Crown rump length (cm)
 ‡
 Nose to end of tail 
Head length (cm)
 ‡
 Nose to occiput 
Month of presentation for this admission (March, 
June, September, December) 
 
Year of presentation for this admission (year) 1995 - 2005 
Weight at presentation (kg)
 ‡
  
Crown rump length (cm)/ weight at presentation 
(kg)
 ‡
 
 
Head length (cm)/ weight at presentation (kg)
 ‡
  
Eye swabs
*
 (Y/N) Clearview Chlamydia MF enzyme-linked 
immunosorbent assay (ELISA), Inverness Medical 
Australia, Sinnamon Park, Qld, Australia 
Date of eye swab test  
Result of eye swabs
*
 (positive/negative/not 
recorded) 
 
Urogenital tract swabs
*
 (Y/N) Clearview Chlamydia MF enzyme-linked 
immunosorbent assay (ELISA), Inverness Medical 
Australia, Sinnamon Park, Qld, Australia 
Date of urogenital swab test  
Result of urogenital tract swabs
*
 
(positive/negative/not recorded) 
 
Blood tests
*
 (Y/N) Routine haematological & serum biochemical analysis. 
Symbion Vetnostics, North Ryde, NSW, Australia 
Ultrasound
*
 (Y/N)  
Oxytetracycline/ polymyxin B eye ointment
*
 
(Y/N) 
Terramycin® Ophthalmic Ointment, Pfizer, New York, 
USA 
Other eye ointment
*
 (Y/N)  
Which other eye ointment? 
 
Table 3-2 
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Table 3-1 cont. 
 
Variable (units/ categories) Comments 
Eye surgery
*
 (Y/N)  
Enrofloxacin
*
 (Y/N) Baytril® oral suspension 25 mg/mL, or injectable 
solution 50 mg/mL, Bayer Animal Health, Pymble, 
NSW, Australia 
Days on enrofloxacin
‡ 
  
Dose of enrofloxacin (mg/kg)  
Route of enrofloxacin
*
 (p.o./s.c./n.r.)  
Other systemic antibiotic
*
 (Y/N)  
Which other systemic antibiotic?  
Days on other systemic antibiotic
‡
  
Meloxicam
*
 (Y/N) Metacam® oral suspension 1.5 mg/mL or injectable 5 
mg/mL, Boehringer Ingelheim, North Ryde, Australia 
Route of meloxicam (p.o./s.c./n.r.)  
Days on meloxicam
‡
  
Ancillary treatment
*
 (Y/N)  
Which ancillary treatment? Table 3-2 
Table 3-3  
Total days in care
‡
  
Final result
†
 (released/not released)  
Days until next admission
‡ 
 Released animals only 
Breeding status at next admission (joey/no joey) Released females only 
Presence of young noted in medical records 
Categorical explanatory variables (*) and outcome variable (†): univariate binary logistic regression model; 
and continuous variable: Mann Whitney test (‡).  
p.o: per os; s.c: subcutaneous; n.r: not recorded; Y/N: yes/no; M/F: male/female. 
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3.4 RESULTS 
3.4.1 Animals included in the study 
The method of case retrieval identified 88 records for inclusion in the study. Of these, 54 
(61.4%) of animals were classified as “wet” and 34 (38.6%) as “eye” and there was bias in 
the type of presentation (chi-sq = 2.3, d.f. = 1, p = 0.13). Fifty-one animals (58%) were 
female and 37 (42%) were male and there was no sex bias (chi-sq = 1.12, d.f. = 1, p = 
0.29). Juveniles (2 animals: 2.3%) were less frequently admitted than other age groups 
(aged adults: 15 animals (17%); young adults: 35 animals (39.8%); mature adults: 35 
animals (39.8%); undetermined: 1 animal (1.13%); chi-sq = 28, d.f. = 3, p < 0.0001). There 
was no seasonal bias in included cases (December: 29 cases (33%); March: 16 cases 
(18%); June: 22 cases (25%); and September: 22 cases (25%); chi-sq = 1.9, d.f. = 3, p = 
0.593). 
3.4.2 Common diagnostic tests performed 
Data indicated that swab-based chlamydial antigen ELISA (Clearview Chlamydia MF 
ELISA, Inverness Medical Australia, Sinnamon Park, Qld, Australia) and ultrasonography 
of the urogenital tract were selectively used on anatomical sites displaying clinical signs 
(Figure 3-1). Animals in the “eye” category were more likely to have eye swabs (chi-sq = 
21.863, d.f. = 1, p < 0.0001), and animals in the “wet” category were more likely to have 
urogenital swabs (chi-sq = 18.312, d.f. = 1, p < 0.0001) and ultrasound imaging (chi-sq = 
17.18, d.f. = 1, p < 0.0001). Ninety per cent of swabs (40 swabs) were taken within one 
week of admission; only 10 animals (20% of animals swabbed) were swabbed more than 
once. There was no difference in the proportion of animals having blood tests 
(haematological parameters and serum biochemistry) between the “eye” and “wet” groups 
(chi-sq = 0.424, d.f. = 1, p = 0.515).  
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Treatment appeared to be based more on clinical presentation than on test results. Animals 
with negative swab results had similar treatments to animals with positive swabs. All four 
animals that had negative results on eye swabs were treated with oxytetracycline 
polymyxin B sulphate eye ointment for at least seven days (median 7.5, range 7 - 12 days). 
Of the eight animals with negative urogenital swabs, five were treated with systemic 
enrofloxacin for at least eight days (median 12, range 8 - 31). Three swabs had no results 
recorded. 
 
 
 
 
 
Figure 3-1. Percentage of “eye” and “wet” admissions subjected to diagnostic testing, 
illustrating selective use of swab and ultrasound-based diagnostics in clinically affected sites.  
Cases may have received more than one diagnostic test. UGT: urogenital tract. 
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3.4.3 Common treatments used  
Similar to diagnostics, treatment was targeted to affected sites. Animals in the “eye” 
category were more likely to be treated with oxytetracycline/ polymyxin B sulphate eye 
ointment twice daily (chi-sq = 52.62, d.f. = 1, p < 0.0001), other eye ointments (chi-sq = 
14.72, d.f. = 1, p < 0.0001) and eye surgery (chi-sq = 19.97, d.f. = 1, p < 0.0001) than 
animals admitted as “wet” (Figure 3-2). Other eye ointments were most commonly 
chloramphenicol based and frequently contained hydrocortisone acetate (Table 3-2). Eye 
surgery consisted of ablation of proliferative conjunctiva and/or removal of the third eye 
lid (Blanshard, 1994; Blanshard & Bodley, 2008) and was performed in 30% of animals in 
the “eye” group. Eleven animals (12.5%) received no treatments. 
 
Figure 3-2. Percentage of “eye” and “wet” admissions administered different treatments. 
Cases may have received more than one treatment. Eleven animals (12.5%) received no treatments. EO: eye 
ointment; oxytet: oxytetracycline/ polymyxin B; Rxs: treatments. 
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Table 3-2. Detail of eye ointments other than oxytetracycline/ polymyxin B, and ancillary treatments
*
 
given to 34 “eye” cases. 
 
Treatment Active ingredients Reason
1
 Route Brand and Manufacturer n 
Other eye 
ointment 
Chloramphenicol Chlamydial 
conjunctivitis 
Topical Chlorsig®, Sigma 
Pharmaceuticals Ltd, South 
Croydon, Australia; Opticin®, 
Troy Laboratories, Glendenning, 
NSW, Australia 
2 
 Chloramphenicol & 
hydrocortisone 
acetate 
Chlamydial 
conjunctivitis 
Topical Chloroint®; Troy Laboratories, 
Glendenning, NSW, Australia; 
Chlorosone®, Jurox, 
Rutherford, NSW, Australia 
6 
 Ofloxacin Chlamydial 
conjunctivitis 
Topical Ocuflox®, Allergan Inc, Irvine, 
California, USA 
1 
 Benzathine 
cloxacillin 
Chlamydial 
conjunctivitis 
Topical Orbenin® eye ointment, Pfizer, 
West Ryde, NSW, Australia 
1 
 Atropine sulphate Uveitis  Ilium Atropine eye ointment®, 
Troy Laboratories, Glendenning, 
NSW, Australia 
1 
Ancillary 
treatment 
Saline bathing of 
eyes 
Remove ocular 
discharge 
Topical   
 Vitamin B12 Nutritional support s.c. 
injection 
Troy Vitamin B12®, Troy 
Laboratories, Glendenning, 
NSW, Australia 
2 
 Vitamin B complex Nutritional support s.c. 
injection 
Multibex Sterile injection®, 
Heriot Agencies, Boronia, Vic, 
Australia or Jurox, Rutherford, 
NSW, Australia 
2 
 Iron Nutritional support s.c. 
injection 
Anaemex ™, Ausrichter Animal 
Health, Annandale, NSW, 
Australia 
 
 Yoghurt Probiotic Oral  1 
 Paraffin oil Laxative Oral  1 
 Neomycin 
thiostrepton, nystatin, 
triamcinolone 
Wound treatment 
unrelated to 
chlamydial disease 
Topical Panolog®, Fort Dodge 
Australia, Baulkham Hills, 
Australia 
1 
 Metacresolsulfonic 
acid and 
formaldehyde 
Wound treatment 
related to urine scald 
Topical Lotagen®, Schering-Plough, 
North Ryde, Australia 
1 
* other than oxytetracycline/ polymyxin B eye ointment, systemic antibiotics and meloxicam.  
s.c: subcutaneous; n: number of koalas treated.
                                                 
1
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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Animals admitted as “wet” were significantly more likely to be treated with the systemic 
antibiotic, enrofloxacin, than animals admitted as “eye” (chi-sq = 14.17, d.f. = 1, p < 
0.0001). Approximately half of animals (n = 30; 55%) admitted as “wet” were treated with 
enrofloxacin (Figure 3-2). Only a minority of animals in “wet” and “eye” groups were 
treated with other systemic antibiotics or the non-steroidal anti-inflammatory drug, 
meloxicam (Figure 3-2), which was administered for anti-inflammatory and analgesic 
purposes (C. Flanagan, pers. comm.)
2
. There was no significant difference between these 
groups in the proportion of animals treated with these modalities. Other than enrofloxacin, 
the systemic antibiotic used most frequently was chloramphenicol, used in 11 cases, with 
one additional case each treated with sulphatroxazole/ trimethoprim, nystatin, 
amoxicillin/clavulanic acid, or a combination product containing sulphadiazine, 
streptomycin sulphate and neomycin sulphate.  
3.4.4 Ancillary treatments used  
Ancillary treatments were frequently used in the “eye” and “wet” groups (Figure 3-2), the 
most frequent being nutritional supplements, probiotics, and bathing of eyes with saline 
(Table 3-3). Animals in the “wet” category were frequently treated with one or more non-
prescription remedies used for treatment of cystitis (methenamine hippurate, Hiprex®, 
Sanofi-aventis, Bridgewater, New Jersey, U.S.A; sodium citrotartrate, Ural®, Sigma 
Pharmaceuticals, South Croydon, Vic, Australia) and vaginal candidiasis in people (topical 
yoghurt (4 cases; 7.4%); nystatin, Nilstat® topical cream, Sigma Pharmaceuticals, South 
Croydon, Vic, Australia (1 case; 1.85%); clotrimazole, Clonea® Antifungal skin cream, 
Alphapharm, Glebe, NSW, Australia (1 case; 1.85%); topical yoghurt in combination with 
nystatin (5 cases; 9.25%) or in combination with clotrimazole (1 case; 1.85%)). Topical 
                                                 
2
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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antiseptics (chlorhexidine gluconate) and barrier cream (sorbolene) were also occasionally 
directed at preventing or treating urine scald in “wet” animals (6 animals, 11.1%). Other 
ancillary treatments were usually administered to one or two animals only (pentosan 
polysulphate, intracystic povidone iodine) or were unrelated to treatment for chlamydiosis, 
cystitis or incontinence. Use of multiple ancillary treatments in the same animal was more 
common in “wet” cases (21 animals, 38.9% of “wet” cases) than “eye” cases (4 animals, 
11.7% of “eye” cases) (chi-sq = 7.62, d.f. = 1, p = 0.006). Single agent ancillary therapy 
was most frequently saline bathing of eyes (9 animals, 26.4% of “eye” cases), or use of 
methenamine hippurate (Hiprex®, Sanofi-aventis, Bridgewater, New Jersey, USA) in four 
“wet” cases (7.4% of “wet” cases). One case each was treated with single agent ancillary 
therapy of cloacal yoghurt, oral sodium citrotartrate, oral paraffin oil or a multivitamin B 
injection. All other cases given ancillary treatment (29 cases, 32.9% of all cases) received 
more than one ancillary therapy. 
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Table 3-3. Detail of ancillary treatments
*
 given to 54 “wet” cases. 
 
Treatment Reason
3
 Route Brand and Manufacturer No. treated† 
Vitamin B12 Nutritional support Subcutaneous injection Troy Vitamin B12®, Troy Laboratories, Glendenning, NSW, 
Australia 
1 
Vitamin B complex Nutritional support Subcutaneous injection Multibex® Sterile Injection, Heriot Agencies, Boronia, Vic, 
Australia or Jurox, Rutherford, NSW, Australia 
7 
Saline bathing Removal of ocular discharge Topical around eyes  2 
Probiotics Refaunation Oral Innerhealth®, Health World Limited, Virginia BC, Qld, 
Australia 
5 
Protexin® powder, International Animal Health Products, 
Huntingwood, NSW, Australia 
2 
Koala faeces 1 
Chlorhexidine gluconate  Prevention/treatment of urine scald Topical around rump Hexawash® skin cleaner, Apex Laboratories, Somersby, NSW, 
Australia 
4 
Sorbolene  Barrier cream/moisturising for urine 
scald 
Topical  2 
Yoghurt Natural remedy for vaginal candidiasis 
in women 
Intracloacal  8 
Methenamine hippurate Acidification and sterilisation of urine Oral Hiprex®, Sanofi-aventis, Bridgewater, New Jersey, U.S.A 8 
Sodium citrotartrate Alkalanisation of urine Oral Ural®, Sigma Pharmaceuticals, South Croydon, Vic, Australia 3 
Antifungals 
(Nystatin, Clotrimazole) 
Remedy for candidiasis in women Topical around cloaca Nilstat® topical cream, Sigma Pharmaceuticals, South Croydon, 
Vic, Australia 
4 
Clonea® Antifungal cream, Alphapharm, Glebe, NSW, 
Australia  
1 
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Table 3-3 cont. 
    
Treatment Reason
3
 Route Brand and Manufacturer No. treated† 
Povidone-iodine Topical antisepsis of the bladder Intracystic Betadine® antiseptic liquid, Symbion Consumer Products, 
Rydalmere, NSW, Australia 
1 
Pentosan polysulphate Repair of glycose- amino-glycans layer 
of the bladder 
Injectable Cartrophen Vet®, Biopharm, Bondi Junction, NSW, Australia 2 
Bromazepam Sedation Oral Lexotan®, Roche Products, Dee Why, NSW, Australia 2 
Antiseptic Topical antiseptic Topical skin Teatree ointment 1 
“Antiseptic” cream, brand and manufacturer unknown 1 
Activated charcoal Natural therapy for flatulence, 
gastrointestinal pain 
Oral Charcotabs® Activated Charcoal, Key Pharmaceuticals, North 
Ryde, NSW, Australia 
1 
Peppermint oil Natural therapy for flatulence, 
gastrointestinal pain 
Oral Peppermint water, Orion Laboratories, Pty. Ltd., Balcatta, WA, 
Australia 
1 
Kaolin/Pectin Treatment of diarrhoea Oral Kaomagma and pectin solution, Wyeth Australia, Baulkham 
Hills, NSW, Australia 
1 
Praziquantel 
(± pyrantel pamoate and 
febantel) 
Tapeworm treatment Oral Droncit® or Drontal®; Bayer Animal Health, Australia, Pymble, 
NSW, Australia 
1 
1 
Nandrolone laurate Anabolism Injectable Laurabolin®, Intervet/Schering Plough Animal Health, Bendigo 
East, Vic, Australia 
1 
Cisapride Gastrointestinal motility Oral Prepulsid®, Janssen Cilag Pty Ltd, Sydney, NSW, Australia 1 
*
 other than oxytetracycline/ polymyxin B eye ointment, systemic antibiotics and meloxicam.  
† Cases may have received more than one treatment. 
 
_________________________________ 
3
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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3.4.5 Duration of treatment 
Antibiotic courses of systemic enrofloxacin and oxytetracycline/ polymyxin B eye 
ointment were administered for a median of 15 days, although the range of treatment 
duration was wide (Figure 3-3). Median duration of treatment with chloramphenicol was 
longer (25 days) for animals in the “eye” group than the “wet” group, although the former 
group consisted of only three animals. Non-steroidal anti-inflammatory treatment 
(meloxicam) was typically given for shorter periods of time to “eye” cases (median 5.5 
days) than “wet” cases (median 26 days). The route of systemic medication was most 
frequently oral for enrofloxacin and meloxicam, and parenteral for chloramphenicol, 
although route of enrofloxacin administration was not recorded in a high percentage of 
records (Table 3-4). The method of injection (subcutaneous or intramuscular) was recorded 
for only five animals receiving parenteral medication. Meloxicam route could only be 
inferred by assuming the word “drops” was related to oral administration. Median dose 
rates were consistent with those used in small animal practice for enrofloxacin (5 - 10 
mg/kg once daily) and meloxicam (0.1 - 0.2 mg/kg once daily) and consistent with equine 
doses of chloramphenicol (10 - 50 mg/kg twice daily) (Figure 3-4) (Plumb, 2005).  
 
 
Table 3-4. Route, frequency, and number of animals subjected to systemic drug 
administration. 
 
Drug Frequency Oral Injectable Both Not 
recorded 
Total 
Enrofloxacin Once daily 18 2 (subcutaneous) 2 14 36 
Meloxicam Once daily 17  2  19 
Chloramphenicol Twice daily 1 9 (intramuscular) 1  11 
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Figure 3-3. Median (range) duration of treatments administered to 77 koalas admitted for 
treatment of suspected chlamydiosis.  
Included cases may have received more than one treatment. Eye: “eye” admissions; Wet: “wet” admissions. 
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Figure 3-4. Dose ranges of systemic drugs administered in this study.  
Chloramph: chloramphenicol. 
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3.4.6 Recovery and release analysis 
The majority of animals (n = 21; 62%) in the “eye” admission group and approximately 
half of the animals (25 cases; 46%) in the “wet” group were released following treatment. 
The non-released group mainly consisted of animals that were euthanased (27 animals, 
50% “wet” admissions; 8 animals, 23.5% “eye” admissions). Deaths were infrequent (2 
cases, 6% “eye” admissions; 1 animal, 2% “wet” admissions). Two animals (5.8% of “eye” 
cases) were “transferred” and therefore lost to further study. The outcome for one case 
from each group (3% “eye” admissions, 2% “wet” admissions) could not be determined 
from the medical records.  
Using logistic regression modeling, few factors were identified that were predictive of 
release. Animals that received ancillary treatments were more likely to be released than 
those that did not, although 95% confidence intervals were wide (Table 3-5). Young adults 
and mature adults were more likely to be released than aged animals (p = 0.003), although 
95% confidence intervals were also very wide (Table 3-5). Animals that not released (i.e. 
euthanased or died) had significantly fewer days in care (median 11, range 1 - 236 days; 
Mann Whitney test, p = 0.02) than animals that were released (median 19, range 1 - 393 
days). 
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Table 3-5. Summary of significant odds ratio (OR) and 95% confidence intervals (CI) for 
explanatory variables calculated using univariable binomial logistic regression predicting 
risk of whether animals were released or not released. 
 
Explanatory variable  Odds ratio (95% CI) p 
Age class Juvenile 7.6 (0.29 - 200.9) 0.003 
 Young 14.62 (2.68 - 79.7) 
 Mature 10.59 (1.96 - 57.3) 
 Aged 1 
    
Ancillary treatments No 1  
 Yes 3.2 (1.23 - 8.3) 0.014 
Reference groups were “aged” and “no ancillary treatment”. Age classified according to tooth wear class 
(TWC) (Martin, 1981) where Juvenile: TWC I - II; Young: TWC III; Mature: TWC IV; Aged: TWC V - VII. 
 
Among animals that were released, 43% of animals that had been admitted as “eye” and 
58% of animals admitted as “wet” re-presented at least once before March 1st 2007. The 
median (range) number of days between release and re-presentation were not significantly 
different between “eye” and “wet “groups (656.5 (225 - 1939) days; 241 (16 - 1536) days, 
respectively; Mann Whitney test, p = 0.15). None of the animals originally admitted in the 
“eye” category re-presented with eye disease, but one re-presented with wet bottom 
(Figure 3-5), and one had ovarian bursal cysts diagnosed at post mortem examination after 
re-presenting as debilitated. Of the “wet” animals released, the majority (9 animals; 64%) 
re-presented with clinical signs of “wet bottom” (7 animals; 50%) or eye disease (2 
animals; 14%) and one, which re-presented as a trauma case, had ovarian bursal cysts at 
post mortem examination (Figure 3-5). In the 14 re-presenting females (4 originally “eye” 
cases; 10 originally “wet” cases) evidence of breeding was uncommon: one animal 
originally presenting as “wet” re-presented with pouch young 23 days after release, and 
one originally treated for eye disease re-presented with pouch young 393 days after release. 
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Both those with joeys presented in winter. Other females re-presented in summer (5 
animals, 36%), autumn (2 animals, 14%), winter (3 animals, 21%), or spring (2 animals, 
14%).  
 
 
Figure 3-5. Reasons animals were readmitted post-release.  
Eye: clinical signs of eye disease; wet: clinical signs associated with urogenital chlamydiosis; trauma: motor 
vehicle accident, dog attack; other: includes dangerous area (n = 2), debilitated (n = 2), lymphosarcoma (n = 
1), unknown (n = 2). 
 
3.5 DISCUSSION 
This study found diagnosis of chlamydiosis and treatment decisions at the Koala Hospital 
depended mostly on clinical signs rather than diagnostic tests. Most animals were treated 
from a small number of drug choices for a median period of two weeks, and systemic 
drugs were usually administered orally. Ancillary supportive treatments were common. 
Few prognostic indicators for successful release were identified. Released animals 
frequently re-presented after extended time in the wild, indicating successful survival of 
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many animals; however, the majority of the “wet” animals released re-presented with 
similar clinical signs, suggesting either re-infection or continuation of infection. In 
contrast, all those that presented initially with eye infection did not re-present with clinical 
signs of eye disease, suggesting that treatment had been effective.  
From this study it is evident that many clinical decisions at the Koala Hospital are based on 
clinical signs alone. Diagnostic testing and treatment were aimed at the anatomical site 
with clinical signs: animals with clinical eye disease had eye swabs tested and topical eye 
treatments; animals with clinical urogenital tract disease had urogenital tract swabs tested, 
ultrasonography and systemic enrofloxacin treatment. In particular, little confidence was 
evident in sensitivity of swabbing in detecting chlamydiosis: many animals were not tested 
using the ELISA; types of treatment given to animals with a negative swab result mostly 
did not differ from other groups, and repeat swabbing to monitor clinical response was 
rarely performed. This emphasis on clinical signs dictating diagnostics and mode of 
treatment does not take into account the possibility of subclinical disease in koalas or the 
possibility of non-chlamydial disease with similar clinical signs. Multiple studies have 
confirmed the high prevalence of subclinical disease in different koala populations (Brown, 
Carrick et al., 1984; Mitchell, Bilney et al., 1988; Weigler, Girjes et al., 1988; White & 
Timms, 1994; Jackson, White et al., 1999; McLean, 2003), although this is yet to be 
quantified in the clinical setting. Reliance on diagnostic tests aimed only at external 
clinical signs will miss both subclinical infections and infertile animals with structural, 
inactive disease and will misdiagnose unrelated conditions with similar clinical signs. This 
approach to diagnosis and treatment reflects the lack of sensitive, simple and reasonably 
priced diagnostic tools, a lack of evidence base for treatments and lack of information 
regarding the prevalence of systemic rather than local infections in koalas. There may be a 
tendency for lay carers to treat obvious clinical problems, rather than undertaking or 
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requesting more involved diagnostic tests or treatments, particularly when such tests may 
be perceived as poorly sensitive and specific, finances are limiting, results of diagnostic 
tests may preclude release, or use of other treatments may extend time in captivity. The 
development of a cheap, practical, point-of-care test is urgently required for diagnosis and 
monitoring of treatment of chlamydiosis in koalas, a similar situation to that of diagnostics 
for trachoma in people in the developing world (Mahilum-Tapay, Laitila et al., 2007). 
Such tests are not widely available or have not been widely evaluated for diagnosis of 
chlamydiosis in koalas. This finding prompted the formulation of a study examining the 
sensitivity and specificity of clinical signs as a diagnostic test in detecting chlamydiosis in 
koalas presenting to the Koala Hospital (Chapter 8). The results of this latter study would 
be useful to better inform carers making decisions regarding likely diagnosis; and better 
inform animal management, including decisions regarding isolation of animals, 
replacement of cage furniture, choice of treatment modalities and decisions regarding end 
point of treatment.  
The most frequent recorded route of systemic medication was the oral route. This route is 
commonly used in koalas given their relatively placid nature (Blanshard, 1994). 
Pharmacokinetics of orally administered medications in koalas might be expected to be 
unusual, as hepatic metabolism of bromosulphalein is increased in comparison to other 
species, such as sheep and macropods (Pass & Brown, 1990), and small intestinal transit 
time is short (particulate matter: 6 minutes; soluble material: 60 minutes) (Cork & Warner, 
1983). Investigations of pharmacokinetics of antibiotics in marsupial species are limited 
(Clark, Milton et al., 1982; Kirkwood, Gulland et al., 1988; McLelland, Rich et al., 2009), 
and study of this area in koalas is warranted as the barriers to gastrointestinal absorption in 
this species may be profound. This background motivated the formulation of a study 
examining fluoroquinolones given by parenteral and oral routes (Chapter 7).  
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In the current study, the mainstay of treatment for conjunctivitis was oxytetracycline/ 
polymyxin B eye ointment, usually for two weeks. There is little data regarding the success 
of topical therapy in koalas (Cockram & Jackson, 1976; Markey, Wan et al., 2007) despite 
its wide use (Blanshard, 1994; Connolly, 1999; Blanshard & Bodley, 2008). Typical 
courses of topical oxytetracycline/ polymyxin B in this study were not consistent with the 
length of courses of topical medications recommended in other species to treat conjunctival 
chlamydiosis (6 weeks in people, 1 - 2 weeks past clinical cure in cats) (Francis & Turner, 
1993; Glaze & Gellat, 1999) and such short courses might be expected to lead to treatment 
failure. Similarly, the use of enrofloxacin for two weeks to treat urogenital chlamydiosis 
(“wet bottom”) might be expected to be unsuccessful. Third generation fluoroquinolones 
have been used to treat chlamydial disease in people (Ridgway, 1997), although studies 
using veterinary fluoroquinolones to treat chlamydiosis are few, and have conflicting 
reports of success (Lindenstruth & Frost, 1993; Bodetti, Johnston et al., 2002; Penguin 
Taxon Advisory Group, 2005; Gerhardt, Schulz et al., 2006; Hartmann, Helps et al., 2008). 
One study found that koalas treated with enrofloxacin for up to 6 months were still positive 
for chlamydial organisms by PCR, suggesting treatment failure (Bodetti, Johnston et al., 
2002). Despite these treatments being theoretically unsatisfactory, the majority of koalas 
treated for eye disease and approximately half of koalas treated for wet bottom were 
released. Further animals with eye disease did not tend to re-present with eye disease, 
suggesting successful resolution. The apparent success of fluoroquinolone treatment of 
chlamydiosis in koalas evident in the current study conflicts with the equivocal results or 
treatment failure in other species (Lindenstruth & Frost, 1993; Ridgway, 1997; Bodetti, 
Johnston et al., 2002; Penguin Taxon Advisory Group, 2005; Gerhardt, Schulz et al., 2006; 
Hartmann, Helps et al., 2008) and this apparent contradiction provided the background for 
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further work in this dissertation: a study examining the response of animals presenting with 
chlamydiosis to treatment with fluoroquinolones (Chapter 7 and Chapter 8).  
At least 50% of released animals survived for quite extended periods in the wild, a finding 
in agreement with other studies in koalas (Starr, 1990; Carrick, Beutal et al., 1996; 
Lunney, Gresser et al., 2004) but in contrast to the poor success of rehabilitation efforts in 
many other species (Craven, 1982; Robertson & Harris, 1995; Anderson, Gress et al., 
1996; Fajardo, Babiloni et al., 2000; Goldsworthy, Giese et al., 2000; Ben-David, Blundell 
et al., 2002; Beringer, Mabry et al., 2004). It appears koalas may be particularly suitable 
for rehabilitation and thus effort in improving techniques is warranted. 
The use of medical records proved useful in confirming the survival of at least half of 
animals released. The conclusions drawn from this type of study are heavily dependent on 
whether animals are likely to re-present. The high frequency of re-presentations in this 
study, possibly due to a high likelihood of reporting of diseased or displaced koalas by the 
public, suggest further investigation of the success rates of rehabilitation in koalas using 
this technique is justified within the Port Macquarie population. It would be particularly 
interesting to use the records to assess the survival and evidence of breeding for the 
different admission cohorts (Chapter 2) of animals admitted to the Koala Hospital. 
Statistical modelling using these data might be used as a passive “mark-release-recapture” 
method to determine the relative survival of rehabilitated animals originally presenting for 
different reasons, providing the underlying assumptions of equal capture probability, 
independent capture and retention of identification marks discussed by Borchers et al. 
(2002) can be satisfied. This type of study suggests that permanently identifying released 
animals and accurate record keeping can be valuable tools for assessing success rates of 
rehabilitation.  
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An interesting observation was that animals originally treated for eye disease did not 
commonly re-present with chlamydiosis, in contrast to those originally treated for wet 
bottom. It is impossible to determine from the current study whether chlamydial infection 
at re-presentation was due to recurrence of the original infection due to treatment failure, 
re-infection, or a damaging and self-perpetuating host immune response leading to overt 
clinical signs. Ocular chlamydiosis may be self-limiting in koalas (Kempster, Hall et al., 
1996) and self-resolution may explain the apparent successful treatment of these animals 
with theoretically inadequate treatments. Animals with urogenital tract infections 
frequently have concurrent urogenital structural disease (McLean, 2003; Higgins, Hemsley 
et al., 2005b). Such animals may appear to improve initially, but relapse later due to 
damage sustained in initial episodes of disease predisposing animals to subsequent 
infections (chlamydial or secondary bacterial infections), resulting in recurrence of clinical 
signs. This hypothesis might explain the suspected poor breeding success of females and 
recurrence of urogenital tract disease in “wet” cases described in this study. It appears that 
the prognosis for animals treated for eye disease is better than that for animals treated for 
urogenital disease, although both groups may survive for quite extended periods post-
treatment.  
From a population perspective, perhaps the most important determinant of rehabilitation 
success is whether animals retain their fertility (Sigg, Goldizen et al., 2005). Chlamydiosis 
in koalas can cause occlusive fibrosis of the upper reproductive tract, which may be 
difficult to diagnose ante-mortem (Higgins, Hemsley et al., 2005a) and associated 
structural changes are highly correlated with poor fertility (Brown, Carrick et al., 1984; 
McLean, 2003). The potential fertility of animals at the point of release in this study was 
unknown. The fertility rate of re-admitted females was low (14.2%), although sample size 
was small (n = 14). Females that re-presented did so throughout the year, encompassing the 
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seasons in which accompanying young might be expected in animals of normal fertility 
(pouch young in summer and autumn, back young in winter and spring) (Martin & 
Handasyde, 1999). Studies of a small number of wild caught female koalas (n = 14) from 
bush habitat adjacent to Port Macquarie suburbs estimate fertility of approximately 43% in 
Port Macquarie koalas (Biolink, 2005; Biolink, 2008), which is similar to populations at 
Oakey and Mutdapilly in south-east Queensland (Gordon, McGreevy et al., 1990; White & 
Timms, 1994). Unfortunately, these small sample sizes limit certainty of any conclusions 
as to the fertility of released females treated for chlamydiosis in comparison with the wild 
population. Should released females have extremely poor fertility, they may contribute 
little to the wild population. In addition, if these animals remain persistently infected with 
Chlamydiaceae they may undergo multiple infertile matings per season, increasing 
potential for transmission. Such animals may be detrimental to the local population, 
although their impact would depend on prevalence rates of chlamydiosis in the wild. 
Further studies, with a focus on whether these animals have successfully cleared 
chlamydial infections or are released still infected, and their impact on wild populations are 
vital to assess whether treatment of these animals is worthwhile. Prospective treatment 
trials examining systemic fluoroquinolone therapies (Chapter 7 and Chapter 8), a larger 
case controlled retrospective study using the records of the Koala Hospital, or a 
prospective radio-tracking study would be extremely useful in determining the prognosis 
and fertility of treated animals. An assessment of wild populations by a capture, test and 
release study as a comparison would be extremely useful.  
Nutritional supplementation, probiotics and nursing care were commonly employed to treat 
chlamydial disease between 1995 and 2005 at the Koala Hospital. That the use of ancillary 
treatments was associated with increased probability of release is worthy of further 
investigation, although 95% confidence intervals were very wide. Most ancillary 
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treatments were generally supportive, rather than those associated with specific efficacy 
against chlamydiosis in other species. It is possible that some factors within the ancillary 
treatments are associated with treatment success, or that those animals more likely to be 
released for other reasons were more likely to receive such treatments (for example, longer 
times spent in care might increase probability of receiving ancillary treatments). A 
prospective study or a larger retrospective study examining this association would be 
useful in clarifying the role of these treatments.  
There was a tendency for animals in the “wet” group to receive non-prescription remedies, 
normally associated with cystitis or vaginal candidiasis treatment in women. Such 
treatments have no known role in treating chlamydiosis in people and this highlights the 
need for evidence-based veterinary input to treatment regimes. Although supportive care 
may be an important part of treatment of a wild animal, such treatments should only be 
administered where benefit is likely. All ancillary treatments have the potential to do harm 
as administration will usually require extra handling of a wild animal and little data exist as 
to whether such treatments can be safely used. In such cases the employment of the maxim 
“first, do no harm” should be foremost. A close and trusting relationship between 
veterinarian and carer is important, so that open discussion as to the use and potential 
benefit or harm of such treatments is possible. The more unconventional ancillary 
treatments (probiotics, home remedies for vaginal candidiasis and cystitis in women, 
sedatives) have been phased out since 2000, when the current supervisor began working at 
the Koala Hospital (C. Flanagan, pers. comm.)
4
. 
This study found few factors predicting whether an animal was likely to be released or not. 
The finding that aged unwell animals are less likely to be released from the Koala Hospital 
                                                 
4
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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than younger animals fits with the Koala Hospital policy where aged animals are regarded 
as having a poorer prognosis for survival after release (C. Flanagan, pers. comm.)
5
. As 
95% confidence intervals were wide, a larger sample size is required to confirm this 
finding.  
Interestingly, morphometrics, in particular ratios between weight and crown rump length, 
or head length (size mass indices) (McLean, 2003), were not predictive of prognosis for 
release. Thus, other than age, a prognostic indicator based on physical condition of koalas 
at presentation was not identified. Such factors would be extremely useful in allowing 
efficient use of resources. A larger sample size may be required to identify such factors. 
Body condition score using scapular muscle mass (Connolly, 1999) was not analysed in 
this study, but may be a better prognostic indicator for release than those examined here.  
In conclusion, this study identified common diagnostic methods and treatments employed 
at a major koala hospital. Decisions were often based on clinical signs alone and many 
medical treatments were given orally. Apparent treatment success was evident with 
approximately 50% of animals being released and many survived in the wild for extended 
periods. In particular, animals treated for eye disease did not often re-present with this 
problem, suggesting animals were cured of, or fully recovered from, clinical ocular 
chlamydiosis. In contrast, animals treated for wet bottom had high re-presentation rates 
with the same clinical signs, suggesting treatment failure or susceptibility to re-infection. 
This work provided the basis for a prospective clinical trial examining the validity of using 
clinical signs to diagnose and assess response to treatment, the pharmacokinetics of 
fluoroquinolones administered by different routes, and the response of animals to treatment 
using these drugs (Chapter 8). 
                                                 
5
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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CHAPTER 4 - GENERAL METHODS FOR CLINICAL 
STUDIES 
4.1 INTRODUCTION 
This chapter describes the animal husbandry and diagnostic methods common to the 
clinical studies described in Chapter 5 to Chapter 8, and their associated challenges and 
limitations. The development of these methods was a learning process, as there are few 
large scale published studies of the treatment of disease in Australian wildlife. Such trials 
are difficult to undertake due to expense, access to animals and the public perception of 
research involving iconic species. Recruitment of animals often relies on opportunistic 
treatment of naturally occurring disease, which limits numbers. Methods of medication and 
sampling usually need to be adapted to the species under investigation. Specialised 
facilities to house wild animals may only be available in wildlife hospitals, allowing study 
of animals within the facilities and circumstances in which future treatment is likely to be 
undertaken, but necessitating adaption of scientific work within the framework and 
infrastructure of these institutions. Further, working within a volunteer based organisation 
offers unique challenges in communicating the scientific method to lay people.  
4.2 RECRUITMENT TO THE STUDY 
Koalas were recruited to this study opportunistically. As per normal operating procedures, 
members of the public reported sick, injured or displaced koalas located in dangerous 
areas, to the Koala Hospital, Port Macquarie, NSW for assessment in situ by volunteers 
from the Koala Preservation Society of NSW. If deemed necessary, for example due to 
clinical signs of disease, proximity to hazards such as dogs or main roads, or abnormal 
behaviour, volunteers retrieved koalas. Flags or plastic bags attached to extendable (up to 4 
m long) poles with slightly hooked ends were placed above the koalas‟ heads and agitated 
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to encourage koalas to descend the tree to a point where they were retrieved into large 
canvas holding bags (Blanshard, 1994). 
On presentation, the animal was assessed by the supervisor of the Koala Hospital. In cases 
where there was external evidence suggestive of chlamydial disease (conjunctivitis, 
keratitis, ocular discharge; and/or malodour, dampness and staining of the rump), animals 
were forwarded to investigators for assessment for entry into the clinical trial. From early 
2006 (approximately half way through the first of three field seasons), healthy animals 
without evidence of clinical chlamydiosis were screened for chlamydial DNA collected 
from ocular and/or urogenital swabs by PCR (see 4.11). Animals were assessed within 12 - 
24 hours of being brought into the hospital. 
4.2.1 Anaesthesia 
To facilitate thorough assessment, koalas were anaesthetised. Following pre-oxygenation, 
general anaesthesia was induced by mask and a Bain paediatric circuit using a C.I.G 
Midget 3 anaesthetic machine (VetQuip, Castle Hill, NSW, Australia) by gradually 
increasing the percentage of isofluorane in oxygen from 0 to 3.5% over 5 min. Anaesthesia 
was maintained with 1.5 - 2% isofluorane and 1 - 2 litres per minute 100% oxygen 
delivered via mask. Animals were recovered on mask oxygen and when righting reflex was 
re-established, they were transferred to recovery cages. 
During anaesthesia, apnoea was encountered occasionally and resolved by administration 
of positive pressure ventilation by mouth using the reservoir bag, stimulation of breathing 
by toe pinch or extending both forearms laterally. Cardiac arrhythmias were encountered 
infrequently and assessed by auscultation only. Where arrythmias were encountered, 
isofluorane concentration was decreased, the procedure shortened and subsequent 
anaesthetic procedures performed only when deemed essential.  
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4.2.2 Clinical examination 
Animals underwent a full clinical examination (Blanshard, 1994) whilst anaesthetised at 
presentation to assess animals for inclusion in the study. Briefly, this examination included 
aging by tooth wear class (Martin, 1981); weighing on scales (TI 1583, Wedderburn, 
Summer Hill, NSW, Australia or 235-6S, Salter Brecknel, Fairmont, Minnesota, USA); 
thoracic auscultation; palpation of lymph nodes; examination of the oral cavity; body 
condition scoring by palpation of infraspinatus, supraspinatus and frontalis muscles 
(Connolly, 1999); examination of the pouch for reproductive status and presence/ absence 
of young; abdominal palpation including assessment of gut fill, hydration status 
(Blanshard, 1994); assessment and subjective grading of ocular abnormalities (discharge, 
conjunctival proliferation, chemosis); scoring of wet bottom (see 4.7 and Table 4-1); 
ultrasound examination (see 4.8); collection of blood for full biochemistry and 
haematology profiles (see 4.10) and collection of swabs from the conjunctivae and 
urogenital sinus (females) or penile urethra (males) for chlamydial DNA PCR (see 4.11.5). 
4.2.3 Exclusion of animals 
Past studies of chlamydiosis in koalas have suggested that overt expression of 
chlamydiosis may be more common in koalas debilitated through concomitant disease 
(Canfield, Love et al., 1991a) or subjected to environmental stressors (Weigler, Girjes et 
al., 1988). Animals were carefully examined for simultaneous disease and excluded if it 
was detected under the supposition that intercurrent disease could interfere with the 
outcomes of the investigation, or in the case of hepatic or renal disease, interfere with drug 
metabolism, and for welfare reasons. 
Koalas were excluded under any of the following criteria: wet bottom score of four or 
more (Flanagan, 2009), healthy animals in which chlamydial DNA (by PCR see 4.11) or 
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antigen (by Clearview Chlamydia MF ELISA (Inverness Medical Australia, Sinnamon 
Park, Qld, Australia)) was not detected, presence of other disease, structural renal 
pathology detected by ultrasound examination, condition score of two or less, or where 
weight loss over a three day premedication observation period exceeded 250 grams for 
females and 300 grams for males. Mothers with joeys were excluded to minimise the stress 
on joeys. 
4.3 ALLOCATION TO TREATMENT GROUPS 
Following recruitment, koalas were allowed to acclimatise for 3 - 7 days, during which 
they were assessed 1 - 2 times daily to determine whether oral medication could be used, 
by attempted administration of 50 mL oral supplement twice daily (Di-vetelact® Low 
Lactose Milk Powder, Sharpe Laboratories, Ermington, NSW, Australia, 9 g; or Karicare® 
Soya All Aged Formula, Nutricia, North Ryde, NSW, Australia, 7.1 g; or Infasoy® 
Progress Step 2, Wyeth Australia, Baulkham Hills, NSW, Australia, 8.9 g; each in 50 mL 
water).  
If animals were amenable to oral medications they were randomly assigned to one of 
several oral medication groups and supplementation continued twice daily. Animals 
strongly resistant to oral supplementation (exhibiting flinching, ear flicking, vocalisation, 
aggression and/or retreating) were randomly assigned to one of several subcutaneous or 
intramuscular injectable groups and supplement ceased or was substituted with 1.5 cm 
Nutrigel® (Troy Laboratories, Glendenning, NSW, Australia) administered orally twice 
daily. Nutrigel® is a sticky paste and easier to administer to resistant animals; it can be 
quickly placed in the mouth leaving the animal to masticate it without further intervention. 
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4.4 MEDICATION 
When medications were administered subcutaneously, koalas were injected over the dorsal 
thorax (the “scruff”), a standard area for injecting domestic species; or laterally, dorsal to 
the axilla, as skin is loose in this area. Intramuscular injections were into the dorsal 
quadriceps under general anaesthesia. Where possible, injection sites were alternated 
between left and right sides. Oral suspensions were administered by syringe. Tablets were 
crushed using a pill crusher and suspended in soya or low lactose formula. Eye ointments 
were administered using standard technique, (i.e. a small amount of ointment was applied 
to the conjunctiva and massaged using the palpebrae to aid spread throughout the 
conjunctival sac). 
4.5 HUSBANDRY 
Koalas were kept according to standard methods (Blanshard, 1994). Briefly, koalas were 
housed individually for the first three weeks in solid-walled indoor enclosures 
approximately 2.0 x 2.5 x 2.5 m with a wire-netted observation and ventilation window 
and perches of Eucalyptus microcorys (Figure 4-1, Figure 4-2). Branches of at least three 
different species of forage trees (Eucalyptus robusta, E. microcorys, E. tereticornis, E. 
nicholii, E. macrorhyncha, Melaleuca quinquenervia or Corymbia maculata), collected by 
professional leaf cutters from the streets and surrounds of Port Macquarie, a small tray of 
soil and a trough of water were offered fresh daily. Newspaper lining the floor of the 
indoor units was changed once daily and the floors mopped with dilute bleach. Between 
cases, perches were changed completely, walls and cage furniture disinfected with dilute 
bleach and the enclosure rested. Cage furniture and cleaning apparatus were dedicated to 
each unit. After three weeks, animals were usually transferred to individual outdoor pens 
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of 3.0 x 4.0 m fenced to a height of 1.5 m with similar perches (Figure 4-3). Outdoor pens 
were raked daily and faeces removed, and leaf and water refreshed as above. 
4.6 OBSERVATIONS 
In the first field season, appetite was monitored subjectively. In subsequent field seasons, 
appetite was scored daily: the amount of leaf eaten was scored from 0 (no evidence of 
provided leaf eaten) to 3 (most provided leaf eaten) (Figure 4-1). The species of leaf 
preferred was recorded. The animal‟s demeanour was assessed as dull, depressed, quiet, or 
bright, alert and responsive. The rump of the animal was inspected daily. The presence and 
character of urine and urination were recorded. Faeces were observed daily and the 
character recorded. In the first field season, all faeces over a 24 hour period were collected 
and weighed daily for the first two weeks of treatment. In subsequent field seasons, total 
volume of faeces was recorded on a scale from 0 (no faeces observed) to 3 (many faecal 
pellets observed) (Figure 4-2) and, as it appeared that pellet size was an important variable, 
10 random faeces were collected, placed side-by-side along the plane of their longest and 
shortest axes and the total length and width of 10 faecal pellets recorded. Twice weekly, 
animals were weighed and the condition score was monitored. Animals were examined 
under anaesthesia as per 4.2.2 on the day before treatment commenced (day 0), weekly 
during treatment and every two weeks after treatment had finished.
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a) b) 
  
c) d) 
Figure 4-1. Grading of the amount of leaf eaten by koalas. 
a) Grade 0: No evidence of leaf eaten 
b) Grade 1: Evidence of small amount of leaf eaten; few stalks 
c) Grade 2: Moderate amounts of leaf eaten; many stalks present 
d) Grade 3: Evidence of much leaf eaten; many to most stalks denuded of leaf 
Photographs illustrate indoor enclosures. 
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a) 
 
b) 
 
c) 
 
Figure 4-2. Grading of the koala faecal output in indoor enclosures. 
Grade 0: No faeces present (not shown) 
a) Grade 1: Few faecal pellets present; approximately 10 - 20 pellets total per enclosure 
b) Grade 2: Moderate faecal pellets present; approximately 20 - 80 pellets total per enclosure 
c) Grade 3: Many faecal pellets present; 80+ pellets total per enclosure 
Photographs illustrate indoor enclosures. 
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Figure 4-3. Outdoor yards where koalas were held after the first two weeks of treatment.
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4.7 WET BOTTOM SCORE 
Koalas were graded at admission, then weekly throughout treatment according to a wet 
bottom score developed by staff of the Koala Hospital (Flanagan, 2009) and modified to 
include the category 0 and 0.5 (Table 4-1). 
Table 4-1. Koala wet bottom score modified from Flanagan (2009). 
Grade Description 
0 Normal fur, normal cloaca 
 
0.5 Discolouration of fur around cloaca 
 
1 Slight discolouration of fur around cloaca 
Evidence of mild fresh urine leakage 
Slight “wet bottom” smell 
 
2 Slight discolouration of fur around cloaca/tail area 
Occasional urine dribbles 
Mild yet discernible “wet bottom” smell 
 
3 Discolouration of tail area fur more evident 
Stronger “wet bottom” smell 
Urine discharge, greasy texture evident around cloaca/tail area 
 
4 Fur stained, greasy, darkened 
Strong pungent “wet bottom” smell 
Inflammation of the cloacal margins, clitoris, vestibule 
Discharge containing urinary calculus/debris 
 
5 Stained greasy fur covering a large area 
Very strong pungent acidic smell 
Blood in urine, crying and straining when urinating 
Clots, blood in both male and female urine and urogenital tracks 
Coat brown dry and lustreless 
Cloaca and tail area swollen (oedema) 
Grinding teeth 
 
6 Stained, greasy, wet matted fur around rump/cloaca area 
Blood in urine, clots, and constant purulent discharge 
Crying, straining, grinding teeth, distressed, flat, ear flicking 
Ulcerated, oedematous cloaca/tail area 
 
7 - 10 Progressive decline 
Often becomes maggot infested 
Death ultimately results if intervention/removal of suffering does not occur 
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4.8 ULTRASOUND EXAMINATION 
Anaesthetised animals were placed in dorsal recumbency. A small amount of fur 
(approximately 2 cm x 5 cm) was clipped over the left and right cranial abdomen, in areas 
corresponding with the kidneys, and, in males, a similar amount of fur removed from the 
caudal abdomen in the area over the bladder. In females, the unhaired region of the pouch 
was used to visualise this area. The skin was cleansed with 70% ethanol and ultrasound 
coupling gel was applied. 
B-mode grey-scale ultrasonography was performed using an ultrasound machine (Toshiba 
ECCOCEE SSA-340A, Toshiba Medical, North Ryde, NSW, Australia) with a convex 
3.75 MHz, 76 mm convex probe (PVF-375MT) for the kidneys and 6.5 MHz, 11 mm 
endo-vaginal probe (PVF-621VT) for the bladder and reproductive organs. Images of each 
organ were captured using a digital capture device (ADS Video Xpress, ADS tech, Walnut, 
California, USA) and Ulead Movie Wizard software (Ulead Systems, Torrance, California, 
USA). 
Ultrasound examination followed previously reported methods in the koala (Mathews, 
Wolff et al., 1995; Stalder, 2003). Briefly, the endo-vaginal probe was placed in the 
midline between epipubic bones (within the pouch in females) and the bladder located on 
the midline, recognisable by its distinct round to triangular to ovoid shape, thin walls and 
anechoic lumen. Bladder wall and lumen measurements were taken from the vertical, 
horizontal and two diagonal axes of a captured image (Figure 4-4). The shape of the 
bladder and abnormalities of the bladder wall or echolucent material present in the lumen 
of the bladder were described.
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Figure 4-4. Example of a digitally captured sonogram of the bladder. 
Showing measurements of the bladder wall and lumen (left). Stylised version demonstrating measurements 
(right). VW: vertical width (1 & 2); TW: transverse width (1 & 2); LDW: left diagonal width (1 & 2); RDW: 
right diagonal width (1 & 2); VL: vertical lumen; TL: transverse lumen; LDL: left diagonal lumen; RDL: 
right diagonal lumen. 
 
In females, left and right uteri were located on the midline and described in terms of their 
size, shape and position where possible. The wall thickness and lumen was measured. The 
transducer was then placed laterodorsally to the epipubic bones and moved cranially on left 
and right sides, respectively. Abnormalities of the reproductive tract, such as echolucent 
masses, were described in terms of size and the presence of multiple chambers. Ovaries 
were not detected in this study, a similar finding to that of past researchers (Stalder, 2003). 
As only a limited number of ultrasound probes were available for use during this work, it is 
possible that such structures might be detected with alternative probes. 
Left and right kidneys were imaged using the convex probe placed on the ventral body 
wall just caudal to the last rib and 2 - 3 cm lateral from the midline. The sagittal and 
transverse planes were examined and described for size, shape and relative echogenicities 
within the kidney. Measurements were obtained from the cranial to caudal pole of the 
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sagittal plane when it was maximal in size (sagittal length) ("a" in Figure 4-5). The 
transducer was rotated 90 degrees and maximum measurements were obtained from the 
hilus to the most lateral aspect (horizontal width) and from the dorsal to ventral surface of 
the kidney (D-V width) at the hilus (“b” in Figure 4-5).  
 
a) 
 
b) 
 
Figure 4-5. Examples of digitally captured sonograms of the left kidney.  
Showing measurements a) sagittal length; b) D-V width, horizontal width. 
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4.9 GRADING OF THE EYES 
Animals (n = 22) were anaesthetised weekly as per 4.2.1. The eyes were examined without 
opening of the eyelids, and then again with gentle traction of the palpebrae dorsally and 
ventrally by the investigator‟s fingers to visualise ocular pathology. Photographs of the 
right and left eyes were taken before and during palpebral traction. Each eye was graded as 
0 (normal), 1 (mild), 2 (moderate) or 3 (severe) for chemosis, proliferation of the 
conjunctiva, and amount of discharge. Scores were summed to give a total eye score. 
Corneal opacity, lens opacity, pallor of conjunctiva, nature of discharge, blepharospasm 
and corneal vascularity were described. 
4.10 CLINICAL PATHOLOGY 
Haematological and biochemical analyses of blood and urinalysis were performed prior to 
commencing treatment, weekly during treatment and at least fortnightly post-treatment.  
Blood (0.5 mL), collected into potassium EDTA from the cephalic vein using a 22 g 
butterfly catheter and 3 mL syringe, was subjected to haematological analysis for: 
haematocrit, haemoglobin concentration, erythrocyte count, nucleated erythrocyte count, 
erythrocyte indices (mean corpuscular volume, mean corpuscular haemoglobin, mean 
corpuscular haemoglobin concentration), total leukocyte count, leukocyte differential 
counts (neutrophils, lymphocytes, monocytes, eosinophils and basophils) and platelet count 
using standard methods (Symbion Vetnostics, North Ryde, NSW, Australia). Blood (1.5 
mL) was collected similarly into plain tubes, centrifuged and serum assayed for 
concentrations of sodium, potassium, chloride, urea, creatinine, glucose, total bilirubin, 
albumin, globulin, calcium, phosphate, cholesterol, triglycerides and the activity of: 
aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, 
alkaline phosphatise and creatinine kinase, with a Roche Modular Chemistry Analyser 
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using Roche reagents (Roche, Basel, Switzerland) and standard methods by the same 
laboratory.  
Urine was expressed manually from the bladder, and urinalysis performed (Bayer-
Multistix®, Bayer Australia, Pymble, NSW, Australia). Urine specific gravity was 
determined using a refractometer and methylene blue stained sediment was examined 
under light microscopy.  
4.11 FIELD PCR 
Initially, diagnosis of chlamydiosis was made using the Clearview Chlamydia MF enzyme-
linked immunosorbent assay (ELISA) (Inverness Medical Australia, Sinnamon Park, Qld, 
Australia). Poor sensitivity of this assay (described in 5.3.1) prompted the author to 
investigate the use of nucleic acid amplification tests such as PCR, which is regarded as 
more sensitive than other diagnostic tests for chlamydiosis in other species (Ostergaard, 
Birkelund et al., 1990; Sykes, Studdert et al., 1999; Amin, 2003) and is the diagnostic test 
of choice for chlamydial infections in people (Harindra, Underhill et al., 2003). With the 
advent of non-toxic nucleic acid dyes for visualisation of DNA in agarose gels after 
electrophoresis (Williams, 2001; Invitrogen, 2007), a field site laboratory incorporating 
PCR became feasible. The PCR method utilised Chlamydiaceae specific primers  
(5‟ -ATGCAAAATTACTGTATGGGTAAA- 3‟ and 5‟- CTGTAGAGTTTTCTGTTACCTTGAAAG- 3‟) 
designed to amplify a 1030 bp fragment of the outer membrane protein B gene (Demkin & 
Zimin, 2005). Demkin and Zimin (2005) reported this gene as highly specific for 
Chlamydiaceae. Thus the primers used amplified both C. pecorum, C. pneumoniae, and 
any other novel pathogenic Chlamydiaceae, but not phylogenic neighbours of 
Chlamydiaceae such as Simkania negevensis. This section describes optimisation of the 
field PCR and the final method used. 
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4.11.1 Reduction of contamination risk 
To reduce contamination, the following procedures were adhered to: certified DNA-ase 
and RNA-ase free, filtered pipette tips, mixing vials and PCR tubes were autoclaved (120 
ºC for 20 minutes) before use, and bench tops and pipettes were wiped with 70% ethanol 
before and after use. DNA extraction, reaction set-up and post-PCR procedures were each 
performed in separate rooms in a facility separate from the Koala Hospital using dedicated 
equipment. Post-PCR product never entered the clean room. After processing, PCR 
product was discarded and waste products and waste consumables in contact with PCR 
product were discarded. 
4.11.2 Optimising the PCR  
The PCR reaction was optimised by increasing the time from the published method 
allowed for each reaction step, applying a gradient for the annealing step with temperatures 
of 45 - 55 ºC and performing a magnesium titration from 1.5 - 5 mM MgCl2. The final 
reaction conditions chosen were those that delivered the brightest band of the appropriate 
length without non-specific bands. 
4.11.3 Sensitivity of the PCR 
An experiment to detect the limit of the reaction was performed using C. pneumoniae 
DNA template from culture, diluted 1:100, 1:10,000, 1:20,000, 1:40,000 1:80.000, 
1:160,000. The amount of DNA in the sample was unknown, meaning that this experiment 
was a subjective measure of the sensitivity of the assay. Strong bands were visible at each 
dilution until 1:40,000 and just visualised at 1:80,000. A clinical animal was included in 
this experiment and yielded a strong positive band equivalent in brightness to the C. 
pneumoniae culture dilutions of between 1:100 and 1:10,000. 
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4.11.4 Specificity of the PCR 
Primers were tested against DNA extracted using a commercial kit (QIAamp® DNA Mini 
Kit, QIAGEN Pty Ltd, Doncaster, Vic, Australia) according to manufacturer‟s instructions 
from seven species of bacteria (Staphylococcus aureus (Veterinary Pathology and 
Bacteriology Culture Collection (VPB) 236), Staphylococcus epidermidis (VPB 238), 
Proteus mirabilis (VPB 261), Serratia marcescens (VPB 255), Enterococcus faecalis 
(VPB 185), Pseudomonas aeruginosa (VPB 591) and Escherichia coli (VPB 2716)) 
commonly found on mucous membranes of the anogenital area. There was no cross 
reactivity with these species. Phylogenetic neighbours of Chlamydiaceae such as Simkania 
spp, Waddlia spp and novel koala Chlamydiales genotypes (Devereaux, Polkinghorne et 
al., 2003) were not available for study. In work by previous researchers reactions using 
these primers and Simkania negevensis have not produced product (Demkin & Zimin, 
2005) and the basic local alignment search tool (Altschul, Gish et al., 1990) did not suggest 
cross reactivity with these organisms. Urogenital and ocular swabs were collected 
opportunistically as per 4.11.5 from eight koalas bred and held in a captive facility isolated 
from wild animals and with no history of chlamydial disease. DNA extracted as per 4.11.6 
from these animals was subjected to PCR using the protocol described in 4.11.7. All 
animals were negative using this method. 
4.11.5 DNA collection 
Plain aluminium applicator, rayon-tipped swabs (Copan, Murrieta, California, USA) were 
moistened with sterile saline. Gross discharge was removed from eyes with gauze swabs. 
Each conjunctival sac was sampled three times by vigorously rolling the tip of the swabs 
around the conjunctiva and external aspect of the nictitating membrane. The urogenital 
tract was sampled by inserting the moistened swab into the penis to the level of the prostate 
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(4 - 5 cm; males) or the common urogenital sinus, cranioventrally, until gentle resistance 
was encountered (4 - 5 cm; females). The swab was then rotated or jiggled vigorously for 5 
- 10 seconds. The rectum was accidentally sampled rarely using this technique and such 
sampling was obvious due to faecal contamination. In these cases, a fresh swab was used 
and the faecally contaminated swab discarded. The second and third swab were sampled as 
above then labelled in the order taken and frozen at -20 °C.  
4.11.6 DNA extraction 
The second swab collected from each site was used preferentially. Individual swabs were 
placed in 250 µL of QuickExtract™ (Epicentre® Biotechnologies, Madison, Wisconsin, 
USA) solution in a 0.6 mL collection tube and rotated vigorously a minimum of five times. 
The swab was pressed against the sides of the tube to retain as much extraction solution as 
possible and then the remaining solution was vortexed for 10 s and incubated at 65 °C for 
one min. The tube was vortexed again for 15 s and incubated at 98 °C for 2 min, and was 
then vortexed for 15 s. This method of DNA extraction was chosen for use in the field as is 
did not require centrifugation (initially unavailable in the field laboratory) and was rapid. 
Where possible outside of the field DNA was extracted using a commercial kit (QIAamp® 
DNA Mini Kit, QIAGEN Pty Ltd, Doncaster, Vic, Australia) according to manufacturer‟s 
instructions to minimise the risk of PCR inhibitors that may interfere with the efficiency of 
the PCR ((Munoz-Cadavid, Rudd et al., 2010). 
4.11.7 Field PCR method 
The PCR reaction mixture contained PCR grade 2mM MgCl2 (QIAGEN, Doncaster, Vic, 
Australia), 200 µM of each dNTP (QIAGEN, Doncaster, Vic, Australia), 160 nM of each 
primer, 0.83 U Taq polymerase (HotStarTaq® DNA Polymerase, QIAGEN, Doncaster, 
Vic, Australia), 2.5 µL of extracted DNA template and 2.5 µL buffer (10x PCR buffer, 
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QIAGEN, Doncaster, Vic, Australia) made up to a final volume of 25 µL using autoclaved 
purified water (Milli-Q® Ultrapure filtration system, Millipore, North Ryde, NSW, 
Australia). The amplification reactions were carried out in a thermal cycler (MJ Mini™ 
Gradient Thermal Cycler, Bio-Rad, Gladesville, NSW, Australia) using cycling conditions 
of: 95 ºC for 15 min (Taq activation) then 40 cycles of 95 ºC for 45 s (denaturation), 54 ºC 
for 45 s (annealing), 72 ºC for 60 s (extension) and then a final extension of 72 ºC for 3 
min. An 18 µL aliquot of each PCR product was mixed with 2 μL loading buffer (10% 
Ficoll with blue dye) and subjected to electrophoresis through a 1.5% agarose gel with 
SYBR® Safe 0.5X in 45 mM Tris-borate, 1 mM EDTA (TBE) buffer (Invitrogen Australia 
Pty Ltd, Mt Waverley, Vic, Australia) at 100 V for 30 min. Product was visualised using 
blue light (Dark Reader® Transilluminator, Bioscientific, Gymea, NSW, Australia) and 
documented using a digital camera. Samples were assayed in duplicate and compared to a 
250 bp ladder (Invitrogen Australia, Pty Ltd Mt Waverley, Vic, Australia). Autoclaved 
purified water was used as a negative control. DNA extracted from C. pneumoniae culture 
was used as a positive control. Dilutions of 1:100 of DNA template were used routinely in 
PCR reactions. Clinically diseased sites negative by PCR at this dilution were re-assayed 
using DNA template diluted 1:10. A band at 1030 bp was considered a positive PCR result. 
4.12 END POINTS 
PCR was performed on swabs taken prior to beginning treatment (screening day) then 
weekly from week 3 for animals with subclinical disease, and weekly from week 5 for 
animals with clinical disease, to inform cessation of treatment.  
Medication was continued for 6 weeks in animals with structural disease of the 
reproductive tract, as determined by ultrasound examination; until negative results were 
achieved on two weekly consecutive PCRs in animals without structural disease; or until 
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animals exhibited adverse effects such as weight loss (> 10% of starting body weight), 
appetite loss and depression. Animals with structural disease present at the end of 
treatment were euthanased. Animals without structural disease at the end of treatment were 
monitored for four weeks then released into suitable bush habitat near where they had been 
found. Animals showing severe side effects were withdrawn from the study and rescue 
therapy begun (Table 5-3). 
4.13 POST MORTEM EXAMINATION AND COLLECTION OF 
 SAMPLES 
Animals that died or were euthanased underwent a standard midline post mortem 
examination (Blanshard, 1994). Where animals were euthanased, blood was collected pre-
mortem for biochemistry analysis and haematological examination. Where animals could 
not be examined immediately post mortem, the carcase was kept at 4 °C and examined 
within 48 hours. Routine tissues taken for histopathology were: inguinal lymph node, 
axillary lymph node, liver, spleen, adrenals, heart, lungs, caecum, ileocaecal junction and 
ileocaecal lymphatic patch, duodenum, ileum, pancreas, thyroids, thymus (when located), 
palpebrae, brain, kidneys, bladder, ureters, prostate in the male, and vaginae, uteri, 
oviducts and ovaries in the female. Swabs were collected from the conjunctiva and urethra 
(males) or urogenital sinus (females) for chlamydial PCR. Bone marrow was collected in 
animals suspected of haematopoetic disease or lymphoproliferative disorders based on pre-
mortem blood examination and/or clinical signs, by longitudinal transection of the femur 
using parrot-beaked by-pass pruning loppers. 
All samples were placed in 10% formalin for up to 24 hours. Selection of tissues for 
processing followed routine procedure, apart from the urogenital tract of females, which 
followed standard methods for examination of koala reproductive tracts (Obendorf, 1981). 
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Tissues were stained with haematoxylin and eosin according to routine procedure and 
examined with light microscopy.  
4.14 ANIMALS RECRUITED FOR TREATMENT TRIALS 
In the first season (August 2005 - April 2006), 55 animals were screened. Of the 33 koalas 
with clinical signs of chlamydiosis, 20 were recruited and 13 animals were rejected 
(condition score < 2, concurrent disease). Twenty-two koalas without signs of clinical 
chlamydiosis were examined. Of these, 16 were not tested further and were released, four 
animals were rejected due to concurrent disease, one animal was tested negative with the 
Clearview ELISA and was released, and one animal tested positive by PCR and was 
recruited as a subclinical chlamydial case.  
In the second season (September 2006 - April 2007), 68 animals were screened. Of these, 
14 clinical and 10 subclinical animals were recruited. Thirty-six were rejected due to: 
negative PCR (n = 7), mother with joey (n = 3), concurrent disease (n = 8), condition score 
< 2 or structural reproductive tract disease (n = 18). Eight were released due to lack of 
accommodation. 
In the third season (February - March 2008), 11 clinical animals were recruited. Treatment 
groups are displayed in Table 4-2. 
The results of the clinical and ultrasound examination, haematological parameters, 
biochemistry analytes, appetite and faecal scoring, body weight and post mortem 
examinations are discussed in Chapter 5 for animals treated with non-fluoroquinolones and 
Chapter 8 for animals treated with fluoroquinolones. 
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Table 4-2. Number of koalas in each treatment group. 
 
Drug Clinical Subclinical 
Marbofloxacin 10 mg/kg p.o. SID 4 2 
Marbofloxacin 1.3 - 3.3 mg/kg p.o. SID 6  0 
Marbofloxacin 5 mg/kg s.c. SID 1 1  
Enrofloxacin 5 mg/kg p.o. SID 1 0 
Enrofloxacin 5 mg/kg s.c. SID 7
‡
 0 
Enrofloxacin 10 mg/kg s.c. SID 12 4 
Enrofloxacin 20 mg/kg p.o. SID 5 3 
Doxycycline 5 mg/kg p.o. SID  1 0 
Doxycycline 0.25 mg/kg p.o. SID 1 0 
Doxycycline 10 mg/kg i.m. SIW 1
* 
 0 
Doxycycline 5 mg/kg i.m. SIW 1
† 
 1 
Doxycycline 2.5 mg/kg i.m. SIW 1 0 
Azithromycin 10 mg/kg p.o. SID 1 0 
Azithromycin 5 mg/kg p.o. SID 1 0 
Azithromycin 2.5 mg/kg p.o. BIW 1 0 
Chloramphenicol 50 mg/kg p.o. BID 2 0 
Oxytetracycline eye ointment BID 1 0 
Total 47 11 
The following animals were treated with two different regimes and are thus counted twice: 
*one animal re-treated after 42 days of marbofloxacin 2.5 mg/kg p.o. SID. 
†one animal re-treated after 28 days of marbofloxacin 2.5 mg/kg p.o. SID. 
‡ one animal re-treated after 42 days of enrofloxacin 10 mg/kg s.c. SID with enrofloxacin 5 mg/kg s.c. SID. 
SID: once daily medication; BID: twice daily medication; SIW: once weekly medication; BIW: twice weekly 
medication; p.o: per os. 
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4.15 ISSUES ASSOCIATED WITH RECRUITMENT AND USE 
 OF ANIMALS FOR TREATMENT TRIALS 
Recruitment of animals relied upon naturally occurring disease in wild animals. An 
advantage of this strategy was that animals were drawn from, and represented, the 
spectrum of clinical disease currently treated in koala facilities in Australia. The major 
disadvantage of this strategy was that opportunistic recruitment of suitable animals 
suffering naturally occurring disease was slow (approx. two animals per three weeks), 
requiring long periods of time in the field. An experimental population of koalas, and 
facilities for their husbandry, or alternative hospital facilities that receive greater numbers 
of cases did not exist at the commencement of the study. Examination of previous 
admission rates to the Koala Hospital may have helped to predict the recruitment rate, 
however detailed information as to whether such animals would have been suitable for 
inclusion in a treatment trial was not always available due to differences in examination 
procedures between the Koala Hospital and this trial. The slow recruitment meant that 
planned clinical groups were reduced, and one treatment group (subcutaneous 
chloramphenicol) was transferred to another facility. Data from this group does not form 
part of this study. 
Randomised controlled trials are the experimental design of choice for studies examining 
efficacy of treatment but may be difficult and/or expensive to implement. In this study, 
treatments were not blinded to investigators. Complete blinding of the trial would have 
been expensive as drugs would have had to be specially compounded and, as different 
routes of delivery were used, may not have been possible. In addition, it would have 
required extra sham injections and/or oral medication of wild animals, compromising 
welfare.  
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A placebo treatment group of subclinical animals was initially planned but had to be 
abandoned due to low numbers of subclinical cases recruited. Ethical considerations of 
withholding treatment precluded an untreated clinically diseased control group and thus 
experimental design involved comparison between treatment groups. This study was a 
compromise between the practicalities of working with pre-formulated commercial 
pharmaceuticals, cost, lay co-workers‟ perceptions, animal welfare and experimental 
design.  
Medication of some animals proved to be challenging. Although koalas are generally 
placid, and often take oral medication well (Blanshard, 1994), some animals resisted oral 
supplementation vigorously. Despite three different formulas being trialled, there was no 
difference noted in formula acceptability or palatability and reluctance of animals to take 
oral medications and supplements probably related to handling rather than palatability or 
formulation. Pharmacological studies require that all medication be reliably consumed at 
one time. Animals strongly resistant to oral supplementation in a pre-treatment 
acclimatisation period had to be allocated to a parenteral treatment group to guarantee 
accurate drug administration. This meant that random allocation of koalas to treatment 
groups was not always possible. Animals strongly resistant to oral medication may have 
been more stressed in captivity. Such animals might be expected to have higher circulating 
stress hormones, such as cortisone, that could have influenced response to treatment. A 
three to seven day training period prior to beginning medication was introduced, but the 
length of the training period had to be balanced against extending time in captivity, the 
ethics of holding animals without treatment and risks to the animal of aspiration of oral 
medications or supplements. Generally animals amenable to oral dosing continued to 
accept this route throughout treatment.  
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The commencement of a major scientific investigation within a wildlife care hospital 
offered a number of major of advantages and posed unique challenges. Hospital staff often 
had intimate knowledge of koala disease, husbandry and behaviour through long 
association with their care. Lay workers provided a large, enthusiastic workforce to help 
with many aspects of experimental work and koala husbandry. Specialised facilities and 
trained staff for keeping the koalas were mostly already in place at the Koala Hospital, 
requiring little input from researchers prior to the commencement of the study. A long 
association (approx. 25 years) between the Koala Hospital and the Faculty of Veterinary 
Science, University of Sydney, provided a solid basis for the co-operative relationship 
cemented by this research. However, unique challenges in working in such an environment 
will inevitably occur. Although some of these challenges were anticipated in advance, 
some, particularly the building of infrastructure, required demonstration of a real need. 
Others, in relation to change of protocol and demands on facilities, required careful 
education and explanations to lay staff. 
The Koala Hospital policy - that volunteers retrieve koalas from dangerous areas (such as 
in the vicinity of dogs, or main roads) and immediately relocate them to suitable nearby 
bush habitat if deemed well on superficial inspection - had to be revised to allow screening 
of animals for subclinical chlamydial disease. Adoption of this policy took time, thus a 
number of potential recruits (n = 14) in the first few months of the 2005 - 2006 season 
were released without full physical examination under general anaesthesia or testing for 
subclinical disease, resulting in recruitment of only one subclinical case in 2005 - 2006. 
Detection of subclinical carriers of Chlamydiaceae by PCR and detection of clinical cases 
without structural disease offered hope that disease might be treated before structural 
damage occurred: a position enthusiastically embraced by lay workers. In the 2006 - 2007 
and 2008 field seasons recruitment of such animals became a priority, whilst animals with 
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structural disease were euthanased soon after diagnosis to minimise the stress on lay 
workers that extensive time spent caring for an animal with a hopeless prognosis may 
bring.  
The lack of holding space for animals severely limited the numbers of animals that could 
be enrolled in the study, particularly in the first season (2005 - 2006) and the first half of 
the second season (2006 - 2007). Koalas enrolled in this study were maintained for a 
minimum of nine weeks. Prior to the commencement of this study the Koala Hospital had a 
holding capacity of 18, if animals were individually housed. Three of these were already 
occupied by permanently disabled animals kept for educational display, and two were not 
available for use. As the Koala Hospital admits roughly 200 koalas a year for a variety of 
reasons (Chapter 2), space needed to be set aside for these animals, particularly those 
requiring long-term rehabilitation.  
During the study, three animals escaped their enclosures, necessitating recapture, and one 
animal was lost to follow up by escaping from the hospital grounds completely. Escape of 
patients from the Koala Hospital is a relatively frequent occurrence and wild males are 
often found to have entered the facilities overnight (personal observation). Koalas require 
specialised enclosure design to prevent escape (Blanshard, 1994), which may prove 
expensive to build and maintain. The fencing of the Koala Hospital was due to be upgraded 
at the commencement of the study as part of a generalised hospital redevelopment. Fences 
prior to the upgrade consisted of sheet metal (1.2 m) with cyclone fencing (0.6 m) above, 
conforming to recommended standards (Blanshard, 1994). Although escapes from 
enclosures were not witnessed, they may have occurred as a result of items such as 
rakes/sun umbrellas, or smaller aviary-style enclosures present within the enclosures 
allowing koalas to acquire purchase on wire netting, or koalas acquiring purchase on the 
top of the sheet metal, as it did not have a rounded top edge as has been recommended 
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(Blanshard, 1994). Wild animals entering enclosures presumably did so by leaping from 
surrounding trees, which occasionally had branches overhanging enclosures. Lopping of 
these trees, although performed regularly by professional contractors, was not under the 
direct control of the Koala Preservation Society of NSW, making control of ingress 
challenging. As interlopers tended to end up in one large yard closest to such trees, study 
animals were held in yards furthest from this area to minimise risk of contact. Escapes 
early in the study necessitated indoor housing of the larger animals, or those that had 
escaped previously. As indoor spaces were few (four), this decision initially limited the 
ability to recruit animals into the study. The Koala Hospital staff worked with researchers 
to improve facilities by building an extra 10 holding yards with improved fencing and two 
enclosed aviaries for use by research staff, and providing exclusive use of nine previously 
built accommodation spaces. Cage furniture was removed or placed flush with the ground 
to minimise risk of escape. The development of ingress- and egress-proof yards of 
sufficient quantity and quality to house study koalas was a significant cost, requiring 
approval of the membership body of the Koala Preservation Society of NSW. The approval 
for and building of these yards took time but the yards were available midway through the 
second field season (2006 - 2007).  
Performing research with wild animals within a rehabilitation setting offered many 
advantages but was not without difficulty. Although some challenges might be anticipated 
(e.g. communication of changed procedures with lay staff), others might not be predictable 
(e.g. difficulty in medicating animals orally, slow recruitment of suitable cases). The 
problems encountered in this study highlight the need for careful planning and involvement 
of staff of the field work site, prior to the commencement of, and during, a major scientific 
study. Careful planning with regard to infrastructure is ideal; however, as such changes 
may involve significant financial outlay, clear demonstration of its necessity may require 
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an initial smaller pilot study. Flexibility and the ability to adapt the study, where possible, 
to better suit the facilities, recruitment rate and staff expectations are ideal. A “softly, 
softly” approach, particularly when changes to procedures are initially implemented might 
be warranted. Extensive and on-going communication is required to explain the scientific 
process to lay staff, particularly where animal experimentation is required, as gaining the 
support of staff is crucial for the success of research within such facilities.  
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CHAPTER 5 - PILOT STUDY INTO TREATING AND 
MONITORING KOALAS WITH CHLAMYDIOSIS 
5.1 INTRODUCTION 
Chlamydophila pneumoniae and Chlamydophila pecorum can infect up to 85% of 
individuals in some populations of the koala, causing significant morbidity (Jackson, 
White et al., 1999). Animals with clinical signs consistent with chlamydiosis account for 
approximately 20% of admissions to the Koala Hospital, Port Macquarie (Chapter 2). 
Clinical signs of chlamydiosis in koalas include conjunctivitis (Cockram & Jackson, 1976), 
rhinitis (Nicolson, 2002), cystitis and/or reproductive tract disease (Brown & Grice, 1986). 
Systemic treatment of chlamydiosis in koalas has long proved problematic due to the 
paucity of studies into effectiveness (Cockram & Jackson, 1976; Osawa & Carrick, 1990; 
Markey, Wan et al., 2007), and the reported syndrome of wasting and death in koalas 
within two or six weeks of treatment with erythromycin (Brown, Wood et al., 1984) or 
oxytetracycline (Handasyde, 1986; Osawa & Carrick, 1990; Osawa, Bird et al., 1993), 
respectively. It is hypothesised that disturbance or loss of gastrointestinal microbial flora 
leads to this syndrome in antibiotic treated koalas (Osawa, Bird et al., 1993). 
Recommendations for treatment of chlamydiosis in other species (people, cats, birds) have 
included azithromycin (Workowski, Levine et al., 2002), doxycycline (Workowski, Levine 
et al., 2002; Dean, Harley et al., 2005) and fluoroquinolones (Dorrestein, 1993; 
Lindenstruth & Frost, 1993; Workowski, Levine et al., 2002). In people, azithromycin 
exhibits high efficacy, rapid and extensive tissue penetration (Alvarez-Elcoro & Enzler, 
1999; Lau & Qureshi, 2002) and a long mean tissue half-life (2 - 4 days) allowing single-
dose therapy (Alvarez-Elcoro & Enzler, 1999). Doxycycline remains an excellent 
alternative treatment choice for cats, in which azithromycin has not proved to be an 
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effective treatment (Owen, Sturgess et al., 2003), and for people (Lau & Qureshi, 2002). 
Newer generation fluoroquinolones have been recommended for treatment of chlamydial 
infections of people (Nightingale, 2000; Workowski & Berman, 2006) and have showed 
some promise in treating chlamydial infections in cats (Gerhardt, Schulz et al., 2006) and 
birds (Lindenstruth & Frost, 1993; Jung, 1994). 
Revisiting the use of tetracyclines and macrolides for treatment of chlamydiosis in koalas 
is worthwhile as modern forms of these drugs, such as doxycycline and azithromycin, 
respectively, possess attributes that might decrease their side effect profile in koalas. 
Azithromycin has fewer gastrointestinal side effects in people than erythromycin (Hopkins, 
1991); and doxycycline has better bioavailability than oxytetracycline (Plumb, 2005), 
allowing the use of lower doses. In addition, a slightly different spectrum of activity to the 
older forms of these drugs (Williams, 1991; Joshi & Miller, 1997) might cause less 
disturbance of gastrointestinal flora and fewer side effects. 
Systemic chlamydiosis is currently treated in wildlife hospitals with chloramphenicol 
and/or enrofloxacin at various dose rates and routes (Table 5-1). Alternatively, animals 
with conjunctivitis alone are often treated with topical tetracycline based eye ointments 
and/or debulking surgery to remove proliferative conjunctiva (C. Flanagan, pers. comm.
1
; 
A. MacKinnon, pers. comm.
2
). If azithromycin was effective in koalas, it would be 
extremely attractive as it could dramatically reduce time in captivity compared with current 
treatment regimes of up to six weeks (C. Flanagan, pers. comm.)
3
.  
                                                 
1
Personal communication: C. Flanagan, Supervisor, Koala Preservation Society of NSW, Port Macquarie, 
NSW, August, 2005. 
2
 Personal communication: A. MacKinnon, Manager, Moggill Koala Hospital, Toowoomba, Qld, August, 
2005. 
3
Personal communication: C. Flanagan, Supervisor, Koala Preservation Society of NSW, Port Macquarie, 
NSW, August, 2005. 
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This pilot study was instigated to provide preliminary information on the effectiveness and 
tolerability of medications: 1/ presently employed on an empirical basis to treat 
chlamydiosis in koalas (fluoroquinolones, chloramphenicol, tetracycline eye ointment) and 
2/ currently used commonly to treat chlamydiosis in other species (doxycycline, 
azithromycin).  
It was anticipated that the results from the pilot study would allow the refinement of 
diagnostic and treatment protocols, and their monitoring for efficacy and adverse effects, 
for future studies in this thesis. 
 
Table 5-1. Systemic drug dosage regimes for treatment of chlamydiosis in specialised koala 
treatment facilities. 
 
Drug Dose/route/frequency Facility Reference 
Chloramphenicol 60 mg/kg s.c. SID Australia Zoo, Beerwah, Qld, 
Australia 
J. Hanger,  
pers. comm.
4
 
Chloramphenicol 50 mg/kg p.o. BID The Koala Hospital, Port 
Macquarie, NSW, Australia 
C. Flanagan,  
pers. comm.
3 
Chloramphenicol 50 mg/kg i.m. BID 
for 3 days then s.c. 
The Koala Hospital, Port 
Macquarie, NSW, Australia 
C. Flanagan,  
pers. comm.
 3 
Enrofloxacin 8.33 - 12.5 mg/kg  
p.o. SID 
Moggill Koala Hospital, 
Toowoomba Qld, Australia  
A. MacKinnon, 
pers. comm.
5
 
Enrofloxacin 10 mg/kg s.c. SID The Koala Hospital, Port 
Macquarie, NSW, Australia 
C. Flanagan,  
pers. comm.
 3
 
Enrofloxacin 5 - 10 mg/kg p.o. SID The Koala Hospital, Port 
Macquarie, NSW, Australia 
C. Flanagan,  
pers. comm.
 3
 
s.c: subcutaneous; i.m: intramuscular; p.o: per os; SID: once daily; BID: twice daily. 
                                                 
4
 Personal communication: J. Hanger, Principal Veterinarian, The Australian Wildlife Hospital, Beerwah, 
Qld, August, 2005. 
5
 Personal communication: A. MacKinnon. Manager, Moggill Koala Hospital, Toowoomba, Qld, August, 
2005. 
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5.2 METHODS 
Animals were recruited, screened, housed, examined, allocated to treatment groups, 
supplemented, sampled from and observed as described in Chapter 4. Koalas were treated 
using dose regimes as per Table 5-2 (Results).  
5.2.1 Diagnostic ELISA 
Nine animals (seven females and two males) with clinical signs consistent with chlamydial 
disease were swabbed as per 4.11.5. The third swab from both eyes and the urogenital tract 
(three swabs in total) were pooled and subjected to analysis by Clearview Chlamydia MF 
ELISA (Inverness Medical Australia, Sinnamon Park, Qld, Australia). Due to perceived 
insensitivity of the diagnostic ELISA (see 5.3.1 and Discussion) and the initial lack of 
facilities to perform PCR in the field, nine animals with clinical signs consistent with 
chlamydiosis did not undergo diagnostic testing prior to treatment. Diagnosis based on 
clinical signs was confirmed retrospectively using qPCR. 
The procedure followed was that provided by the manufacturer for chlamydial diagnosis 
from endocervical swabs from women. All reagents, reaction strips and collection tubes 
were provided by the manufacturer. Most samples were tested within 24 hours of 
collection although occasionally samples were refrigerated at 4 °C and tested within 48 
hours, in accordance with the manufacturer‟s guidelines.  
5.2.2 Response to treatment 
Treatment was continued for up to six weeks or was discontinued when serious side effects 
were noted (consistent inappetence for more than three days, weight loss exceeding 10% of 
starting weight, depression, decreased faecal output and/or anaemia). Rescue treatments, 
which were administered to animals experiencing side effects, consisted of combinations 
of gastrointestinal motility modifiers, oral or parenteral fluids, nutritional supplements, 
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vitamin injections and attempted caecal refaunation (Table 5-3, Results). When 
inappetence, depression and faecal output continued for greater than seven days, animals 
were euthanased on grounds of welfare.  
5.2.3 Appetite, body weight and faecal output 
For the first two weeks (n = 20) or three weeks (n = 8) of treatment, all faecal pellets were 
collected over each 24 hour period, weighed, and the mass converted to a percentage of the 
faecal mass measured on day 0 or day 1 (i.e. immediately prior to treatment). Mean weekly 
body weights were converted to a percentage of body weight on day 0 or day 1. 
5.2.4 Haematological parameters and biochemistry analytes 
Detail of methods used to collect and analyse samples of urine and blood has been 
provided previously (4.10). 
5.2.5 Statistical models 
Residual plots of total eye scores and relative faecal and body weights were first examined 
to determine whether data approximated normality, and non-parametric data were 
transformed (usually with log transformation) before restricted maximum likelihood 
analysis (REML) using GenStat for Windows (2008, 11
th
 ed., VSN International Ltd., 
Hemel Hempstead, Hertfordshire, UK). The model examined the effects of drug and time 
(week) and the interaction of drug and time. Statistical significance was concluded when p 
≤ 0.05. 
REML analysis of biochemical and haematological analytes examined the effects and 
interactions of drug, route and dose; time by week and by stage of treatment (pre-
treatment, in-treatment and post-treatment); and whether animals maintained, gained or 
lost body weight. 
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5.2.6 Post mortem examination 
Animals euthanased during or immediately after the study had blood sampled immediately 
prior to death for haematological and biochemistry analysis. All animals that died or were 
euthanased underwent a routine post mortem and histological examination as per 4.13.  
5.3 RESULTS 
Twenty animals were recruited into the study with clinical signs of chlamydial disease (n = 
19), and/or ultrasonographic abnormalities of the reproductive tract (ovarian bursal cysts; n 
= 10) and/or chlamydial DNA detected by PCR (n = 2) and/or ELISA (n = 4) (Table 5-2).  
5.3.1 Diagnostics 
Of the nine clinically diseased animals tested by ELISA, five animals were negative and 
four positive (Table 5-2). One subclinical animal (EF) tested positive for urogenital tract 
infection by PCR. 
5.3.2 Response to treatment 
Of the 20 koalas treated, 10 completed four - six weeks of treatment with marbofloxacin (n 
= 5), enrofloxacin (n = 5), oxytetracycline hydrochloride/polymyxin B sulphate ophthalmic 
ointment (n = 1), or doxycycline (n = 1). Eight animals (four treated with doxycycline, 
three treated with azithromycin and one treated with chloramphenicol) failed to complete 
treatment due to serious side effects and were euthanased (n = 7) or died (n = 1) (Table 5-2 
and 5.3.3). One animal treated with chloramphenicol had treatment withdrawn after 
developing anaemia (see 5.3.4 and Figure 5-7). 
Of the animals that completed treatment (Table 5-2): one animal developed ovarian bursal 
cysts (RG), ovarian bursal cysts present at the start of treatment did not resolve in six 
animals (TM, WR, CR, SS, KH, KS), and three koalas failed to resolve clinical signs of 
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cystitis (LJ, OA, AG). Two of these latter animals (OA, AG) were retreated with 
doxycycline and were eventually euthanased. In animals with conjunctivitis that completed 
four weeks of various treatments, total eye scores decreased significantly (p = 0.004; n = 7; 
Figure 5-1). One animal treated with oxytetracycline hydrochloride/polymyxin B sulphate 
ophthalmic ointment (ED; Table 5-2) escaped after 36 days of treatment and was lost to 
follow up. 
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Figure 5-1. Change in mean (± SEM) total eye scores in seven animals treated with 
fluoroquinolones or oxytetracycline/ polymyxin B ointment.  
s.c: subcutaneous; p.o: per os; SID: once daily. 
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Table 5-2. Signalment, clinical presentation, diagnostic tests, treatment regimes and incidence of side effects of animals recruited in the pilot study. 
Koala Sex Age 
(years) 
Clinical findings at presentation Diagnostics (ELISA 
or PCR) 
Drug Serious side effects 
necessitating treatment 
withdrawal  
MO F 11.5 Rump pelage stain 
Bilateral conjunctivitis 
ELISA negative Chloramphenicol 50 mg/kg p.o. BID for 35 days Anaemia 
NK M 9 Rump pelage stain 
Inflamed and ulcerated pericloacal 
skin and penile mucosa 
Haematuria 
ELISA positive Chloramphenicol 50 mg/kg p.o. BID for 23 days Depression 
Decreased faecal output, 
appetite and body weight  
OC F 2 Inflamed vestibule 
Bilateral ovarian bursal cysts 
Pyuria 
Not done Doxycycline loading dose 0.5 mg/kg p.o. am, 
0.25 mg/kg p.o. pm, then 0.25 mg/kg p.o. BID for 
two days, stopped 48 hours, then 5 mg/kg p.o. 
SID for four days, then 2.5 mg/kg p.o. SID for 
three days 
Depression 
Decreased faecal output, 
appetite and body weight 
TH F 8 Rump pelage stain 
Unilateral conjunctivitis 
Unilateral ovarian bursal cyst 
Not done Doxycycline p.o. 0.25 mg/kg BID for eight days Depression 
Decreased faecal output, 
appetite and body weight 
EF M 3.5 Subclinical  PCR positive Doxycycline 5 mg/kg i.m. SIW for 42 days None 
CP M 12 Rump pelage stain 
Incontinence and haematuria 
Unilateral conjunctivitis 
Not done Doxycycline 2.5 mg/kg i.m. SIW for 28 days Depression 
Decreased faecal output, 
appetite and body weight 
OA M 7 Pelage stain  
Dysuria 
ELISA negative Marbofloxacin 2.5 mg/kg p.o. for 42 days, 
stopped 48 hours, then doxycycline 10 mg/kg i.m. 
SIW for 21 days 
Depression 
Decreased faecal output, 
appetite and body weight after 
beginning doxycycline 
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Table 5.2  cont.      
Koala Sex Age 
(years) 
Clinical findings at presentation Diagnostics (ELISA 
or PCR) 
Drug  
AG F 4 Conjunctivitis & dysuria Not done Marbofloxacin 1.3 mg/kg p.o., stopped 48 hours, 
then doxycycline 5 mg/kg i.m. SIW for 21 days 
Depression 
Decreased faecal output, 
appetite and body weight after 
beginning doxycycline 
MM F 5.5 Pelage stain PCR positive Azithromycin 5 mg/kg p.o. SID for four days Depression 
Decreased faecal output, 
appetite and body weight  
OP F 12 Pelage stain 
Bilateral ovarian bursal cysts 
Not done Azithromycin 2.5 mg/kg p.o. SID day 1, 4, 8 and 
12 
Depression 
Decreased faecal output, 
appetite and body weight 
OK F 12 Pelage stain 
Purulent vaginal discharge 
Bilateral ovarian bursal cysts 
Not done Azithromycin 10 mg/kg p.o. SID for seven days 
then once day 11 and day 14 
Depression 
Decreased faecal output, 
appetite and body weight 
TM F 12 Rump pelage stain 
Bilateral conjunctivitis 
Unilateral ovarian bursal cyst 
Pyuria 
Not done Marbofloxacin 1.3 mg/kg p.o. SID for 42 days None 
WR F 5 Rump pelage stain 
Bilateral ovarian bursal cysts 
Unilateral conjunctivitis 
ELISA negative Marbofloxacin 3.34 mg/kg p.o. SID for 42 days None 
RG F 5 Pelage stain 
Inflamed pericloacal skin 
ELISA positive Marbofloxacin 2.3 mg/kg p.o. SID for 42 days None 
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Table 5.2  cont.      
Koala Sex Age 
(years) 
Clinical findings at presentation Diagnostics (ELISA 
or PCR) 
Drug  
CR F 10 Unilateral ovarian bursal cysts 
Bilateral uterine distension 
Rump pelage stain 
ELISA positive Enrofloxacin 5 mg/kg s.c. SID for 42 days None 
SS F 7 Rump pelage stain 
Unilateral conjunctivitis 
Bilateral ovarian bursal cysts 
ELISA negative Enrofloxacin 5 mg/kg s.c. SID for 42 days None 
KH F 5 Rump pelage stain 
Bilateral ovarian bursal cysts 
ELISA negative Enrofloxacin 5 mg/kg s.c. SID for 42 days None 
KS F 12 Rump pelage stain 
Incontinence 
Unilateral conjunctivitis and 
keratitis, corneal ulceration 
Thickened bladder wall 
Bilateral ovarian bursal cysts 
ELISA positive Enrofloxacin 5 mg/kg s.c. SID for 42 days None 
LJ F 3 Pelage stain 
Unilateral conjunctivitis 
Incontinence and pyuria 
Not done Enrofloxacin 5 mg/kg p.o. SID for 28 days None 
ED M 4.5 Bilateral conjunctivitis Not done Oxytetracycline hydrochloride/polymyxin B 
sulphate ophthalmic ointment BID for 36 days 
None 
BID: twice daily; SID: once daily; SIW: once weekly; p.o: per os; s.c: subcutaneous injection; i.m. intramuscular; PCR: polymerase chain reaction; ELISA: enzyme linked 
immunosorbent assay. Age estimated based on tooth wear class (Martin, 1981) and past admission records. 
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5.3.3 Appetite, body weight and faecal output 
All three animals treated with azithromycin (MM, OP, OK; Table 5-2), one animal treated 
with chloramphenicol (NK; Table 5-2), and five of six animals treated with doxycycline 
(AG, OA, OC, TH, CP; Table 5-2) experienced loss of appetite, decreased faecal output 
(Figure 5-2), decreased body weight (Figure 5-3, Figure 5-4 and Figure 5-5) and 
depression, necessitating discontinuation of treatment (Table 5-2). Two animals (AG, OA) 
maintained weight whilst being treated with marbofloxacin for four and six weeks, 
respectively (Figure 5-6) but lost weight after commencing treatment with doxycycline 
(Figure 5-5), used due to non-resolution of clinical signs on the initial treatment. Weight 
loss relative to starting weight (week 0) became significant (p < 0.001) by week two for 
azithromycin (Figure 5-4), by week three for doxycycline (Figure 5-5) and week four for 
chloramphenicol (Figure 5-3). In all animals that lost weight, sustained appetite loss 
(median 9 days, range 4 - 23 days) was first observed a few days prior to a sustained 
decline in weight (Figure 5-3, Figure 5-4 and Figure 5-5). Twenty-four hour faecal output 
appeared to decline in all animals that were inappetent and lost weight; however this was 
not statistically significant (Figure 5-2). No rescue therapy (Table 5-3) reversed the loss of 
appetite, body weight, faecal output or depression. Eight of these koalas were euthanased 
on grounds of welfare when inappetence, depression and weight loss persisted for at least 
one week and the remaining one died. 
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Table 5-3. Rescue treatments attempted in animals suffering side effects of azithromycin (n = 3), doxycycline (n = 5), or chloramphenicol (n = 1). 
 
Rescue treatment Dose and route Frequency Formulation n 
Vitamin B12 injection 0.05 - 0.1 mg/kg 
s.c. 
Once Troy Vitamin B12® 1 mg/mL Troy Laboratories, Glendenning, NSW, Australia 3 
Fresh caecal contents 15 - 25 mL p.o. SID - BID up to five days Fresh caecal contents from animals that died or were euthanased for other reasons 
(e.g. trauma) 
4 
Oral rehydration salts 20 - 200 mL p.o. Once Vy‟Trate®, Jurox, Rutherford, NSW, Australia 2 
Parenteral fluids 50 - 300 mL s.c. SID over one to four days Compound sodium lactate (Hartmann‟s) intravenous solution or 0.45% sodium 
chloride & 2.5% glucose intravenous infusion BP both Baxter Viaflex, 
Toongabbie, NSW, Australia 
4 
260 - 500 mL i.v. Once 
Metoclopromide 0.5 mg/kg s.c.  Four to six doses SID - BID Maxolon® 5 mg/ mL, GlaxoSmithKline, Boronia, Vic, Australia 3 
Pumpkin and sweetcorn baby 
food 
20 mL p.o. SID for one - six days Heinz® pureed pumpkin and sweetcorn, H.J. Heinz company, Australia Ltd. 
Southbank, Vic, Australia 
3 
Pulverised Eucalyptus leaf 30 - 50 mL p.o. Once Leaf tip selected from Eucalyptus robusta, E. microcorys, E. tereticornis, E. 
nicholii, E. macrorhyncha, or Corymbia maculata 
2 
Cisapride 0.2 mg/kg p.o. BID for one day Prepulsid® liquid 1 mg/mL, Janssen-Cilag Australia, North Ryde, NSW, 
Australia 
1 
Soya supplement 7 - 35 g in 20 - 50 
mL water p.o. 
SID - BID up to 44 days Karicare® Soya All Ages Formula, Nutricia, North Ryde, NSW, Australia 7 
Low lactose milk supplement 9 g in 50 mL water 
p.o. 
BID up to 35 days Di-vetelact® Low Lactose Milk Powder, Sharpe Laboratories, Ermington, NSW, 
Australia 
5 
High energy vitamin gel  1.5 cm p.o. BID for 16 days Nutrigel®, Troy Laboratories, Glendenning, NSW, Australia 1 
s.c: subcutaneous; i.v: intravenous; p.o: per os. 
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Figure 5-2. Change in mean (± SEM) 24 hour faecal output for each drug group for the first 
three weeks relative to day 0.  
Drug doses and regimes are detailed in Table 5-2. Two animals are included in both doxycycline and 
marbofloxacin groups due to retreatment. 
 
 
0 7 14 21 28 35 42 49 56 63 70 77
70
80
90
100
110
*
Day
P
e
rc
e
n
ta
g
e
 o
f 
d
a
y
 0
b
o
d
y
 w
e
ig
h
t
 
Figure 5-3. Change in body weight in two animals treated with oral chloramphenicol (50 
mg/kg twice daily) relative to day 0.  
Arrow indicates when appetite decline was first noted. Treatment was withdrawn in one animal on day 35 (*) 
due to anaemia. The other animal was euthanased on day 21. 
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Figure 5-4. Changes in body weight in three animals treated with oral azithromycin relative 
to day 0. 
Arrows indicate when appetite decline was first noted, p.o: per os; SID: once daily.  
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Figure 5-5. Change in body weight in six animals treated with doxycycline relative to day 0.  
Arrows indicate when appetite decline was first noted, p.o: per os; i.m: intramuscular; SID: once daily; BID: 
twice daily; SIW: once weekly. AG & OA: animals previously treated with 28 and 42 days oral 
marbofloxacin 1 - 3.3 mg/kg, respectively. 
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Figure 5-6. Change in body weight (mean ± SEM) in 10 animals treated with 
fluoroquinolones and one animal treated with oxytetracycline/ polymyxin B ophthalmic 
ointment relative to day 0. 
p.o: per os; s.c: subcutaneous; SID: once daily; BID: twice daily. 
 
5.3.4 Haematological parameters and biochemistry analytes 
Anaemia, which occurred by day 35 in one animal treated with chloramphenicol, resolved 
after drug withdrawal (Figure 5-7). Biochemical and haematological values of other 
animals remained within published reference intervals (Canfield, O'Neill et al., 1989; 
Blanshard, 1994) with the exception of creatinine kinase activity. This was significantly 
greater (p < 0.001) in animals undergoing daily s.c. injections with enrofloxacin, when 
compared with other drug groups and with pre- or post-treatment groups. The last available 
biochemical and haematological values for inappetent animals (n = 9), were generally non-
specific or attributable to debilitation or the stress of handling. Animals exhibited 
hypoalbuminaemia (n = 5), increase in creatinine kinase activity (n = 7), decrease in 
creatinine (n = 3), mildly increased cholesterol (n = 5) and hypoglycaemia (n = 2) 
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(Appendix III). Two animals (NK and OK) with severe acute renal oxalate nephrosis 
detected at post mortem had biochemical changes consistent with renal insufficiency 
(Appendix III), although in one of these (OK), the observed azotaemia could have been 
partly pre-renal and partly renal, as urine specific gravity was not available. Other changes 
were mild and usually confined to one animal. 
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Figure 5-7. Anaemia in one animal (MO) treated with oral 50 mg/kg chloramphenicol twice 
daily with reduced haematocrit (a), red cell count (b) and haemoglobin (c). 
 Arrow represents treatment withdrawal. Dashed lines indicate reference intervals (Canfield, O'Neill et al., 
1989). 
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5.3.5 Post mortem examination 
Post mortem examination results for animals that were euthanased (n = 17) or died (n = 1) 
are presented in Appendix II. Most findings related to chronic inflammation and fibrosis of 
the urogenital tract, consistent with chlamydial disease. Of animals that declined during 
treatment (n = 9), all animals were thin to emaciated (condition scores 1 - 2.5) with eight of 
these exhibiting poor, absent or very liquid gut fill. In seven of the nine cases, post mortem 
examination was unremarkable, but in two declining animals, gastrointestinal tract disease 
and severe renal oxalate nephrosis appeared sufficiently extensive to have contributed to 
the significant morbidity observed. One of these animals had moderate diffuse chronic 
active peritonitis, associated with a small amount of plant material, without an obvious 
point of abdominal wall or gut penetration. Similar findings have been described in aged 
koalas and were attributed to perforation of the bowel by poorly masticated stems, leading 
to localised or subclinical peritonitis (Blanshard, 1994). The other animal had fungal 
gastritis, a finding not described in koalas, but associated with broad spectrum antibiotic 
use or generalised disease and debilitation in other species (Neitzke & Schiefer, 1974; 
Zwoliska-Wcislo, Budak et al., 2001). Other mild, probably incidental, observations were: 
mild cerebral multifocal idiopathic gliosis (n = 4), evidence of previous hip trauma (n = 1), 
gingival recession (n = 1), mild focal aspiration pneumonia (n = 1), peritonitis (n = 1), 
Lafora-like cerebral bodies (n = 1) and very mild scattered tubular oxalate nephrosis (n = 
1). 
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5.4 DISCUSSION 
The results from this pilot study informed significant refinement of diagnostic, treatment 
and monitoring protocols for later seasons. Moreover, it clarified and led to effective 
monitoring of side effects for certain antibiotics, and the development of tools for 
objectively assessing ocular disease, ultrasonographic images, appetite and faecal output in 
koalas. The pilot study was a learning process, not just for the author, but also for the staff 
of the wildlife hospital in which the study was set. Significant challenges were encountered 
in the first season while adapting planned regimes to the reality of the infrastructure 
provided, time constraints and the experimental animals themselves.  
In this study, diagnosis of clinical and subclinical chlamydial infections in koalas was 
required within a 24 hour period to allow swift return of non-infected animals to the wild. 
Although regarded as the gold standard for diagnosis of chlamydial infection in the past, 
cell culture has been criticised due to the difficulty of obtaining viable samples in the field, 
and because it is laborious and time consuming in nature, with diagnosis taking up to a 
week. Other screening tests such as radiology, immunofluorescence against chlamydial 
antigen in infected cells, complement fixation tests and antibody enzyme-linked 
immunosorbent assays (ELISA) have been widely criticised due to poor sensitivity and 
specificity and/or require specialised equipment (Brown, Carrick et al., 1984; Handasyde, 
Martin et al., 1988; Weigler, Girjes et al., 1988; Carlisle, Brown et al., 1989; Canfield, 
Love et al., 1991b; Girjes, Ellis et al., 1993; Emmins, 1996; Jackson, White et al., 1999; 
Bodetti & Timms, 2000; Higgins, 2004).  
Despite the Clearview Chlamydia MF ELISA having been recommended for diagnosis of 
chlamydiosis in koalas (Connolly, 1999), the results of this pilot study suggest poor 
sensitivity in the cohort of animals tested, in contrast with a previously published study 
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reporting a sensitivity of 91% and a specificity of 100% (Wood & Timms, 1992). 
Positivity was assumed based on clinical signs alone, as other diagnostic tests were not 
available as point-of-care assays at this time. This assumption is flawed if clinical signs 
observed were the result of another organism, or if the clinical response in koalas lags 
behind microbial cure, as may occur in trachoma infection in people (Michel, Solomon et 
al., 2006). However, given clinical signs were also used in the original study of 11 
clinically diseased female wild koalas as a gold standard (Wood & Timms, 1992), high 
sensitivity of this test in this cohort was expected in the current study population. One 
difference between this study and that of Wood and Timms (1992) is that the previous 
work examined swabs only from the urogenital sinus of females, whereas the current study 
combined conjunctival swabs with a urogenital swab and also screened both sexes. 
Furthermore, the test was required to be sensitive in subclinically infected animals. Pooling 
of swabs from multiple sites was undertaken to increase the sensitivity of the test by 
providing more test material, as has been suggested by other authors (Schachter, 1985; 
Wood & Timms, 1992); however this technique could have introduced additional 
inhibitors present in conjunctival and/or penile swabs. In addition, koalas in this study 
were not from the same geographical population as that of the original study, and could 
have had different strains or species of Chlamydiaceae, affecting test results. Low 
sensitivity could also have been due to lower numbers of test organisms present in swabs, 
as might occur in animals with chronic fibrotic disease of the urogenital tract (Higgins, 
Hemsley et al., 2005b), from the eyes (Markey, Wan et al., 2007) or animals with recurrent 
infections, as occurs in people (Gomes, Borrego et al., 2006). Further investigation of the 
sensitivity of this diagnostic technique in this koala population was beyond the scope of 
this study.  
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This small pilot study showed clearly that koalas tolerate poorly the medications 
commonly used to treat chlamydiosis in other species (doxycycline, azithromycin) but 
tolerate fluoroquinolones and tetracycline eye ointment well. Data on chloramphenicol was 
more equivocal, but presence of weight loss, inappetence and depression in one subject and 
reversible bone marrow suppression in the other, supports the view that use of 
chloramphenicol in koalas for extended periods should be closely monitored through 
haematological assessment (Plumb, 2005) and body weight and appetite appraisal.  
In this study, systemic drugs with an anaerobic spectrum (doxycycline (Giguere, 2006), 
chloramphenicol (Plumb, 2005), azithromycin (Merriam, Citron et al., 2006)) caused 
severe wasting, inappetence and depression in nine of the 11 animals treated, while no such 
effects were observed in the 10 animals systemically treated with drugs lacking anaerobic 
spectrum (fluoroquinolones) (Brown, 1996) and one animal treated with topical 
ophthalmic ointment. In the current study, even extremely low or infrequent doses of 
doxycycline and azithromycin (Table 5-2) resulted in decline, suggesting extreme 
sensitivity, possibly idiosyncratic, in some animals. 
Observed declines in body weight, appetite and demeanour for animals treated with 
doxycycline or azithromycin may have been due directly to gut flora disturbances. Other 
factors, such as intercurrent disease or „captive stress‟, appeared less likely to contribute to 
the declines with doxycycline or azithromycin administration because, in most cases, 
significant causes of morbidity were not observed at post mortem, and declines were not 
noted in other animals held and examined in a similar way, but treated with 
fluoroquinolones, or tetracycline eye ointment alone (weight change < 5% of starting 
weight; Figure 5-6). Anecdotally, two animals initially administered marbofloxacin 
without deleterious effects declined when treated with doxycycline. 
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In the current study, animals that declined still had a caecal bacterial layer that was 
indistinguishable by light microscopy from that found in untreated animals. Had animals 
been allowed to decline until death, this may have been lost, as found by other researchers 
in one koala treated with oxytetracycline for cystitis (Osawa, Bird et al., 1993). The 
predominant organism of the bacterial matt that coats the caecum and proximal colon of 
koalas is a facultative anaerobic, Gram-negative pleomorphic rod that, although currently 
poorly characterised, is likely to fall within the family Enterobacteriaceae (Osawa, 1992). 
It is involved in degradation of tannin-protein complexes and is sensitive to many 
antibiotics including oxytetracycline, erythromycin, and chloramphenicol (Osawa, 1992; 
Osawa, Bird et al., 1993). It has been hypothesised that disturbance or loss of this 
organism leads to wasting and death in antibiotic treated koalas (Osawa, Bird et al., 1993). 
Unfortunately, no quantitative assessment of the types of microbes within the caecal 
bacterial matt was undertaken in the current study to provide direct evidence that 
disturbance of this organism was the cause of the decline. Molecular techniques such as 
terminal restriction fragment length polymorphism are now available to examine the 
changing bacterial populations in serial faecal samples collected throughout treatment or in 
caecal content at post mortem (Wang, Ahrne et al., 2004) and might be useful to better 
describe these effects in such animals.  
Two cases of severe acute renal oxalate nephrosis are described in this study. Oxalate 
nephrosis is described very rarely in koalas from Port Macquarie (Canfield & Dickens, 
1982; Canfield, 1989; Stalder, 2003). In a large necropsy series (n = 1061), most of which 
were sourced from the Koala Hospital, only 15 koalas were reported to have oxalate 
nephrosis (Stalder, 2003). Oxalate nephrosis may be spontaneous or related to dehydration. 
Alternatively, it might be associated with a treatment-related loss of the gastrointestinal 
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oxalate-degrading commensals, as is postulated in people (Mittal, Kumar et al., 2005). 
Although the link between antibiotic use and oxalate nephrosis is not established in koalas, 
investigation of this area may be warranted as loss of commensals during treatment might 
predispose animals to later develop disease.  
This study sought to find observations that might inform the earliest possible withdrawal of 
any drugs causing side effects, so that koalas could recover from deleterious effects. 
Observation of persistent appetite loss was the earliest clinical sign associated with decline, 
however, as koala appetite may vary from day to day, it was really only useful in 
retrospect, when persistent appetite loss, together with weight loss starting a few days later 
was observed. Although treatment was withdrawn in all cases where side effects occurred, 
animals continued to decline, despite efforts to maintain nutrition and hydration, restore 
gastrointestinal motility and gastrointestinal refaunation. It is possible that nutritional 
supplementation might have avoided death had it been continued long enough, as found by 
previous authors (Richardson, 1984; Osawa & Carrick, 1990; Blanshard, 1994), however, 
as the broad aim of the research project was to investigate the treatment of chlamydiosis in 
koalas, therapies resulting in such severe side effects, extensive nursing and time in care, 
would be likely to be unacceptable to veterinarians and wildlife rehabilitators, even if 
koalas did eventually recover.  
Past observations that inappetent animals produce fewer, smaller and drier faeces than 
healthy animals (Blanshard, 1994) were confirmed by this study, but total 24 hour faecal 
output weight was not useful in predicting appetite decline. This observation is consistent 
with the extended gastrointestinal transit time of koalas (99 hours for particulate matter, 
213 hours for solutes) (Cork & Warner, 1983); as a result of which, changes in faecal 
output and character might be expected to occur several days after appetite changes. 
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Resolution of ocular disease, as evidenced by declining eye scores, was consistent in six 
animals that presented with conjunctivitis and were treated with fluoroquinolones and was 
suggestive of some clinical response to this drug. This grading system gave a rough 
estimate of clinical improvement, necessary to make clinical decisions as to the prognosis 
of animals for release.  
Non-resolution of structural disease in all koalas in the current study is not surprising due 
to the severe fibrotic changes seen in this disease, associated with tubal occlusion, ovarian 
bursal cysts and infertility (Obendorf, 1981; Brown, Carrick et al., 1984; Higgins, Hemsley 
et al., 2005b). Such structural lesions might be expected to be resistant to antimicrobial 
therapy alone and return to normal function would be extremely unlikely in most cases. In 
further studies, described in Chapter 7 and Chapter 8, recruitment of animals without 
evidence of structural disease was prioritised.  
5.5 IMPLICATIONS OF THE PILOT STUDY ON THE 
 EVOLUTION OF TREATMENT PROTOCOLS FOR 
 CHLAMYDIOSIS  
At the end of the pilot study protocols for recruitment, treatment and monitoring were 
evaluated and refined based on the results of the pilot, the numbers of animals likely to be 
recruited in subsequent field seasons and the infrastructure and logistics available. 
It seems likely that commensal anaerobic microflora disruption due to antibiosis played a 
role in the pathogenesis of the decline observed in koalas treated with azithromycin or 
doxycycline. The exact nature of the disruption; and why it caused such catastrophic 
effects in most, but not all, koalas; and whether gastrointestinal microbial disruption plays 
a role in the pathogenesis of oxalate nephrosis in koalas remain to be elucidated. A 
sensitive indicator of decline associated with treatment was not detected by this study, and 
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as decline was not reversed, avoidance of any decline, rather than treatment withdrawal 
and rescue therapy, became a key factor for studying antibiotic treatments in koalas. 
Uncomplicated disease such as conjunctivitis had improved in this study whilst animals 
were on treatment with fluoroquinolones, suggesting that these drugs might have some 
benefit in treating this form of chlamydiosis in koalas; whereas complicated disease 
involving structural changes to the reproductive tract failed to resolve, precluding release 
of animals at the end of the study. As space to house animals was limited and caring for 
animals with poor prognosis for release for extended lengths of time was contributing to 
poor morale in lay staff, future recruitment concentrated on animals with a good prognosis 
for release after treatment (e.g. subclinical disease or uncomplicated clinical disease).  
Concerns as to the possible low sensitivity of the antigen ELISA in clinical chlamydiosis; 
unknown sensitivity in subclinically infected koalas, male koalas, or in pooled samples; 
and cost of the test (approximately A$10 or $30 per koala if swabs were tested separately) 
prompted the investigation of PCR as a more sensitive point-of-care assay, as this 
technique is generally regarded as more sensitive than other diagnostic tests for chlamydial 
disease by many authors (Ostergaard, Birkelund et al., 1990; Sykes, Studdert et al., 1999; 
Amin, 2003). With the advent of non-toxic nucleic acid dyes for visualisation of DNA in 
agarose gels after electrophoresis (Williams, 2001; Invitrogen, 2007) and equipment 
becoming available towards the end of the first field season, a field site laboratory 
incorporating PCR became feasible (previously described in 4.11). Diagnosis of 
chlamydial disease and response to treatment in subsequent seasons were based on clinical 
signs of disease (previously described in 4.7 to 4.9) and/or PCR results. 
Twenty-four hour faecal collection, found to be insensitive in predicting appetite decline, 
was replaced with subjective observation of faecal character and measuring of the length 
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and width of 10 randomly collected faeces placed length-ways and side-by-side 
(previously described in 4.6). Moreover, changing methods of faecal observation to a much 
quicker technique eased morning husbandry duties of lay staff. As appetite loss had been 
the earliest indicator of decline, appetite was more closely monitored with the instigation 
of a daily grading system out of three (previously described in 4.6) rather than subjective 
observations. 
Grading of eyes in the field was not blinded, was undertaken by six different operators, 
was complicated by the allowance of a continuous scale and was not compared to reference 
photographs as these did not exist at the start of the study. To improve rigour, a study was 
designed to regrade the blinded randomised images of the eyes against rigorous criteria and 
reference photographs by the author (Chapter 8). 
The findings of the present study generated the hypothesis that uncomplicated chlamydial 
disease might be treated successfully and safely with fluoroquinolones in koalas and the 
focus of the study was shifted to evaluating these drugs. By the beginning of the second 
field season refined diagnostic, recruitment, treatment and monitoring protocols were in 
place, allowing a more comprehensive investigation into this question.  
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CHAPTER 6 - PILOT STUDY USING A MODIFIED AGAR 
DIFFUSION METHOD TO ANALYSE THE PLASMA 
CONCENTRATIONS OF FLUOROQUINOLONES IN 
TREATED KOALAS 
6.1 INTRODUCTION 
The study of pharmacokinetics across species is important to determine appropriate 
species-specific dosage regimes, and may be useful for extrapolating efficacy and safety. 
Although pharmacokinetics of commonly used antibiotics in domestic species may be well 
studied, studies are performed infrequently in more exotic species; and rarely in marsupials 
(Clark, Milton et al., 1982; Kirkwood, Gulland et al., 1988; McLelland, Rich et al., 2009). 
Veterinarians treating wildlife have estimated drug doses in these species through various 
methods of interspecies scaling, but these may not be accurate, particularly when species-
specific differences in hepatic metabolism exist (Hunter & Isaza, 2008).  
Koalas have been treated with various drugs since at least the 1960s, based on doses 
extrapolated from domestic animal species and “trial and error” (Bolliger & Finckh, 1962; 
Dickens, 1975; Brown, Woolcock et al., 1986; Handasyde, 1986; Brown, Girjes et al., 
1987; Osawa & Carrick, 1990; Canfield, Love et al., 1991a; Blanshard, 1992; Blanshard, 
1994; Connolly, 1999; Markey, Wan et al., 2007; Blanshard & Bodley, 2008). As serious 
side effects have been observed in koalas treated with oxytetracycline (Handasyde, 1986; 
Osawa & Carrick, 1990; Osawa, Bird et al., 1993) and erythromycin (Brown, Wood et al., 
1984), enrofloxacin is now used extensively for treatment of chlamydiosis in koalas 
(Blanshard & Bodley, 2008) without the guidance of pharmacokinetic information. 
Pharmacokinetics in koalas may be unusual as koalas have increased bromosulphalein 
clearance compared to other species such as sheep and macropods (Pass & Brown, 1990), 
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and are expected to have unique metabolic pathways allowing survival on eucalypts at 
levels that in other species would be toxic (McLean & Foley, 1997; Stupans, Jones et al., 
2001). A major aim of this thesis was to investigate the pharmacokinetics of some 
commonly used drugs in koalas, the fluoroquinolones enrofloxacin and marbofloxacin. 
Pharmacokinetic indices are calculated from sequential plasma drug concentrations taken 
from treated animals. One method used to determine drug concentration in plasma is an 
antibiotic agar diffusion assay modified by utilising paper disks (Wilson, Norris et al., 
2006). This method has the advantage that small volumes of plasma are required, which is 
particularly beneficial when dealing with wild animals. Further, the method requires little 
equipment, is inexpensive and has high throughput (Bennett, Brodie et al., 1966). This 
chapter describes a pilot study evaluating this method for determining concentrations of the 
fluoroquinolones enrofloxacin and marbofloxacin in the plasma of treated koalas. 
6.2 METHODS 
Koalas (n = 6) were recruited, housed, examined, allocated to treatment groups, sampled 
from, observed and monitored as described in Chapter 4. All animals were medicated once 
daily. Two koalas were treated with 1.2 - 1.4 mg/kg oral marbofloxacin (Zeniquin® 25 mg, 
Pfizer, West Ryde, NSW, Australia), two with 5 mg/kg subcutaneous injections of 
enrofloxacin (Baytril®
 
injectable solution 50 mg/mL,
 
Bayer Animal Health, Pymble, 
NSW, Australia) and two with oral enrofloxacin (Baytril® oral suspension 25 mg/mL, 
Bayer Animal Health, Pymble, NSW, Australia) dosed at 5 mg/kg in one animal and 10 
mg/kg in the other.  
A 35.6 cm
2
 lidded plate was constructed according to the method described by Bennett et 
al. (1966) and sterilised by autoclaving. Iso-sensitest™ agar (31.4 g/L, Oxoid Australia, 
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West Heidelberg, Vic, Australia) was prepared by autoclaving for 15 minutes, then poured 
on the plate to a depth of 2.7 mm and allowed to set for at least two hours at room 
temperature in a fume hood, prior to inoculation and placement of the disks and samples. 
Klebsiella pneumoniae ATCC 10031 (Heinen, 2002) was obtained from the Australian 
Collection of Micro-organisms (Department of Microbiology, University of Queensland, 
Brisbane, Qld, Australia), inoculated into 10 mL Lemco yeast extract broth (Oxoid 
Australia, West Heidelberg, Vic, Australia), incubated overnight at 37 ºC, then added to 
another 100 mL of Lemco yeast extract broth. This was incubated in a shaking incubator at 
85 revolutions per minute at 37 ºC, until the turbidity reached that of a McFarlane 0.5 
barium sulphate standard. Forty evenly spaced drops of bacterial broth were placed on the 
prepared agar plate using a sterile glass pipette, and then spread evenly using a glass 
pipette spreader. 
Five milligrams each of enrofloxacin, ciprofloxacin (both from Sigma-Aldrich, Castle Hill, 
NSW, Australia) and marbofloxacin (Pfizer Inc, Groton, Connecticut, USA) was each 
added to purified water to a final concentration of 2 mg/mL. To enable dissolution, 5 µL 
NaOH 50% (Sigma- Aldrich, Castle Hill, NSW, Australia) was added to solutions of 
enrofloxacin. Antibiotic solutions were vortexed for 20 s then ultrasonicated for 5 min until 
the drug was dissolved. Stock solutions (2 mg/mL) were stored at -20 ºC, protected from 
light and used within three months of preparation. Aliquots of the antibiotic stock solution 
were added to pooled blank koala plasma at 1, 2, 4, 8, and 16 µg/mL to prepare a fresh 
calibration curve for each day‟s analysis.  
Plasma from antibiotic treated koalas was stored at -20 ºC and protected from light until 
assay. One hour prior to use, samples were defrosted at room temperature, briefly 
vortexed, then centrifuged for five minutes at 15,000 x g.  
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Immediately after inoculation of the plate with K. pneumoniae, blank disks (6 mm CT 
998B Oxoid Australia, West Heidelberg, Vic, Australia) were placed using sterile forceps 
over evenly spaced predetermined locations on the agar plate. Sample (16 µL of plasma 
from koalas treated with antibiotics samples at different time points) was carefully 
inoculated to ensure no spillage occurred onto the appropriate paper disks using a 
calibrated 20 µL pipette (Gilson Pipetman®; Gilson, Middleton, Wisconsin, USA) and 
fresh sterile pipette tips. The negative control was pooled blank koala plasma. Each 
sample, standard and negative control was assayed in triplicate. 
After sample placement, the plate was incubated on a flat surface at 37 ºC for 18 hours. 
The diameter of the zones of bacterial inhibition (Figure 6-1) were measured in at least six 
different directions using Vernier‟s callipers (Mitutoyo series 505 dial Vernier‟s callipers, 
Mitutoyo, Tokyo, Japan) and the mean and standard deviation calculated for each sample. 
The concentrations of the unknown samples were determined by interpolation from the 
regression curve of the standards (Bennett, Brodie et al., 1966). 
 
Figure 6-1. An example of a plate after incubation at 37 ºC for 18 hours demonstrating the 
zones of inhibition in the K. pneumoniae lawn caused by fluoroquinolone diffusion. 
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6.3 RESULTS 
The zones of inhibition of marbofloxacin and enrofloxacin in koalas dosed with oral 1.2 - 
1.4 mg/kg for marbofloxacin and oral 5 mg/kg for enrofloxacin were barely detectable at 
all time points analysed (Figure 6-2 and Figure 6-3), suggesting extremely low plasma 
concentrations of drug in these animals. Animals subcutaneously injected with 5 mg/kg 
enrofloxacin had higher plasma enrofloxacin concentrations (0.6 - 1.0 µg/mL; Figure 6-3) 
than those treated with oral medications.  
The diameter of the blank disks was 6 mm. The diameter of the zone of inhibition of the 
lowest antibiotic standard (1 µg/mL) was 15 mm for both enrofloxacin and marbofloxacin, 
which represents a 4.5 mm zone between the edge of the zone of inhibition and the edge of 
the disks. Inhibition zones produced by plasma samples of treated animals were even 
smaller, raising concerns that stochastic and measurement error would significantly affect 
results where the zones of inhibition could be measured, and the measurement of plasma 
drug concentration in animals dosed orally would not be possible.  
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Figure 6-2. Concentration of marbofloxacin in plasma of two koalas. 
Animals were dosed once daily per os (p.o.) with 1.2 mg/kg or 1.4 mg/kg marbofloxacin.  
D = day of treatment; T = time since dose (h). 
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Figure 6-3. Concentration of enrofloxacin in plasma of three koalas.  
Animals were dosed once daily with 5 mg/kg enrofloxacin per os (p.o.) or by subcutaneous injection (s.c.). D 
= day of treatment; T = time since dose (h). 
 
6.4 DISCUSSION  
The results of this pilot study indicated that at the doses administered, plasma drug 
concentrations for enrofloxacin and marbofloxacin in koalas were less than 1 µg/mL at the 
time points examined. In particular, animals dosed orally had very low or undetectable 
plasma concentrations of fluoroquinolones, suggesting poor bioavailability by this route. 
Although they have some advantages, modified agar diffusion assays are regarded as being 
less sensitive to low concentrations than high performance liquid chromatography (HPLC) 
(Klein & Edberg, 1996) and cannot distinguish antimicrobially active metabolites present 
in the sample from the parent compound (Heinen, 2002). Reverse phase HPLC is a method 
by which closely related substances dissolved in a liquid (the mobile phase) are separated 
by selective, polarity-based, retention onto a solid matrix (the column) (Klein & Edberg, 
1996). Advantages of HPLC include the ability to separate and analyse closely related 
substances (e.g. drug metabolites), extreme sensitivity (usually able to quantitate between 
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0.5 and 1.0 µg/mL) and rapidity if automated (Klein & Edberg, 1996). The disadvantages 
of HPLC include a high level of technical skill required to develop methods and the initial 
high financial outlay for equipment (Klein & Edberg, 1996). The preliminary results of this 
pilot study indicated that drug concentrations in plasma of koalas dosed orally were 
expected to be very much less than 1 µg/mL; clearly a more sensitive method was required 
for quantification of plasma concentrations of fluoroquinolones in these animals. In 
addition, as koala metabolism is likely to be unusual, it was seen as desirable to use HPLC 
to detect possible metabolites. For these reasons, and because access to appropriate 
equipment became available from 2007, the author decided to validate a published HPLC 
assay (Liang, Kays et al., 2002) for analysis of plasma concentrations of fluoroquinolones 
in treated koalas. 
The final method used for HPLC analysis and key features of its validation are outlined in 
Chapter 7. Additional steps in the development and validation of the HPLC method, not 
presented in this thesis, included selection of sensitive excitation and emission frequencies 
for each drug of interest by “trial and error”, confirmation that a displacing agent was not 
required to improve recovery, verification of linearity of the standard curve and 
confirmation of the stability of samples in storage. 
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CHAPTER 7 - ABSORPTION OF ENROFLOXACIN AND 
MARBOFLOXACIN AFTER ORAL AND SUBCUTANEOUS 
ADMINISTRATION IN DISEASED KOALAS 
(PHASCOLARCTOS CINEREUS) 
The following is a re-formatted manuscript, currently in press: 
Griffith, J. E., Higgins, D. P., Li, K. M., Krockenberger, M. B., Govendir, M. (2010), 
“Absorption of enrofloxacin and marbofloxacin after oral and subcutaneous administration 
in diseased koalas (Phascolarctos cinereus)” Journal of Veterinary Pharmacology and 
Therapeutics (in press: accepted 1 Dec 2009). 
The study was designed, executed and reported by the candidate under the general 
supervision of the remaining authors, who were the candidate‟s appointed supervisors 
(principal and associate), with the exception of Dr K. M. Li, who provided assistance in 
high performance liquid chromatography method development and validation.  
7.1 ABSTRACT 
Koalas (n = 43) were treated daily for up to eight weeks with enrofloxacin: 10 mg/kg 
subcutaneously (s.c.), 5 mg/kg s.c., or 20 mg/kg per os (p.o.); or marbofloxacin: 1.0 - 3.3 
mg/kg p.o., 10 mg/kg p.o. or 5 mg/kg s.c. Serial plasma drug concentrations were 
determined on day one and again at approximately two weeks, by liquid chromatography. 
The median (range) plasma maximum concentrations (Cmax) for enrofloxacin 5 mg/kg s.c. 
and 10 mg/kg s.c. were 0.83 (0.68 - 1.52) and 2.08 (1.34 - 2.96) µg/mL and the median 
(range) Tmax were 1.5 h (1 - 2) and 1 h (1 - 2), respectively. Plasma concentrations of orally 
dosed marbofloxacin were too low to be quantified. Oral administration of enrofloxacin 
suggested absorption rate limited disposition pharmacokinetics; the median (range) Cmax 
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for enrofloxacin 20 mg/kg p.o. was 0.94 (0.76 - 1.0) µg/mL and the median (range) Tmax 
was 4 h (2 - 8). Oral absorption of both drugs was poor. Plasma protein binding for 
enrofloxacin was 55.4 ± 1.9% and marbofloxacin 49.5 ± 5.3%. Elevations in creatinine 
kinase activity were associated with drug injections. Enrofloxacin and marbofloxacin 
administered at these dose rates and routes are unlikely to inhibit the growth of chlamydial 
pathogens in vivo. 
Key words: 
koala, absorption, Chlamydophila, enrofloxacin, marbofloxacin  
7.2 INTRODUCTION 
Chlamydophila pneumoniae and C. pecorum infect up to 85% of some populations of the 
koala (Phascolarctos cinereus), a threatened, iconic Australian marsupial, causing 
significant morbidity (Jackson, White et al., 1999). Clinical signs may include: 
conjunctivitis (Cockram & Jackson, 1976), rhinitis (Nicolson, 2002), cystitis and/or 
reproductive tract disease (Brown & Grice, 1986).  
Chlamydial infection status has implications for movement of wild koalas into captive 
collections, export from Australia and translocation of animals between wild populations 
(Blanshard & Bodley, 2008). A reliable treatment for this disease is vital. Drugs such as 
erythromycin and oxytetracycline, used to treat chlamydiosis in other species, are poorly 
tolerated in koalas resulting in wasting and death (Brown, Wood et al., 1984; Osawa & 
Carrick, 1990). Consequently, koalas with chlamydiosis are often treated with 
fluoroquinolones, due to their perceived safety and anecdotal effectiveness, despite a lack 
of information on their therapeutic efficacy or pharmacokinetics. Current treatment 
regimes are based on dose rates and dosage frequencies extrapolated from dogs and cats, or 
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by “trial and error”.  
Koalas survive on a diet of eucalypt leaves, high in toxic plant secondary metabolites, and 
are monogastric hindgut fermentors with the largest relative caecal surface area of any 
animal (Snipes, Snipes et al., 1993) and a short small intestinal transit time (particulate 
matter; 6 minutes, soluble material; 60 minutes) (Cork & Warner, 1983) which are 
recognised as important factors impacting on species-dependent pharmacokinetics (Lin, 
1995). In addition, koalas have significantly increased bromosulphalein (BSP) 
clearance, compared with sheep, kangaroos and wallabies (Pass & Brown, 1990), 
indicating an increased rate of hepatic metabolism. Therefore, koalas may have 
unique pharmacokinetics due to reduced absorption, and increased metabolism and 
excretion rates of xenobiotics (McLean & Foley, 1997; Stupans, Jones et al., 2001). 
Fluoroquinolones have limited activity against Chlamydiaceae (Ridgway, 1997). In 
particular, sub-therapeutic plasma concentrations (e.g. 0.5 µg/mL ciprofloxacin or 1 µg/mL 
ofloxacin in vitro) (Dreses-Werringloer, Padubrin et al., 2000) may induce a state of 
“persistence,” whereby the pathogens remain viable within their host cell and cannot be 
cultured, but result in recrudescence when antibiotics are withdrawn (Hogan, Mathews et 
al., 2004), or may select for resistant chlamydial strains (Yokoi, Yasuda et al., 2004) as 
well as other normal and/or opportunistic flora. Thus, knowledge of the pharmacokinetics 
of fluoroquinolones in koalas has important implications for the likelihood of successful 
treatment and resolution of chlamydiosis.  
The objectives of this study were to investigate absorption of enrofloxacin and 
marbofloxacin in koalas following oral and subcutaneous administration and report any 
identifiable adverse effects. 
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7.3 MATERIALS AND METHODS 
7.3.1 Animals  
As a prospective, parallel group, clinical pharmacokinetic study, 43 wild koalas, (21 males, 
22 females; age 5.98 ± 2.7 years (mean ± SD); 1.5 - 12 years (range)) were recruited 
opportunistically from those admitted to the Koala Preservation Society of NSW‟s Koala 
Hospital at Port Macquarie, NSW, Australia, for treatment of chlamydial clinical signs or 
for relocation from dangerous areas (such as the vicinity of dogs or main roads).  
Physical examination was performed under general anaesthesia, induced and maintained 
by mask with isofluorane in 100% oxygen. Koalas were aged according to previous 
hospital admission records or by tooth wear (Martin, 1981), assessed for body condition 
scores (Connolly, 1999) and weighed. Due to ethical considerations, only animals with 
clinical or subclinical chlamydiosis were recruited. Clinical chlamydiosis (n = 33) was 
defined as the presence of highly suggestive physical signs (urine stained fur and/or 
conjunctivitis, and/or structural changes to the reproductive tract, as determined by 
ultrasound (Toshiba ECCOCEE SSA - 340A)) and subclinical chlamydiosis (n = 10) was 
defined as the presence of chlamydial DNA detected by polymerase chain reaction (PCR) 
from urogenital or conjunctival swabs (Demkin & Zimin, 2005) in the absence of clinical 
signs. Koalas were excluded on the basis of the following criteria: presence of concurrent 
non-chlamydial disease, renal pathology as detected by ultrasound, a body condition score 
of two or less out of five, or when weight loss during the acclimatisation period exceeded 
250 grams for females and 300 grams for males. 
Koalas were acclimatised for three to seven days before commencement of the study, 
housed individually in indoor enclosures (approximately 2.0 x 2.5 x 2.5 m) for the first 
three weeks and then transferred to individual outdoor pens (3.0 x 4.0 m). Fresh branches 
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of at least three different species of trees selected from Eucalyptus robusta, E. microcorys, 
E. tereticornis, E. nicholii, E. macrorhyncha, Melaleuca quinquenervia or Corymbia 
maculata, and water were provided daily.  
Initially, koalas were supplemented twice daily with a soya milk substitute (Karicare® 
Soya All Aged Formula, Nutricia, North Ryde, NSW, Australia, 7.1 g in 50 mL water; or 
Infasoy® Progress Step 2, Wyeth Australia, Baulkham Hills, NSW, Australia, 8.9 g in 50 
mL water) containing 0.9 g protein, 3.3 - 3.45 g carbohydrate, 1.8 - 1.85 g fat, 30.5 - 33 mg 
calcium, 2.55 - 3.35 mg magnesiu51420m, 0.3 - 0.35 mg zinc, 28 - 32 µg copper and 0.6 - 
0.7 µg selenium per 50 mL. Koalas strongly resistant to oral supplementation (exhibiting 
flinching, ear flicking, vocalisation, aggression and/or retreating) (n = 25) were randomly 
assigned to one of three s.c. administration treatment groups and supplementation ceased. 
A summary of the treatment groups is provided in Table 7-1.  
Table 7-1. Koala treatment groups. 
Drug Route Dose Presentation n
**
 
Enrofloxacin p.o. 20 mg/kg Baytril®
*
 oral suspension 25 mg/mL 8 
Enrofloxacin s.c. 5 mg/kg Baytril®
*
 injectable solution 50 mg/mL, or 
Enrotril®
†
 50mg/mL 
7 
Enrofloxacin s.c. 10 mg/kg Baytril®
*
 injectable solution 50 mg/mL, or 
Enrotril®
†
 50 mg/mL 
16 
Marbofloxacin p.o. 1 - 3.3 
mg/kg 
Zeniquin®
‡
 25 mg and 50 mg tablets 6 
Marbofloxacin p.o. 10 mg/kg Zeniquin®
‡
 25 mg and 50 mg tablets 6 
Marbofloxacin  s.c. 5 mg/kg Marbocyl®
§
 injectable 5 mg/mL 2
 
 
 
*Bayer Animal Health, Pymble, NSW, Australia 
†Troy Laboratories, Glendenning, NSW, Australia  
‡Pfizer, West Ryde, NSW, Australia  
§Vetoquinol, Lure cedex, France 
** Two animals were subsequently treated with a different medication regime (see below) and are thus 
counted twice. p.o: per os; s.c: subcutaneous. 
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7.3.2 Drug administration and blood collection 
Dose rates were based initially on those reported previously for koalas (Connolly, 1999) 
and dogs and cats (Pfizer Inc, 2005; Plumb, 2005). The treatment groups of enrofloxacin 
20 mg/kg p.o. and marbofloxacin 10 mg/kg p.o. were formulated based on low plasma 
concentrations detected in koalas administered enrofloxacin 5 mg/kg p.o. (n = 1; data not 
shown) and marbofloxacin 1 to 3.3 mg/kg p.o. (n = 6), respectively. As a small quantity of 
injectable marbofloxacin was available for this study, only two koalas were treated with 
this preparation. These animals were transferred onto other medications (marbofloxacin 10 
mg/kg p.o. or enrofloxacin 5 mg/kg s.c. respectively) after blood collection at 14 days and 
were thus excluded from further study. 
Marbofloxacin tablets were crushed and mixed with soya formula (20 mL). Enrofloxacin 
oral solution was administered by syringe. Following recommended practice for 
supplementing koalas undergoing systemic antibiotic treatment (Blanshard, 1994; 
Blanshard & Bodley, 2008), both groups were then supplemented with soya supplement to 
a maximum of 50 mL. For all treatment groups, koalas were medicated once daily in the 
morning for 4 to 8 weeks. Following cessation of treatment, animals were monitored for at 
least 4 weeks. Two koalas were treated with a different drug or dose rate following a wash 
out period of at least 3 weeks (enrofloxacin 10 mg/kg s.c. followed by 5 mg/kg s.c.; or 
marbofloxacin 10 mg/kg p.o. followed by enrofloxacin 20 mg/kg p.o.) due to recurrence of 
clinical signs during a post-treatment observation period. Animals with conjunctival 
discharge had their eyes cleansed daily with saline. 
For drug concentration determination, blood (2 mL) was collected from the cephalic vein 
into sodium heparin tubes before treatment (t = 0 h) and at 1, 2, 4, 8 and 24 h after 
medication on day 1 and 14 to 16 days later. Plasma, stored at -20 ºC, was protected from 
  149 
light until analysis.  
7.3.3 Drug analysis  
Enrofloxacin and marbofloxacin plasma concentrations were determined by a modified 
reversed-phase, high performance liquid chromatography (HPLC) method (Liang, Kays et 
al., 2002). The HPLC system (Shimadzu, Rydalmere, NSW, Australia) consisted of an 
isocratic pump (LC20AT), autosampler (SIL 20AC) maintained at 15 ºC, column oven 
(CTO 20AC) maintained at 25 ºC, fluorescence detector (RF - 10AXL), a system controller 
(CBM 20A) and Shimadzu Class VP software (version 7.4). Chromatographic separation 
was accomplished on an Apollo C-18, 5 m (4.6 mm x 250 mm) column (Alltech, 
Dandenong South, Vic, Australia) coupled with a 1 mm Optiguard® C-18 guard column 
(Optimize Technologies, Oregon City, Oregon, USA). The mobile phase (pH 2.0) 
consisted of acetonitrile: purified water (50: 50) (Ajax Finechem, Taren Point, NSW, 
Australia), 25 mM citric acid (Sigma-Aldrich, Castle Hill, NSW, Australia) and 10 mM 
sodium dodecyl sulfate (Boehringer Mannheim, Indianapolis, USA). The flow rate was 
maintained isocratically at 1 mL/min and sample injection volume was 5 μL. Enrofloxacin, 
and its major metabolite, ciprofloxacin, were detected using fluorescence at excitation and 
emission of 280 nm and 450 nm, respectively, and marbofloxacin at excitation and 
emission of 300 nm and 500 nm, respectively. Retention times for enrofloxacin, 
ciprofloxacin, marbofloxacin and orbifloxacin were 9.9, 8.0, 7.8 and 10.7 min, 
respectively. Orbifloxacin was used as the internal standard.  
External calibration standards were prepared daily by adding HPLC analytical grade 
enrofloxacin and ciprofloxacin (Sigma-Aldrich, Castle Hill, NSW, Australia) or 
marbofloxacin (Pfizer Inc, Groton, Connecticut, USA) to untreated koala plasma. Prior to 
extraction, 1 µg/mL of internal standard (analytical grade orbifloxacin, (Schering Plough, 
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Kenilworth, New Jersey, USA) dissolved in 25 L untreated pooled koala plasma) was 
added to calibration standards and plasma samples.  
Plasma samples collected from medicated koalas and calibration standards underwent 
solid-phase extraction (SPE) using Oasis® HLB 1 cm
3
 30 mg column filters (Waters, 
Milford, Massachusetts, USA) via a vacuum manifold, according to manufacturer‟s 
instructions. Briefly, the SPE cartridge was conditioned with 1 mL methanol, followed by 
1 mL deionised water. Plasma (250 μL) was loaded, followed by 1 mL 5% methanol. 
Samples were eluted with 1 mL methanol. Eluates were dried at room temperature by a 
vacuum concentrator (SC2000, Savant Instruments, Holbrook, New York, USA) and 
reconstituted in 100 µL of mobile phase. The mean % (± SD) recovery was determined by 
comparing a known concentration of enrofloxacin or marbofloxacin added to untreated 
koala plasma prior to, and after SPE. Enrofloxacin recovery was 93 ± 4.87% and 
marbofloxacin 94.6 ± 1.94%. 
The concentration of either enrofloxacin or marbofloxacin in plasma from treated koalas 
was determined by interpolation from the calibration curve with a minimum co-efficient of 
correlation (r
2
) of 0.99. The limit of detection (LOD) and limit of quantification (LOQ) 
were calculated based on the standard deviation of y-intercepts of regression line of the 
standards (International Conference on Harmonisation, 1996). Inter-assay variation was 
estimated by comparing replicates from the three standards used for calibration curves 
from 16 (enrofloxacin) or 7 (marbofloxacin) different assay days. Intra-assay variation 
(precision) was estimated from six replicates of five standard samples (0.25, 0.5, 1, 2, 4 
µg/mL). The inter-assay and intra-assay variation was < 10% for enrofloxacin for all 
concentrations above the LOQ and < 16% and < 27% for marbofloxacin for all 
concentrations above LOQ, respectively. The LOQ and LOD for enrofloxacin, 
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ciprofloxacin and marbofloxacin were 0.40 & 0.12 µg/mL; 0.25 & 0.08 µg/mL; 0.48 & 
0.16 µg/mL, respectively. 
There were no interfering peaks from endogenous compounds in pooled, drug-free koala 
plasma at the retention times of compounds of interest. Additional peaks at consistent 
retention times were considered potential metabolites if the mean area changed over time 
in a manner similar to that of the parent drug, i.e. peaking within 1 to 2 h of dosage and 
then declining between 4 and 8 h (Bremseth, Lima et al., 1988).  
7.3.4 Plasma protein binding 
The degree of drug-binding to plasma protein was investigated using ultracentrifugation. 
Briefly, enrofloxacin (1 µg/mL), or marbofloxacin (2 µg/mL), in untreated thawed koala 
plasma was incubated at 35 ºC for 30 min and then centrifuged (30 min at 3000 x g), in a 
fixed angle rotor centrifuge (Presvac DCS-16-RVT) through an ultrafiltration device 
(Centricon® YM-30, Millipore, North Ryde, NSW, Australia). The non-protein-bound 
ultrafiltrate was collected by pipette, adjusted to 500 µL with mobile phase and analysed 
by HPLC without SPE. The protein-rich fraction was collected by inverting and 
centrifuging the ultrafiltration device for 2 min at 3000 x g, subjected to SPE and drying as 
described above, reconstituted with 500 μL mobile phase and analysed by HPLC. The 
degree of binding of drug to the ultrafiltration device (i.e. the loss) was calculated by 
replicating the above steps using the same drug concentrations in phosphate buffered 
saline. In addition, aliquots of the same drug concentrations in koala plasma were 
incubated as above, subjected to SPE, dried, reconstituted in 500 μL of mobile phase and 
analysed to determine total (bound and unbound) drug concentration. All samples were 
assayed in triplicate. Percentage plasma protein binding for each drug, after correcting for 
losses from SPE and the ultrafiltration device, were determined by the following formula: 
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% protein binding = bounddrug / (unbounddrug + bounddrug) 
where unbounddrug + bounddrug = totaldrug. 
7.3.5 Pharmacokinetic analysis 
Enrofloxacin and marbofloxacin concentration versus (vs.) time data for each animal were 
subjected to standard non-compartmental pharmacokinetic analysis. Only values above the 
LOQ were used in calculations. Maximum plasma concentration (Cmax) and time to 
maximum plasma concentration (Tmax) were determined graphically. The area under the 
curve (AUC) was determined by the trapezoidal method. The elimination rate constant 
(Kel) was determined by the gradient of the natural log of plasma concentration vs. time, 
where the relationship was linear, the gradient negative (indicating elimination), and the 
concentration was above the limit of quantification. The AUC extrapolated to infinity 
(AUC0-∞) was calculated as the sum of AUC up until the last measurable concentration 
(AUC0-LOQ) plus Ct/Kel (AUCextrapolated), where Ct was the last measurable concentration. 
The percentage of each contribution to the AUC0-∞ was determined. Elimination half life 
(t½) was calculated using the equation t½ = ln2/Kel. 
7.3.6 Animal monitoring procedures 
During drug treatment and post-treatment, observations of feed and water intake, urine and 
faecal production, and demeanour were undertaken daily and animals were weighed at 
least twice weekly.  
Every 7 days during treatment, and 14 days post-treatment, koalas were anaesthetised, 
examined physically and the urogenital tract imaged by ultrasound. In addition, blood was 
collected into potassium EDTA for routine haematological analysis using standard 
methods, or plain tubes for serum biochemical analysis including creatinine kinase activity 
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(CK), with a Roche Modular Chemistry Analyser using Roche reagents (Roche, Basel, 
Switzerland). Urine was expressed manually from the bladder for urinalysis (Bayer-
Multistix®, Bayer Australia, Pymble, NSW, Australia) and determination of urine specific 
gravity. Urine sediment was stained with methylene blue and examined under light 
microscopy. 
Animals that died during treatment (n = 2) or were euthanased at the end of the study for 
other reasons (n = 16), underwent necropsy using standard techniques. Tissues were 
collected into 10% formalin for a minimum of 24 h, embedded in paraffin and sections 
subjected to standard haematoxylin and eosin staining, and examined under light 
microscopy. At the end of the study all other animals were released into a suitable bush 
habitat, close to where they had been originally found. 
7.3.7 Statistical modelling 
Results of serum biochemistry, haematology and weight changes over time (weeks) were 
analysed using residual maximum likelihood for the effect of drug, dose rate, week, route 
and whether the animal was within the pre-treatment, treatment or post-treatment interval. 
Statistical significance was concluded at p ≤ 0.05. 
7.4 RESULTS 
Some pharmacokinetic parameters for enrofloxacin and marbofloxacin are presented in 
Table 7-2. The median (range) plasma concentration vs. time for enrofloxacin and 
marbofloxacin are presented in Figure 7-1 and Figure 7-2, respectively. Plasma protein 
binding for enrofloxacin was 55.4 ± 1.9% and marbofloxacin 49.5 ± 5.3%. Plasma drug 
concentrations did not differ significantly between day 1 and after multiple dosing with 
either drug at any dose rate. The median (range) AUCextrapolated on day 1 were: enrofloxacin 
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5 mg/kg s.c. 47.8% (25.8 - 60.7%); enrofloxacin 10 mg/kg s.c. 30.2% (12.7 - 54.9%) and 
for marbofloxacin 5 mg/kg s.c. 23.5% (18 -28.7%). The plasma concentrations of 
marbofloxacin in animals dosed orally were mostly below the limit of quantification 
(Figure 7-2). Median (range) Tmax for enrofloxacin dosed orally was long 4 h (2 - 8 h) and 
therefore calculation of Kel was not possible as only two points were above the LOQ during 
the elimination phase (Figure 7-2). 
 
 
 
 
 
Figure 7-1. Semi-logarithmic plot of median (± range) plasma concentration of enrofloxacin 
over time in treated koalas. 
Koalas were treated with 5 mg/kg subcutaneous injection (s.c.) () (n = 6), 10 mg/kg s.c. () (n = 10) and 
20 mg/kg per os. () (n = 6) on day 1. LOQ is the level of quantification; LOD is the level of detection; MIC 
is the minimum inhibitory concentration. 
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Figure 7-2. Semi-logarithmic plot of median (± range) plasma concentration of marbofloxacin 
over time in treated koalas. 
Koalas were treated with 5 mg/kg subcutaneous injection () (n = 2), and 10 mg/kg per os () (n = 6) on 
day 1. LOQ is the level of quantification; LOD is the level of detection. 
 
In chromatograms of those animals dosed with enrofloxacin 10 mg/kg s.c., five suspected 
metabolites were detected at retention times 4.0, 7.2, 7.5, 8.0 and 9.2 min. In > 80% of 
plasma concentration vs. time curves, another metabolite at 6.8 minutes was detected in 
two thirds of plasma concentration vs. time curves (n = 12). In animals dosed with 
marbofloxacin 5 mg/kg s.c. (n = 2) or marbofloxacin 10 mg/kg p.o. (n = 6), one suspected 
metabolite (retention time 8.1 min) was noted in all plasma concentration vs. time curves.  
All animals, with one exception, maintained body weight, appetite, normal demeanour and 
normal fecal and urine output throughout the study. Biochemical analytes and 
haematological indices remained within published reference intervals (Canfield, O'Neill et 
al., 1989; Blanshard, 1994) with the exception of CK activity, which was significantly 
elevated in koalas during treatment with daily s.c. injections of both drugs compared to 
pre-treatment samples (approximately eighteen-fold and seven-fold, respectively) and post-
treatment samples (approximately fourteen-fold for enrofloxacin) (Figure 7-3). 
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Table 7-2. Some pharmacokinetic parameters for enrofloxacin subcutaneous (s.c.) and oral (p.o.) administration and marbofloxacin s.c. 
administration in koalas using non-compartmental analysis. 
 
Parameter n Cmax (µg/mL) Tmax (h) Kel (h
-1
) AUC (0-LOQ) 
(µg.h/mL) 
AUC(0-∞) 
(µg.h/mL) 
t½ (h) 
Enrofloxacin 5 mg/kg s.c. (d1) 6 0.83 (0.66 - 1.52) 1.5 (1 - 2) 0.28 (0.15 - 0.38) 2.40 (2.14 - 3.64) 4.9 (4.04 - 5.7) 2.43 (1.8 - 4.65) 
Enrofloxacin 5 mg/kg s.c. (multiple dosing) 6 0.91 (0.58 - 1.46) 1.5 (1 - 2) 0.23 (0.14 - 0.39) 2.53 (1.63 - 2.82) 4.26 (3.18 - 7.2) 2.95 (1.74 - 4.94) 
Enrofloxacin 10 mg/kg s.c. (d1) 10 2.08 (1.34 - 2.96) 1 (1 - 2) 0.32 (0.21 - 57) 5.42 (4.78 - 7.035) 8.32 (5.17 - 9.43) 2.31 (1.21 - 3.44) 
Enrofloxacin 10 mg/kg s.c. (multiple dosing)  14 1.84 (0.99 - 2.74) 1 (1 - 2) 0.33 (0.17 - 0.61) 5.23 (3.08 - 11.43) 10.18 (6.3 - 15.1) 2.11 (1.13 - 3.97) 
Enrofloxacin
*
 20 mg/kg p.o. (d1)  6 0.94 (0.76 - 1.0) 4 (2 - 8)     
Enrofloxacin
* 
20 mg/kg p.o. (multiple dosing)
 
6 0.71 (0.4 - 1.04) 4 (2 - 4)     
Marbofloxacin 5 mg/kg s.c. (d1) 2 2.18 (1.86 - 2.52) 1 0.43 (0.36 - 0.49) 4.63 (4.16 - 5.1) 6.04 (5.83 - 6.24) 1.66 (1.4 - 1.9) 
Parameters are shown as median (range). Cmax: maximum plasma concentration; Tmax: time to maximum plasma concentration; Kel (h-1): the excretion rate constant (first 
order); AUC (0-LOQ): area under the plasma concentration time curve from zero to the last point above the level of quantification; AUC0-∞: area under curve between t = 0 
and t =; t½: half life of terminal phase.  
*calculation of Kel, AUC and t1/2 was not possible as only two points were above the LOQ during the elimination phase.  
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Figure 7-3. Creatinine kinase (CK) activity (mean ± SEM) in serum comparing pre-
treatment, treatment and post-treatment samples in treated koalas. 
Animals were treated with enrofloxacin 10 mg/kg subcutaneous injection (s.c.), 20 mg/kg per os (p.o.), and 
marbofloxacin 5 mg/kg s.c. and 10 mg/kg p.o. Normal range for CK activity in koalas (100 - 300 μmol/L) 
(Blanshard, 1994) shown with dashed lines.  
 
Histological examination of tissues detected only two abnormalities not directly 
attributable to chronic chlamydial disease. One koala dosed with enrofloxacin 20 mg/kg 
p.o. once daily was euthanased due to persistent azotaemia with inappropriately dilute 
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urine, depression and inappetence three weeks after starting treatment. At post mortem 
examination this animal had severe, diffuse, subacute, cortical tubular oxalate nephrosis. 
Another koala died under anaesthesia, as a result of cardiac arrest, 13 days after 
commencement of enrofloxacin at 20 mg/kg p.o. This koala had an anaesthetic induced 
arrhythmia detected by auscultation, prior to treatment and during two subsequent general 
anaesthesia procedures.  
7.5  DISCUSSION 
This study is the first into aspects of selected drug pharmacokinetics in koalas. Our 
findings make a significant contribution to the understanding of drug administration in this 
species. There are many challenges associated with conducting a study such as this in an 
iconic wildlife species. This study was restricted to opportunistic recruitment of clinical 
cases during therapeutic treatment, which limited the size of treatment groups, particularly 
those amenable to oral administration. It was also restricted to conventional routes of drug 
administration in koalas, precluding an intravenous treatment group and six time points, to 
minimise the stress of handling. Despite these limitations, we can report that koalas 
administered oral enrofloxacin exhibit limited oral absorption with a long Tmax compared to 
other species and that marbofloxacin has similarly poor relative oral absorption. 
Conventional dog and cat dose rates, by both administration routes for both drugs produced 
relatively low Cmax compared to other species and lack of drug accumulation. There was no 
clear indication of adverse affects, although CK activity increased in those animals injected 
subcutaneously, which has not been reported previously in this species.  
Relative oral absorption of enrofloxacin compared to the s.c. route was poor, the median 
Tmax was long (4 vs. 2 h) and AUC0-LOQ had high individual variability. Visual inspection 
of the oral data presented in Figure 7-1 suggests absorption rate limited disposition. Poor 
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oral absorption of marbofloxacin and enrofloxacin may occur in koalas for a variety of 
reasons. Firstly, the koala stomach is normally full of dense, finely masticated leaf material 
(Blanshard & Bodley, 2008) that may entrap drugs or contain macromolecules that bind 
drugs, reducing their absorption, as hypothesised in sheep (González, San Andrés et al., 
2001). Secondly, the koala‟s diet of Eucalyptus contains metal cations such as cobalt, 
copper, zinc, calcium, magnesium, iron and selenium (McOrist & Thomas, 1984) that may 
form complexes with fluoroquinolones, reducing oral bioavailability (Turel, 2002). Soya, 
or low lactose milk formulas are routinely administered to sick koalas to supplement 
nutrition and enable administration of oral medications (Blanshard & Bodley, 2008) and 
supplementation was used in our study to duplicate this practice. Such supplementation 
could have contributed to limited absorption of drugs due to chelation with calcium ions as 
occurs with dairy products in people (Kivisto, Ojala-Karlsson et al., 1992; Turel, 2002). 
The effect of chelation of enrofloxacin or marbofloxacin by the supplements in vitro or in 
vivo was not investigated, but should be considered for future studies. Thirdly, active 
transepithelial secretion of many fluoroquinolones occurs at several areas within the 
intestinal tract in different species, and may inhibit absorption (Ramon, Ben-Haim et al., 
2001). Fourthly, the mean intestinal residence time of drugs may influence the rate of 
absorption (Baluom, Friedman et al., 1998) and the small intestinal transit time in koalas is 
short (particulate matter; 6 minutes, soluble material; 60 minutes) (Cork & Warner, 1983). 
Finally, poor oral relative bioavailability could be due to active first-pass metabolism as 
suggested by studies of BSP clearance in koalas indicating an increased rate of hepatic 
metabolism relative to other species (Pass & Brown, 1990). Our results support the 
hypothesis that proposed methods of interspecific scaling used to predict safe drug dose 
regimes in untested species may not be reliable for every drug, particularly when unique 
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interspecific hepatic metabolism is suspected (Hunter & Isaza, 2008). 
Studies of pharmacokinetic aspects in other Australian marsupials that are related to the 
koala are rare (Kirkwood, Gulland et al., 1988), thus aspects of drug absorption are 
compared here between koalas and other „hind-gut fermenting‟ species with similar 
gastrointestinal tract anatomy such as rabbits and horses. Subcutaneous enrofloxacin 
administration (5 mg/kg after d 1) produced a Cmax (median 0.83; range 0.66 - 1.52 µg/mL) 
that was low compared to rabbits (2.23; 1.02 - 2.79 µg/mL) (Broome, Brooks et al., 1991). 
The relatively low Cmax for enrofloxacin could be related to poor vascularity around the 
injection site (the dorsal thorax, or “scruff”) limiting absorption, or rapid clearance by 
efficient local and/or hepatic metabolism and/or excretion. Plasma drug accumulation was 
not a significant factor. The absence of difference between drug concentrations between 
day 1 and multiple dosing suggests enrofloxacin metabolism and excretion is complete by 
24 hours in koalas. The t½ for marbofloxacin administered at the same dose rate and route 
(1.66; 1.4 - 1.9 h) was shorter than in horses (5.47 ± 1.33 h) administered marbofloxacin 2 
mg/kg intramuscularly (Carretero, Rodriguez et al., 2002) and may indicate a more 
efficient rate of elimination in koalas.  
Plasma concentrations of marbofloxacin, when administered orally, were mostly below the 
LOQ, indicating poor oral absorption at this dose rate. A more sensitive method would be 
required to detect the extremely low concentrations of marbofloxacin in koala plasma 
resulting from the oral dose rates used in this study, however, given the apparent poor oral 
absorption of this drug and that the injectable formulation of marbofloxacin is unavailable 
in Australia, further study of oral formulations of this drug may not have practical 
applications in koalas. 
The plasma protein binding for enrofloxacin observed here (55.4 ± 1.9%) was similar to 
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that for enrofloxacin in rabbits 50 ± 2% (Bregante, Saez et al., 1999), but higher than in 
horses (22%) (Papich & Riviere, 2001). Marbofloxacin protein binding (49.5 ± 5.3%), was 
higher than in calves (29 ± 2.2%) (Ismail & El-Kattan, 2007) and dogs (21.8 ± 6.2%) 
(Bidgood & Papich, 2005). These differences may reflect species differences in the number 
of plasma protein binding sites or their affinity for these drugs (Lin, 1995). Frozen plasma 
was used due to the practicalities of transporting samples from the remote field site. Frozen 
plasma may vary in pH compared with fresh plasma, affecting drug-protein binding assays 
(Riedel, 2006) therefore comparison between frozen and fresh plasma would be useful to 
confirm the values presented here. 
Ciprofloxacin concentrations were below the LOD of the assay, suggesting that if present 
at all, low concentrations of this metabolite are produced in the koala (< 0.08 µg/mL), 
similar to other species (Papich & Riviere, 2001). Enrofloxacin is metabolised, via de-
ethylation of the ethyl group on the piperizine ring, to ciprofloxacin. Ciprofloxacin is 
microbiologically active and may contribute to the overall efficacy of enrofloxacin (Papich 
& Riviere, 2001). The six metabolites detected in the enrofloxacin chromatogram could be 
ciprofloxacin, metabolites of ciprofloxacin itself or the parent compound. Marbofloxacin is 
metabolised into N-desmethyl-marbofloxacin in chickens (Anadon, Martinez-Larranaga et 
al., 2002), dogs (Lefebvre, Schneider et al., 1998), cattle (Schneider, Valle et al., 2004), 
ball pythons and blue and gold macaws (Hunter, Koch et al., 2007) and further metabolites 
have been identified in dogs (Lefebvre, Schneider et al., 1998), cattle (Schneider, Valle et 
al., 2004) and blue and gold macaws (Hunter, Koch et al.). The one marbofloxacin 
metabolite observed in this study remains to be identified. 
As this study relied on opportunistic recruitment of wild animals with naturally occurring 
disease, animals were recruited with different states of disease (subclinical versus clinical), 
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varying weights, ages and sex, all factors that may influence pharmacokinetics and 
pharmacodynamics (Mahmood, 2006) and could explain the variability in pharmacokinetic 
parameters observed in this study. Small numbers of animals within each treatment group 
limited analysis of the influence of these factors on pharmacokinetic parameters. Our 
cohort represents the spectrum of expression of koala chlamydial disease for which these 
drugs are most commonly used. Further investigations examining pharmacokinetic 
parameters in healthy animals with attention to uniformity of signalment would be useful 
as a comparison to the results presented here. 
Minimum inhibitory concentrations (MICs) of enrofloxacin or marbofloxacin have not 
been determined for inhibition of the growth of chlamydial species isolated from koalas. 
However, the MIC range of enrofloxacin for C. pneumoniae isolates from bandicoots has 
been determined (0.25 - 0.5 µg/mL) (Kumar, Kutlin et al., 2007) and is similar to that of 
other fluoroquinolones (ofloxacin and ciprofloxacin) for C. pecorum isolates from cattle 
(0.25 - 0.5 µg/mL and 0.25 - 1.0 µg/mL, respectively) (Pudjiatmoko, Fukushi et al., 1998). 
These organisms are most similar to koala Chlamydiaceae genetically (Everett, Bush et al., 
1999; Kutlin, Roblin et al., 2007), and therefore a concentration of 0.25 µg/mL was chosen 
most likely to represent the MIC of enrofloxacin against koala Chlamydiaceae. The MIC of 
marbofloxacin has not been determined for chlamydial species. 
 A Cmax/MIC ratio of 8 - 10 and/or a AUC/MIC ratio of 125 - 250 is generally regarded as 
being 100% bactericidal with minimum risk of mutant selection for fluoroquinolones 
(Papich & Riviere, 2001) although these ratios may not always reflect the in vivo situation 
in naturally acquired disease (Aliabadi, Ali et al., 2003). However, using such ratios as a 
guide, a theoretical in vivo bactericidal action would require a Cmax of at least 2.5 µg/mL 
for enrofloxacin. If plasma protein binding is taken into account (approximately 50%) then 
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a Cmax of 5 µg/mL would be required for a bactericidal effect. Clearly, these concentrations 
were not achieved in koalas by any route and suggest a lack of efficacy. The sub-optimal 
regimes of fluoroquinolones suggested here may induce a state of “persistence” in infected 
animals leading to treatment failure, or select for resistant strains of Chlamydiaceae or 
other normal and/or opportunistic flora. In vivo chlamydial resistance to fluoroquinolones 
has been described occasionally (Yokoi, Yasuda et al., 2004) and has been induced in vitro 
(Dessus-Babus, Bebear et al., 1998). Further, resistant normal and/or opportunistic flora 
might pose a risk to some human care-givers through direct contact with koalas or via 
indirect contact with their faeces and urine (Guardabassi, Schwarz et al., 2004).  
Koalas in this study maintained weight during treatment in contrast to a previous study of 
subcutaneously administered oxytetracycline (Osawa & Carrick, 1990) and anecdotal 
reports of erythromycin use (Brown, Wood et al., 1984), suggesting that fluoroquinolones 
do not cause life-threatening dysbiosis. The observed elevation of plasma activity of CK 
may be associated with a myopathy, although injection site biopsies would be required to 
determine the nature and distribution of lesions. It appears unlikely that CK activity 
elevations in these koalas resulted from capture myopathy (Munday, 1972) or injection 
trauma, as elevations were not detected in koalas handled frequently (e.g. to cleanse eyes 
with saline) or in records of three koalas injected with amoxicillin-clavulanate s.c. 
(unpublished data). Increases in CK activity following intramuscular injections of 
fluoroquinolones in other species have been reported (Nyska, Skolnick et al., 1994; 
Kaartinen, Panu et al., 1997). 
Two koalas died during treatment with enrofloxacin (20 mg/kg p.o.); however neither can 
be directly attributed to enrofloxacin use. Although oxalate nephrosis in people has been 
associated with an antibiotic-induced reduction in gastrointestinal populations of 
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Oxalobacter formigenes, a commensal anaerobe important in oxalate degradation (Mittal, 
Kumar et al., 2005), this disease is also described infrequently in untreated koalas from the 
study location (Canfield, 1989).  
The findings of this study indicate that doses of fluoroquinolones used widely for the 
treatment of chlamydiosis in koalas do not reach likely therapeutic levels required. Future 
studies examining the clinical response to these treatments are required to minimise 
wastage of resources and predict treatment outcomes. In addition to their implications for 
drug administration, our findings of poor oral availability relative to the subcutaneous 
route raise interesting questions on mechanisms for absorption and metabolism of drugs 
and plant xenobiotics in this species.  
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CHAPTER 8 - THE CLINICAL AND MICROBIAL 
RESPONSE TO FLUOROQUINOLONE TREATMENT OF 
KOALAS INFECTED WITH CHLAMYDIACEAE 
8.1 INTRODUCTION  
Chlamydiosis, the most prevalent and important infectious disease in koalas, causes 
significant morbidity in many populations throughout Australia (Obendorf, 1983; Canfield, 
1987; Canfield, 1989; Jackson, White et al., 1999; McLean, 2003; Stalder, 2003). 
Treatment of koalas with clinical signs consistent with chlamydiosis makes up a substantial 
part of the workload of koala rehabilitation facilities in Australia. At the Koala 
Preservation Society of NSW‟s Koala Hospital in Port Macquarie, NSW, such cases 
account for approximately 20% of all admissions (Chapter 2).  
Despite a lack of rigorous evidence demonstrating efficacy, enrofloxacin, often given 
orally, is the mainstay of treatment of urogenital forms of chlamydiosis in two of the three 
major koala rehabilitation facilities in Australia (Blanshard & Bodley, 2008) (Chapter 3 
and Table 5.1). In human medicine, older quinolone antibiotics have been unsuccessful in 
treating chlamydiosis (Ridgway, 1997) although, more recently, third generation 
fluoroquinolones have been recommended for the treatment of Chlamydia trachomatis 
(Ridgway, 1997) and Chlamydophila pneumoniae infections (Hammerschlag, 2003). The 
results of treating animal chlamydiosis with a veterinary fluoroquinolone (enrofloxacin) 
are equivocal. Some authors report successful treatment, possibly as a result of false 
negatives as relatively insensitive diagnostic techniques were used (cell culture 
(Lindenstruth & Frost, 1993), immunofluorescence (Gerhardt, Schulz et al., 2006)); others 
report treatment failure (Penguin Taxon Advisory Group, 2005; Hartmann, Helps et al., 
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2008).  
Previous work in this thesis found the fluoroquinolone plasma concentrations in treated 
koalas to be low and thus likely to be ineffective in treating chlamydiosis (Chapter 7) 
(Griffith, Higgins et al., 2010). This is at odds with its apparent success based on medical 
records (Chapter 3) and anecdotal evidence (Blanshard & Bodley, 2008). Given this 
evident contradiction, this author explored whether treatment with fluoroquinolones in 
koalas effectively reduces clinical signs of chlamydiosis and ultimately achieves microbial 
negativity. This information is important to determine whether it is safe to translocate 
treated animals into populations negative for Chlamydiaceae or with novel chlamydial 
strains, and is important information for future epidemiological studies of the potential 
impact of treated animals on the local population. 
This study also provided the opportunity to study the relationship between chlamydial load 
and clinical signs. Diagnosis of chlamydial infection in koalas is often based on clinical 
signs alone (Chapter 3). The assumption that clinical signs are a sensitive diagnostic test 
dictates management decisions regarding which animals receive treatment, the route and 
end point of treatment, and husbandry decisions regarding disinfection of housing facilities 
and isolation of animals at the Koala Hospital. As previous studies have indicated that 
subclinical chlamydiosis is common in some populations of koalas in Queensland (56%) 
(Jackson, White et al., 1999) and Victoria (39%) (McLean, 2003), and in women (Stamm, 
1999), calves and cats (Shewen, 1980), and birds and sheep (Longbottom & Coulter, 
2003), investigation of the validity of this assumption is warranted. Such information 
would better inform resource allocation and captive husbandry guidelines for koalas in 
rehabilitation centres and contribute to epidemiological studies of disease prevalence in 
wild koalas.  
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Given this background, the following hypotheses were generated and tested: 
1/ clinical signs reflect the presence of chlamydial organisms in koalas 
2/ severity of clinical signs correlate with mucosal load of C. pecorum  
3/ treatment with fluoroquinolones at standard mammalian dose rates eliminate C. pecorum 
and C. pneumoniae from koalas. 
8.2 METHODS 
8.2.1 Design of the study 
To test the hypothesis that clinical signs reflect the presence of chlamydial organisms in 
koalas, the presence of C. pneumoniae and/or C. pecorum was detected using real-time 
polymerase chain reaction (qPCR) of ocular and urogenital swabs collected immediately 
prior to treatment (day 0) and results compared with clinical scores of these sites.  
Mucosal C. pecorum load was then estimated using qPCR and examined relative to 
severity of clinical signs and phase of antibiotic treatment. Sites positive at day 0 were 
subsequently tested weekly for three weeks, on the last day of treatment, two weeks after 
cessation of treatment, and then on the final available swab (usually four weeks after 
treatment end); or, where animals did not stop treatment because clinical signs did not 
abate, they were tested weekly for up to 10 weeks. Two animals that died during treatment 
were not tested. Where multiple sites were positive in one animal at the start of treatment, 
each site was tested individually. Clinical assessments were conducted as per Chapter 4 
and data compared to chlamydial loads at associated time points. 
To test the hypothesis that treatment with fluoroquinolones eliminates C. pecorum and C. 
pneumoniae, both eyes and urogenital tracts of all animals were examined for presence of 
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organisms prior to treatment and at the last time point available, using qPCR. Animals that 
were negative at all three sites after treatment were retested using DNA at two dilutions 
(1:10 and 1:100), extracted from duplicate swabs from the last available time point. 
8.2.2 Animals 
Koalas (16 males, 15 females) of median age 5.5 years (range 2 - 12 years) were recruited, 
housed, examined, allocated to treatment groups (Table 8-1), sampled from, observed and 
monitored as described in Chapter 4. Inclusion and rejection criteria are outlined in 
Chapter 4. Treatment was continued for four to 10 weeks, and was discontinued when 
clinical signs had resolved and animals were negative on two consecutive weekly PCRs 
using primers specific to all Chlamydiaceae (see 4.11). Seventeen animals (14 males, 3 
females) completed treatment and were monitored for another four weeks.  
 
 
Table 8-1. Fluoroquinolone treatments administered, median length of treatment and 
number released of 29 koalas treated for chlamydiosis.  
 
Drug n Length of treatment 
median (range) 
Released 
Marbofloxacin 10 mg/kg p.o. SID 5 34 (31 - 64) 4 
Marbofloxacin 1-3.3 mg/kg p.o. SID 5 44 (28 - 44) 0 
Enrofloxacin 5 mg/kg p.o. SID 1 44 0 
Enrofloxacin 10 mg/kg s.c. SID 11 43.5 (31 - 70) 10 
Enrofloxacin 20 mg/kg p.o. SID 3 30 (30 - 38) 3 
Enrofloxacin 5 mg/kg s.c. SID 4 47 (44 - 48) 0 
Total 29  17 
SID: once daily; p.o: per os; s.c: subcutaneous injection. 
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Two animals died during treatment, following administration of 20 mg/kg enrofloxacin 
p.o. for 20 and 14 days, respectively and were excluded from analysis. The first animal 
was euthanased on day 22 after a five-day history of inappetence, depression, dehydration, 
azotaemia and inadequately concentrated urine, and was found to have acute renal oxalate 
nephrosis on post mortem examination (HL in Appendix IV). The second animal died 
under general anaesthesia at 14 days, after experiencing cardiac arrhythmia detected by 
auscultation at the anaesthetic associated with death and two prior anaesthetic episodes. 
Post mortem examination revealed peracute myocardial hyaline necrosis (BP in Appendix 
IV). Neither pathological process can be directly attributed to fluoroquinolone use. Of the 
12 further animals not released, 10 were euthanased due to structural disease or persistent 
or recurrent clinical signs, and two (OA and AG) were re-treated with intramuscular 
doxycycline and were subsequently euthanased (detail provided in Chapter 5 and 
Appendix II and III). All deceased animals underwent a standard midline post mortem 
examination (Blanshard, 1994) as per Chapter 4. 
8.2.3 Clinical scores 
Methods used clinically to describe urogenital tract disease (modified wet bottom score 
and ultrasonography) and ocular disease are described in Chapter 4 and Chapter 5, 
respectively. Any modified wet bottom score above zero was considered clinical disease. 
Objectivity and consistency for ocular disease scoring were improved for this study by 
blinded scoring of digital photographs taken at time of examination. The left and right eyes 
were photographed, with ocular pathology made visible by gentle manual retraction of the 
palpebrae. Four hundred and four images of eyes from 22 individuals were ascribed non-
identifiable codes and randomised using the random number and sort functions in 
Microsoft® Office Excel® 2003 (Microsoft® Corporation, Redmond, Washington, USA). 
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The author then graded chemosis, proliferation of the conjunctiva, and amount of discharge 
as zero (normal), one (mild), two (moderate) or three (severe) against reference 
photographs and criteria (Table 8-2 to Table 8-4). The scores for each parameter for each 
eye were summed to derive a total eye score. Comparison was made between total eye 
scores determined using the above method and clinical descriptions made in the field. Total 
eye scores of greater than three were always described as “conjunctivitis” in corresponding 
field assessments, and thus a total eye score of greater than three was considered indicative 
of clinical disease. 
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Table 8-2. Grading of ocular pathology (chemosis) showing definitions used and reference 
photographs. 
 
Grade Chemosis: 
(Swelling of the conjunctiva) 
Examples 
Grade 0 None 
 
Grade 1 Swelling < 50% of conjunctiva and the nictitating 
membrane only 
 
Grade 2 Swelling ≥ 50% of conjunctiva and nictitating 
membrane total; obscuring the cornea by ≤ 50% 
 
Grade 3 Severe swelling of the entire conjunctiva  
that obscures the cornea > 50% 
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Table 8-3. Grading of ocular pathology (proliferation) showing definitions used and reference 
photographs. 
 
Grade Proliferation: 
(Papillary conjunctival hypertrophy, i.e. proliferative 
conjunctival tissue exhibiting multiple small 
projections, or cobblestone appearance) 
Examples 
Grade 0 None 
 
Grade 1 Exuberant proliferative vegetative conjunctival 
hypertrophy occupying < 50% of conjunctiva and 
nictitating membrane total 
 
Grade 2 Exuberant proliferative vegetative conjunctival 
hypertrophy occupying ≥ 50% of conjunctiva and 
nictitating membrane total but extending across the 
cornea ≤ 50%  
 
Grade 3 Exuberant proliferative vegetative conjunctival 
hypertrophy occupying > 50% of the conjunctiva and 
nictitating membrane that obscures the cornea > 50% 
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Table 8-4. Grading of ocular pathology (discharge) showing definitions used and reference 
photographs. 
 
Grade Discharge 
(Any excretion or substance emanating from the eye) 
Examples 
 
Grade 0 None 
 
Grade 1 Small amount of crusting, epiphora or mucopurulent 
discharge 
< 1 cm
2
 in total 
 
Grade 2 Surface area of epiphora, mucopurulent discharge or 
crusting 1- 2 cm
2
 in total 
 
Grade 3 Surface area of epiphora, mucopurulent discharge or 
crusting > 2 cm
2
 in surface area and/or obscuring the 
cornea or sticking lids together 
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8.2.4 Real-time PCR 
Real-time PCR has been used previously to monitor chlamydial load of diseased koalas 
during chloramphenicol treatment (Markey, Wan et al., 2007). In this previous work, 
authors used primers targeting a 72 base pair region of the 16S rRNA gene, designed from 
a chlamydial consensus signature sequence. Initial experiments in the current study using 
this previously published method and computer modelling of predicted PCR product 
(Zuker, 2003) found significant production of heat-stable secondary structures when used 
with C. pneumoniae DNA template (Figure 8-1). Secondary structures interfere with the 
efficiency of the PCR reaction, and thus quantitation (Peters, Helps et al., 2004). Extensive 
optimisation of reaction conditions are required to remove secondary structures, however 
this is not always possible, and redesign of primers may be required (Ashton & Headrick, 
2007). A further concern regarding the use of these primers for the current study was their 
inability to differentiate chlamydial species in mixed infections (Markey, Wan et al., 
2007), which are common in koalas (Girjes, Hugall et al., 1993; Devereaux, Polkinghorne 
et al., 2003). Given this background, the author moved to designing species-specific 
primers and a qPCR method for quantifying chlamydial loads in koalas. 
Following recommendations for general primer design for qPCR (Wang & Seed, 2006), 
the primer analysis programs Primer 3 (Rozen & Skaletsky, 2000) and mfold (Zuker, 
2003) were used to select primers using published sequences of the ompB genes of koala 
biovars of C. pneumoniae and C. pecorum (Glassick, Giffard et al., 1996), respectively. 
The primer pair chosen from these and trialled for C. pneumoniae (5‟- 
TCCGTTCCAGAATACGCTAC -3‟; 5‟-CATCACTTGTAGGGGTTGTTTC- 3‟) theoretically amplified 
a 154 base pair (bp) fragment, and the primer pair chosen and trialled for C. pecorum (5‟- 
CCTTGTGAAGCGGAATTTGT -3‟; 5‟- CATCTTTCGCCTTGTCCTAAA -3‟), a 101 bp fragment.  
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Figure 8-1. Predicted secondary structure (Zuker, 2003) of Chlamydophila pneumoniae 
fragment stable to 71.8 °C. 
Mucosal C. pecorum load was normalised for the number of host cells present on each 
swab by dividing estimated pathogen load by the estimated number of host cells present; 
estimated by concurrent qPCR reactions using primers based on the sequence of the koala 
beta-actin gene. Primers for amplification of the koala beta-actin gene were those of 
Markey et al. (2007) and in that study were shown to amplify an 82 bp fragment. DNA 
was extracted from swabs using a commercial extraction kit utilising silica membrane spin-
columns, following manufacturer‟s instructions (QIAamp® DNA Mini Kit, QIAGEN Pty 
Ltd, Doncaster, Vic, Australia). Where DNA had been extracted in the field using a lysis 
and stabilising solution (Chapter 4), DNA aliquots were adjusted to a comparable 
concentration by dilution 1:10 with autoclaved purified water (Milli-Q® Ultrapure 
filtration system. Millipore, North Ryde, NSW, Australia) and then purified as above, but 
omitting the initial lysis and incubation steps. Without a silica based purification column 
reaction efficiency was affected, presumably as a result of DNA inhibitors remaining in the 
sample. DNA, stored at -20 ºC, was subjected to at most one freeze-thaw cycle prior to 
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qPCR.  
Triplicate qPCR reactions comprised 10 µL of 2 x SYBR® Green PCR Master-mix 
(Applied Biosystems, Scoresby, Vic, Australia), 500 nM each primer, 2 µL of DNA 
template, and autoclaved purified water (Milli-Q® Ultrapure filtration system, Millipore, 
North Ryde, NSW, Australia) in a final volume of 20 µL. Reaction conditions were 95 ºC 
for 10 min (activation) followed by 40 cycles of 95 ºC for 15 s (denaturation), and 61 ºC 
(60 ºC for C. pecorum assay) for 60 s (annealing and extension). The melting profile was 
obtained by 90 s pre-melt conditioning at 55 ºC and then heating the reactions in one-
degree increments from 55 ºC to 85 ºC with 5 second stops.  
DNA samples extracted from C. pneumoniae culture, C. pecorum culture or from the buffy 
coat of a koala outside of this study, using a commercial kit (QIAamp® DNA Mini Kit, 
QIAGEN Pty Ltd, Doncaster, Vic, Australia), were used as positive controls and 
autoclaved purified water (Milli-Q® Ultrapure filtration system, Millipore, North Ryde, 
NSW, Australia) was used as a negative control.  
Efficiency of the reaction was > 95% to cycle threshold (CT) = 30, thus this was taken as 
the limit of accurate quantitation and sites positive with CT > 30 were recorded as low 
positive but not quantifiable. During method development chlamydial PCR products, based 
on template from pure C. pneumoniae or C. pecorum cultures, were confirmed to be of 
predicted size using gel electrophoresis; and purified DNA products (Ultraclean™ 15 DNA 
Purification Kit, MO BIO Laboratories, Carlsbad, California, USA) were sequenced by a 
commercial laboratory using a 3730XL DNA sequencer (Macrogen Inc, Seoul, Korea). 
Sequences were aligned using ClustalW (Larkin, Blackshields et al., 2007) and confirmed 
to be those expected using basic local alignment search tool (BLAST) (Altschul, Gish et 
al., 1990).  
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Both C. pneumoniae and C. pecorum primers were tested against DNA extracted using a 
commercial kit (QIAamp® DNA Mini Kit, QIAGEN Pty Ltd, Doncaster, Vic, Australia) 
according to manufacturer‟s instructions from seven species of bacteria (Staphylococcus 
aureus (Veterinary Pathology and Bacteriology Culture Collection (VPB) 236), 
Staphylococcus epidermidis (VPB 238), Proteus mirabilis (VPB 261), Serratia marcescens 
(VPB 255), Enterococcus faecalis (VPB 185), Pseudomonas aeruginosa (VPB 591) and 
Escherichia coli (VPB 2716)) commonly found on mucous membranes of the anogenital 
area, and against DNA extracted from the alternate chlamydial species. There was no cross 
reactivity with these species, or for C. pecorum primers and C. pneumoniae DNA and vice 
versa. Phylogenetic neighbours of Chlamydiaceae such as Simkania spp, Waddlia spp and 
novel koala Chlamydiales genotypes (Devereaux, Polkinghorne et al., 2003) were not 
available for study. DNA extracted as per 4.11.6 from urogenital and ocular swabs taken 
opportunistically from eight koalas bred and held in a captive facility isolated from wild 
animals and with no history of chlamydial disease were subjected to qPCR using the 
protocol described in the previous page. All animals were negative using this method. 
Samples were considered positive for the presence of C. pneumoniae, C. pecorum or beta-
actin when the dissociation curve profile matched that of the positive controls. When the 
melt curve was equivocal, qPCR reactions were repeated using template DNA at two 
dilutions (1:10, 1:100).  
Results were compared to standard curves based on C. pecorum culture or DNA extracted 
from a koala buffy coat, allowing relative pathogen load to be compared longitudinally and 
between individuals. Fresh aliquots of the standards were used for each day‟s analysis. The 
2
-ΔΔC
T method (Livak & Schmittgen, 2001), which controls for difference in starting 
pathogen load between anatomical sites by arbitrarily defining the starting pathogen load 
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as 100%, was used to examine whether changes in C. pecorum load over time differed 
between different treatment groups.  
8.2.5 Sensitivity and specificity of clinical signs 
Sensitivity and specificity of clinical signs as indicators of chlamydial infection at the 
sampled site were calculated using qPCR results as the gold standard, and the equations: 
Sensitivity = true positives / (true positives + false negatives) 
Specificity = true negatives / (true negatives + false positives). 
Anatomical sites sampled were classified as: true positive (total eye score ≥ 3 or wet 
bottom score > 0, and qPCR positive on day 0), false positive (clinical signs as above but 
qPCR negative at that site), true negative (total eye score < 3 or wet bottom score = 0, and 
qPCR negative on day 0) or false negative (no clinical signs i.e. total eye score < 3 or wet 
bottom score = 0, but qPCR positive at that site). 
8.2.6 Statistical analysis 
To assess the association between clinical scores and presence of chlamydial organisms on 
day 0, sites were grouped as “negative on day 0”, “positive for C. pecorum on day 0”, 
“positive for C. pneumoniae on day 0”, or “mixed chlamydial infections on day 0” 
according to whether qPCRs were positive on day 0.  
To assess the response to treatment, animals were grouped according to estimated 
maximum plasma antimicrobial concentration (Cmax), based on data obtained from 
pharmacology assays (Chapter 7). The group defined as “high” (n = 12) possessed a mean 
Cmax of 2.15 ± 0.59 µg/mL following treatment with subcutaneous (s.c.) enrofloxacin 10 
mg/kg. The group defined as “medium high” (n = 4) had a mean Cmax of 0.91 ± 0.37 
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µg/mL following treatment with 5 mg/kg enrofloxacin s.c. once daily. Animals defined as 
“medium” had a mean Cmax of 0.46 ± 0.35 µg/mL following treatment with enrofloxacin 
20 mg/kg (n = 3) per os (p.o.) or marbofloxacin 10 mg/kg p.o. once daily (n = 5). The 
group defined as “low” had a mean Cmax below the limit of detection of the assay (< 0.12 
µg/mL, enrofloxacin; < 0.16 µg/mL marbofloxacin) following treatment with enrofloxacin 
5 mg/kg p.o. (n = 1) or marbofloxacin 1 - 3.3 mg/kg p.o. (n = 5).  
Relative C. pecorum load was grouped as negative (n = 132; 45.1% of all assays), positive 
but not quantifiable (CT > 30; n = 59; 20.1%), between 0.002 and 1 x C. pecorum culture 
standard (n = 66; 22.5%), and ≥ 1 x C. pecorum culture standard (n = 36; 12.3%). As 
animals finished treatment at different times, the stage of treatment was grouped as: pre-
treatment (first screening day to day zero; n = 29), early treatment (day 1 - day 21; n = 29), 
late treatment (day 22 until treatment end; mean 43 ± 9.5 days; n = 29) and post-treatment 
(day 43 until day 71 ± 4.6 days; n = 17).  
To take into account difference in sex and size, ultrasonographic measurements of 
urogenital tract (bladder wall thickness and lumen diameter) were converted to percentages 
relative to the same animal‟s measurements on day 0.  
Clinical scores for conjunctivitis and wet bottom, and ultrasonography, appetite and faecal 
output, biochemical and haematological parameters, body weight and qPCR results were 
analysed using restricted maximum likelihood (REML) analysis using GenStat for 
Windows (2008, 11
th
 ed., VSN International Ltd., Hemel Hempstead, Hertfordshire, UK) 
using fixed effects of presence of different chlamydial species on day 0, stage of treatment, 
estimated Cmax and estimated C. pecorum load and random effects of koala and week. 
Models were built using forwards progression. Where data were non-parametric, they were 
normalised by log or square root transformation and then analysed. Estimated means and 
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standard errors predicted by the models were plotted using Graphpad Prism® 5 for 
Windows (Graphpad Software, La Jolla, California, USA). Statistical significance was 
concluded at p ≤ 0.05. 
8.3 RESULTS 
8.3.1 Clinical signs as an indicator of chlamydial infection on admission 
At the start of treatment (day 0), 21 of 29 chlamydia-positive animals had clinical signs 
consistent with chlamydial disease (total eye score ≥ 3 or wet bottom score > 0), indicating 
that the presence of clinical signs in a koala was a poorly sensitive indicator of presence of 
mucosal Chlamydiaceae in that animal (72%, Table 8-5). Specificity could not be 
calculated as animals negative by qPCR at all three sites (true negatives) were excluded 
from this study.  
Table 8-5. Sensitivity and specificity of clinical signs
*
 in predicting chlamydial infections 
(Chlamydophila pneumoniae, C. pecorum or both) at individual anatomical sites (eyes, 
urogenital tract) in 29 koalas in comparison with qPCR. 
 
Site with clinical signs* Chlamydial species 
detected by qPCR 
Sensitivity of clinical 
signs in detecting 
chlamydial presence 
Specificity of clinical 
signs in detecting 
chlamydial presence 
Eye C. pecorum only 67% 100% 
C. pneumoniae only -- -- 
Both 57% 100% 
Urogenital C. pecorum only 60% 100% 
C. pneumoniae only -- -- 
Both 28.5% 100% 
Any site  Chlamydiaceae at any 
anatomical site 
72% -- 
*total eye score > 3 (eye), wet bottom score > 0 and/or structural change to the reproductive tract (urogenital 
tract); qPCR: real time polymerase chain reaction.
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When sites were examined independently, the presence of clinical signs was also poorly 
sensitive (67% or lower), but highly specific, in determining the presence of chlamydial 
organisms at the individual anatomical site (Table 8-5). Chlamydophila pecorum appeared 
to be more pathogenic: on day 0, total eye scores were greater in eyes where C. pecorum 
was detected, than in eyes that were negative or those infected by C. pneumoniae alone (p 
= 0.004; Figure 8-2). In fact, no site infected with C. pneumoniae alone was described as 
conjunctivitis in the field (i.e. total eye score ≥ 3). In particular, clinical signs were very 
poorly sensitive in predicting the presence of mixed infections at an individual site (chi-sq 
= 9.98, d.f. = 1. p < 0.02; Table 8-5). Also renal ultrasonographic measurements did not 
differ between these groups with respect to qPCR result or wet bottom scores (Table 8-6, 
Table 8-7). 
 
Figure 8-2. Mean (± SEM) eye scores prior to treatment grouped according to infection 
status. 
Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical model using 
scores from 33 eyes from 27 koalas. C. pn: Chlamydophila pneumoniae; C. pec: C. pecorum. Dashed line 
indicates clinical conjunctivitis. 
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Table 8-6. Measurements of the bladder and kidneys determined by ultrasonographic 
imaging of 23 koalas with and without clinical urogenital tract disease (wet bottom score > 0) 
prior to fluoroquinolone treatment. 
Clinical 
signs 
Bladder 
lumen 
diameter 
(mm) 
p Bladder 
wall 
thickness 
(mm) 
p Kidney Sagittal 
length 
day 0 
Horizontal 
length 
day 0 
D-V 
width 
day 0 
n 
Wet 
bottom 
score > 0  
12.9 ± 1.7 < 0.001 4.7 ± 0.3 < 0.001 L 45.3 ± 4.3 29.6 ± 3.4 27.9 ± 2.7 9 
  R 45.5 ± 3.8 28.9 ± 3.0 29.5 ± 3.0 
Wet 
bottom 
score 0  
26.9 ± 2.8  2.83 ± 0.6  L 43.6 ± 4.0 26.7 ± 3.0 27.6 ± 3.4 14 
  R 42.3 ± 4.3 26.8 ± 4.6 26.9 ± 3.1 
Sagittal length (cranial to caudal pole), horizontal length (hilus to most lateral aspect), D-V width (dorsal to 
ventral surface). Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical 
model. There was no statistically significant difference for kidney measurements between left and right 
kidneys, or relating to wet bottom score. 
 
 
Table 8-7. Measurements of the bladder and kidneys determined by ultrasonographic 
imaging, and urogenital infection status of Chlamydophila pecorum and/or C. pneumoniae as 
detected by qPCR in 22 koalas prior to fluoroquinolone treatment. 
Pathogen Bladder wall 
thickness 
(mm) 
Bladder 
lumen 
diameter 
(mm) 
Kidney Sagittal 
length (mm) 
Horizontal 
length (mm) 
D-V width 
(mm) 
n 
C. pecorum 
positive  
C. pneumoniae 
negative  
18.11 ± 10.7 3.70 ± 1.5 L 44.7 ± 4.5 28.3 ± 3.4 27.0 ± 2.7 16 
R 44.8 ± 4.6 27.9 ± 4.3 28.3 ± 3.5 
Positive for  
C. pecorum & 
C. pneumoniae 
22.7 ± 12.0 4.5 ± 3.0 L 44.3 ± 3.5 29.5 ± 1.1 28.8 ± 1.5 4 
R 44.1 ± 4.1 28.3 ± 3.7 28.8 ± 1.8 
Negative for  
C. pecorum & 
C. pneumoniae 
41.7 ± 3.25 1.95 ± 0.3 L 42.4 ± 6.9 28.9 ± 3.0 28.0 ± 5.7 2 
R 42.7 ± 8.2 29.3 ± 0.6 28.9 ± 6.9 
Bladder wall thickness and bladder lumen diameter sagittal length (cranial to caudal pole), horizontal length 
(hilus to most lateral aspect), D-V width (dorsal to ventral surface). Figures shown are the mean ± SEM 
predicted by a restricted maximum likelihood statistical model. There was no statistically significant 
difference for kidney measurements between left and right kidneys, or relating to wet bottom score. 
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Signs of clinical disease were fairly equally distributed between sites (Table 8-8). In 
contrast, presence of C. pecorum showed a significant bias (chi-sq = 23.3, d.f = 1, p < 
0.0001) towards urogenital (93%) over ocular (38%) sites but C. pneumoniae was evenly 
distributed; 25% of ocular and 24% of urogenital tract swabs were positive for C. 
pneumoniae ( chi-sq = 0.33, d.f = 1, p = 0.565) (Table 8-9).  
Absence of signs at sites infected by C. pneumoniae alone and the absence of animals with 
single infections of C. pneumoniae in the urogenital tract (Table 8-9) hampered calculation 
of sensitivity and specificity of clinical signs in predicting C. pneumoniae infections.  
 
 
Table 8-8. Presence of Chlamydophila pneumoniae, C. pecorum or both detected by qPCR and 
clinical signs* according to anatomical site (eyes, urogenital tract) in 29 koalas prior to 
treatment. 
 
Infection status Clinical signs* Eyes Urogenital tract 
 
C. pneumoniae positive  Present 0 0 
C. pecorum negative Absent 7 0 
C. pecorum positive & 
C. pneumoniae negative 
Present 10 12 
Absent 5 8 
Positive for both Present 4 2 
Absent 3 5 
Negative for both Present 0 0 
Absent 28 2 
Total  57 29 
*total eye score > 3 (eyes), wet bottom score > 0 and/or structural change to the reproductive tract (urogenital 
tract). 
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Table 8-9. Presence of chlamydial organisms detected by qPCR and incidence of clinical signs 
prior to treatment in 29 koala treated with fluoroquinolones. 
 
  Ocular
† 
clinical signs 
Urogenital 
tract clinical 
signs
 ‡
 
Ocular
†
 and 
urogenital 
tract clinical 
signs
‡
 
No clinical 
signs 
Total 
qPCR 
positive* 
Ocular only 2 0 0 0 2 
Urogenital 
tract only 
0 5 0 3 8 
Ocular and 
urogenital 
tract 
5 4 5 5 19 
Total  7 9 5 8 29 
*qPCR positive on day 0 for Chlamydophila pecorum, C. pneumoniae or both 
† total eye score > 3 
‡ wet bottom score > 0 and/or presence of ovarian bursal cysts on ultrasound. 
 
8.3.2 Relationship between chlamydial load and clinical signs during 
treatment 
There was no significant difference among treatment groups with different plasma 
antibiotic concentrations (p < 0.845; Figure 8-3) and therefore these data were pooled. 
Using the 2
-ΔΔC
T method to control for differences between animals and anatomical sites, 
mucosal C. pecorum load decreased dramatically during the treatment period (Figure 8-3). 
Ocular clinical scores improved within two weeks of treatment regardless of treatment 
group (p < 0.001; Figure 8-4 and Figure 8-5). Throughout treatment, higher ocular C. 
pecorum loads were associated with significantly higher scores for chemosis (p = 0.05), 
proliferation (p < 0.001) and total eye score (p = 0.002; Figure 8-6). In contrast, despite 
reduction in urogenital chlamydial load, rump pelage stain did not change during treatment 
(Figure 8-7) and, although wet bottom score declined in the high dose treatment group, it 
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showed no clear trend in other treatment groups (Figure 8-8). The highest mean wet 
bottom score was associated with mid-range, rather than the highest C. pecorum load (p = 
0.007; Figure 8-9). Higher urogenital C. pecorum loads were associated with a thicker 
bladder wall (p = 0.021) and approached significance for a smaller bladder lumen diameter 
(p = 0.070; Figure 8-10). Bladder lumen diameter increased (p = 0.012, Figure 8-11) and 
bladder wall thickness decreased over time (p = 0.015; Figure 8-12) in the high group; and 
the bladder lumen diameter also increased by late treatment in two animals in the medium 
high group (Figure 8-11). Renal measurements did not change in any group.  
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Figure 8-3. Changes in Chlamydophila pecorum load in 28 koalas treated with 
fluoroquinolones.  
Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical model. 1 = an 
arbitrary standard (C. pecorum culture). Stage of treatment: Pre (first screening day to day 0); early (day 1 - 
day 21); late (day 22 until treatment end; mean day 43 ± 9.5 SD); and post (day 43 until day 71 ± 4.6 SD). 
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DAY 0 
Chemosis 2, proliferation 2, discharge 3 
Total eye score 7 
DAY 7 
Chemosis 3, proliferation 3, discharge 1 
Total eye score 7 
 
 
DAY 14 
Chemosis 2, proliferation 2, discharge 1 
Total eye score 5 
DAY 29 
Chemosis 0, proliferation 1, discharge 2 
Total eye score 3 
  
DAY 36 
Chemosis 0, proliferation 2, discharge 0 
Total eye score 2 
DAY 43 
Chemosis 2, proliferation 2, discharge 0 
Total eye score 4 
 
Figure 8-4. Example of eye score changes in one animal over time treated with enrofloxacin 
10 mg/kg s.c. for 51 days (continues next page). 
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DAY 50 
Chemosis 0, proliferation 1, discharge 0 
Total eye score 1 
DAY 57 
Chemosis 0, proliferation 0, discharge 0 
Total eye score 0 
  
DAY 70 
Chemosis 0, proliferation 1, discharge 0 
Total eye score 1 
DAY 77 
Chemosis 0, proliferation 0, discharge 0 
Total eye score 0 
 
Figure 8-4 cont. Example of eye score changes in one animal over time treated with 
enrofloxacin 10 mg/kg by subcutaneous injection for 51 days. 
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Figure 8-5. Changes in eye scores of eyes positive for Chlamydophila pecorum prior to 
fluoroquinolone treatment for two groups of animals grouped according to Cmax. 
High: mean enrofloxacin Cmax of 2.15 ± 0.59 µg/mL; medium: mean enrofloxacin or marbofloxacin 0.46 ± 
0.35 µg/mL. Total eye score is represented by total height of the bar. Figures shown are the mean ± SEM 
predicted by a restricted maximum likelihood statistical model. Pre (first screening day to day 0); early (day 1 
- day 21); late (day 22 until treatment end; mean day 43 ± 9.5 SD); and post-treatment (day 43 until day 71 ± 
4.6 SD). 
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Figure 8-6. Eye scores for 10 koalas throughout fluoroquinolone treatment with respect to 
relative Chlamydophila pecorum load.  
Where 1 = an arbitrary standard (C. pecorum culture), “-” = negative qPCR, and “+” = positive but not 
quantifiable. Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical 
model. 
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Day 0  
 
Day 7  
 
  
Day 21 
 
Day 33 
 
 
 
Day 42 
 
Day 49 
 
 
 
Day 56  
Figure 8-7. Rump pelage stain in one koala treated with oral marbofloxacin 10 mg/kg once 
daily for 31 days then retained for post treatment monitoring.  
Wet bottom score was consistently 0.5. 
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Figure 8-8. Changes in wet bottom score during treatment for groups based on maximum 
plasma concentration of fluoroquinolones.  
High: mean Cmax 2.15 ± 0.59 µg/mL; medium high: mean Cmax 0.91 ± 0.37 µg/mL; medium: mean Cmax 
0.46 ± 0.35 µg/mL; low: mean Cmax < 0.16 µg/mL. Figures shown are the mean ± SEM predicted by a 
restricted maximum likelihood statistical model. Stage of treatment: pre (first screening day to day 0); early 
(day 1 - day 21); late (day 22 until treatment end; mean day 43 ± 9.5 SD); and post (day 43 until day 71 ± 4.6 
SD). 
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Figure 8-9. Wet bottom score for 22 koalas throughout fluoroquinolone treatment relative to 
Chlamydophila pecorum load.  
Where 1 = an arbitrary standard (C. pecorum culture), “-” = negative qPCR, and “+” = positive but not 
quantifiable. Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical 
model. 
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Figure 8-10. Bladder lumen diameter and wall thickness measured using ultrasonography for 
23 koalas throughout fluoroquinolone treatment relative to Chlamydophila pecorum load.  
Where 1 = an arbitrary standard (C. pecorum culture), “-” = negative qPCR, and “+” = positive but not 
quantifiable. Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical 
model. 
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Figure 8-11. Changes in bladder lumen diameter over time compared for groups based on 
maximum plasma concentration of fluoroquinolones. 
High: mean Cmax 2.15 ± 0.59 µg/mL; medium high: mean Cmax 0.91 ± 0.37 µg/mL. Figures shown are the 
mean ± SEM predicted by a restricted maximum likelihood statistical model. Stage of treatment: pre (first 
screening day to day 0), early (day 1 - day 21), late (day 22 until treatment end; mean day 43 ± 9.5 SD) and 
post-treatment (day 43 until day 71 ± 4.6 SD). 
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Figure 8-12. Changes in bladder wall thickness compared to pre-treatment measurements for 
groups based on maximum plasma concentration of fluoroquinolones.  
High: mean Cmax 2.15 ± 0.59 µg/mL; medium high: mean Cmax 0.91 ± 0.37 µg/mL. Figures shown are the 
mean ± SEM predicted by a restricted maximum likelihood statistical model. Stage of treatment: pre (first 
screening day to day 0); early (day 1 - day 21); late (day 22 until treatment end; mean day 43 ± 9.5 SD); and 
post (day 43 until day 71 ± 4.6 SD). 
 
Ultrasonographic abnormalities of the reproductive tract, detected in six animals prior to 
treatment, did not change throughout treatment (described in more detail in Chapter 5). 
Two additional animals, one previously described (for detail see Chapter 5) treated with 
once daily marbofloxacin 1-3.3 mg/kg p.o. and one treated with once daily enrofloxacin 10 
mg/kg s.c., developed ovarian bursal cysts between days 7 and 14 of treatment. At post 
mortem examination, the latter animal (DA in Appendix IV) had bilateral ovarian bursal 
cysts, cystic endometrial hyperplasia and mild chronic diffuse vaginitis and ureteritis. A 
further animal (BB in Appendix IV) developed a 11.2 mm diameter spherical echolucent 
area in the renal medulla and hydroureter (8.1 mm width) of the left kidney at day 49 that 
resolved by day 67 (Figure 8-13). At post mortem examination, an area of focal medullary 
tubular nephrosis was found in the left kidney. 
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Figure 8-13. Echolucency in the renal medulla (arrow upper sonogram) and hydronephrosis 
(arrow lower sonogram) that developed between days 49 and 67 in one animal treated with 
oral marbofloxacin 10 mg/kg once daily for 64 days. 
 
Among all biochemistry analytes and haematological parameters, only albumin related 
significantly to C. pecorum load: albumin was significantly lower in animals in early 
treatment with higher C. pecorum loads (p < 0.001, Figure 8-14). Others parameters did 
not differ with respect to pathogen load and time: most changed less than 10% of starting 
values and remained within the published reference intervals (Table 8-10). Trends within 
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these intervals reflected animals improving in health, with haematology parameters 
consistent with decreased inflammation (platelets, eosinophils), and decreased stress 
(increasing red cell count, haematocrit, decreasing glucose) and improved nutrition 
(increasing albumin). Minor changes in electrolytes and creatinine were consistent with 
improved hydration. Creatinine kinase (CK), aspartate aminotransferase (AST) and alanine 
transaminase (ALT) activity were elevated during treatment in animals treated by 
subcutaneous injection (p < 0.001; Figure 8-15, Figure 8-16), with creatinine kinase 
activity exceeding reference ranges. 
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Figure 8-14. Albumin for 29 koalas throughout fluoroquinolone treatment relative to 
Chlamydophila pecorum load. 
Where 1 = an arbitrary standard (C. pecorum culture), “-” = negative qPCR, and “+” = positive but not 
quantifiable. Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical 
model. 
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Table 8-10. Biochemical analytes and haematological parameters that changed significantly in 29 koalas throughout fluoroquinolone treatment for 
chlamydiosis. 
 Reference intervals Pre-treatment 
n = 28 
Early Treatment 
n = 29 
Late Treatment 
n = 29 
Post-treatment 
n = 20 
% change 
(pre/post) 
p 
Haemoglobin  88 - 140 g/L 110.1 ± 2.39 109.5 ± 2.15 112.9 ± 2.02 115.6 ± 2.2 5% 0.001 
Red Cell Count  2.7 - 4.2 x 10
^12
/L 3.48 ± 0.076 3.5 ± 0.07 3.55 ± 0.07 3.64 ± 0.07 4.5% 0.007 
Haematocrit  0.29 - 0.44 L/L 0.36 ± 0.01 0.36 ± 0.01 0.37 ± 0.01 0.38 ± 0.01 5% 0.004 
Neutrophils  0.5 - 6.3 x 10
^9
/L 3.41 ± 0.29 4.15 ± 0.32 3.36 ± 0.29 3.6 ± 0.35 N/A
*
 0.010 
Eosinophils < 1.1 x 10
^9
/L 0.52 ± 0.09 0.32 ± 0.05 0.40 ± 0.05 0.39 ± 0.06 -23.8% 0.031 
Platelets 222 - 508 x 10
^9
/L 278.38 ± 13.80 284.29 ± 12.96 259.56 ± 11.12 263.49 ± 12.3 -5.4% 0.007 
Glucose  2.7 - 7.2 mmol/L 5.60 ± 0.28 5.05 ± 0.22 4.61 ± 0.17 4.68 ± 0.21 -16.4% < 0.001 
Albumin  34 - 50 g/L 35.48 ± 0.73 36.71 ± 0.72 37.86 ± 0.71 38.94 ± 0.77 9.7% < 0.001 
Calcium  2.28 - 2.97 mmol/L 2.62 ± 0.029 2.63 ± 0.03 2.67 ± 0.02 2.68 ± 0.03 2.25% 0.042 
Creatinine  80 - 150 µmol/L 97.81 ± 3.64 94.54 ± 3.33 92.11 ± 3.10 91.01 ± 3.27 -6.85% 0.018 
Cholesterol 1.15 - 3.09 mmol/L 1.7 ± 0.07 1.83 ± 0.07 1.98 ± 0.06 2.05 ± 0.07 21.2% < 0.001 
Triglycerides 0.5 - 3.02 mmol/L 1.59 ± 0.13 1.67 ± 0.11 1.72 ± 0.09 2.03 ± 0.12 28.2% 0.003 
Sodium  132 - 145 mmol/L 141.2 ± 0.66 139.7 +/0.59 140.0 ± 0.51 140.8 ± 0.61 N/A
*
 0.049 
Chloride   93 - 107 mmol/L 99.94 ± 0.69 98.13 ± 0.62 98.98 ± 0.53 100.00 ± 0.63 N/A
*
 0.009 
Figures shown are the mean ± SEM predicted by a restricted maximum likelihood statistical model. Pre-treatment (first screening day to day 0), early treatment (day 1 until 
day 21), late treatment (day 22 until treatment end; mean day 43 ± 9.5 SD) and post-treatment (day 43 until day 71 ± 4.6 SD). Creatinine kinase activity is shown in Figure 8-
15 and ALT and AST activity is show in Figure 8-16. 
*Statistically significant at time points other than between pre- and post-treatment.
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Figure 8-15. Change in creatinine kinase activity for 29 koalas throughout fluoroquinolone 
treatment relative to route of drug administration (subcutaneous injection, oral).  
Stage of treatment: pre (first screening day to day 0); early (day 1 - day 21); late (day 22 until treatment end; 
mean day 43 ± 9.5 SD); and post (day 43 until day 71 ± 4.6 SD). Figures shown are the mean ± SEM 
predicted by a restricted maximum likelihood statistical model. 
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Figure 8-16. Changes in ALT and AST activity for 29 koalas throughout fluoroquinolone 
treatment relative to route of drug administration. 
ALT (▲) and AST (○); Oral, (n = 13), shown in black; subcutaneous injection, (n = 16) shown in blue. Stage 
of treatment: pre (first screening day to day 0); early (day 1 - day 21); late (day 22 until treatment end; mean 
day 43 ± 9.5 SD); and post (day 43 until day 71 ± 4.6 SD). Figures shown are the mean ± SEM predicted by 
a restricted maximum likelihood statistical model. 
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Appetite, weight and faecal output of koalas also indicated improving health during 
treatment. All koalas completing treatment maintained body mass, a robust appetite and 
normal faecal output throughout treatment. Appetite scores as well as faecal area and score 
all increased through pre-treatment, early treatment and late treatment (p = 0.017, appetite 
score; p < 0.001, faecal area and score; Figure 8-17, Figure 8-18).  
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Figure 8-17. Changes in appetite and faecal scores for 29 koalas throughout fluoroquinolone 
treatment.  
Stage of treatment: pre (first screening day to day 0); early (day 1 - day 21); late (day 22 until treatment end; 
mean day 43 ± 9.5 SD); and post (day 43 until day 71 ± 4.6 SD). Figures shown are the mean ± SEM 
predicted by a restricted maximum likelihood statistical model.  
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Figure 8-18. Changes in faecal area for 29 koalas throughout fluoroquinolone treatment.  
Stage of treatment: pre (first screening day to day 0); early (day 1 - day 21); late (day 22 until treatment end; 
mean day 43 ± 9.5 SD); and post-treatment (day 43 until day 71 ± 4.6 SD). Figures shown are the mean ± 
SEM predicted by a restricted maximum likelihood statistical model. 
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8.3.3 Presence of chlamydial organisms after treatment 
After withdrawal of treatment, pathogen load increased significantly (p < 0.001; Figure 
8-3). Twenty-four of the 29 treated koalas shed C. pecorum (n = 14) or C. pecorum and C. 
pneumoniae (n = 10) at the end of treatment or at least once during post-treatment 
monitoring. Of the remaining five, three were not monitored for recurrence following 
removal of treatment and two (6.8%) remained negative for C. pecorum at all three sites 
through post-treatment monitoring.  
8.3.4 Final outcomes of animals enrolled in the study 
Of 29 animals treated with fluoroquinolones, 16 were released and the remaining animals 
were euthanased due to non-resolution or return of dysuria and stranguria (n = 3), non-
resolution (n = 6) or development of ovarian bursal cysts (n = 2), or subsequent treatment 
with doxycycline and decline in appetite, weight and demeanour (n = 2) (described in more 
detail in Chapter 5). Most post mortem findings related to chronic inflammation and 
fibrosis of the urogenital tract, consistent with chlamydial disease (for detail see 
fluoroquinolone treated animals in Appendix II and all animals in Appendix IV). 
8.4 DISCUSSION 
This study is the first to investigate the response of koalas with chlamydiosis to treatment 
with marbofloxacin and enrofloxacin and to assess the validity of commonly used methods 
for diagnosis of chlamydial infection in the clinical setting. Important findings were: the 
poor sensitivity of commonly observed clinical signs in determining presence of 
chlamydial organisms; correlation between ocular pathogen load and some clinical signs; 
improvement of ocular clinical signs during hospitalisation regardless of treatment 
modality; reduction of mucosal C. pecorum load during treatment and corresponding 
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changes in some urogenital clinical signs in the treatment group expected to have the 
highest Cmax; and the rebound in mucosal C. pecorum load after treatment withdrawal, 
illustrating the failure of most animals to achieve microbial cure using these drugs.  
The poor sensitivity of clinical signs as indicators of chlamydial infection (72% or less) 
signifies that their use as a diagnostic tool should be revised because a significant subset of 
positive animals are being missed using this method alone. However, specificity of clinical 
signs as an indicator of C. pecorum at an anatomical site was 100%, indicating that past 
assumptions leading to treatment of clinically affected animals are likely to have been 
correct. The lack of sensitivity of clinical signs in detecting chlamydial infection is perhaps 
not surprising. Previous authors have described subclinical infections in superficially 
healthy koalas (White & Timms, 1994; Jackson, White et al., 1999; McLean, 2003), birds 
(Longbottom & Coulter, 2003), calves (Jaeger, Liebler-Tenorio et al., 2007), people 
(Solomon, Peeling et al., 2004) and cats (Sykes, 2005), but the current study is the first to 
quantify sensitivity and specificity of clinical signs in chlamydiosis in koalas within a 
clinical setting. It is important to note that, although sensitivity and specificity do not 
change, the predictive value of these signs as indicators of infection will vary with 
prevalence in the general hospital population (currently unknown).  
The poor sensitivity of clinical signs in predicting chlamydial carriage and the current lack 
of sensitive, cheap, point-of-care diagnostic tests (Chapter 5) necessitates that all wild 
animals be assumed to be carrying chlamydial organisms regardless of clinical signs in 
relation to quarantine and transfer. Animals should not be transferred into known negative 
populations or outside of their local range, where chlamydial species, strains, and infection 
prevalence may be different, until proven negative with repeated negative tests using 
sensitive molecular techniques. As koala strains of C. pneumoniae may survive for up to 
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28 days at ambient temperatures (18 °C - 23 °C) (Rush & Timms, 1996), strict attention to 
disinfection of pens and change of cage furniture between all animals, regardless of clinical 
signs, will minimise risk of transmission on fomites. Fly control may also prevent 
mechanical transmission of organisms attracted to ocular discharge, as occurs in people 
(Emerson, Lindsay et al., 1999).  
The reasons why clinical signs were less sensitive in predicting mixed infections than 
single C. pecorum infections are unclear. It is possible the presence of C. pneumoniae may 
provide some level of cross-protection against clinical disease associated with C. pecorum; 
however in people, presence of multiple Chlamydiaceae species has been associated with 
more severe clinical signs of ocular disease and the role of mixed infections in 
pathogenesis is poorly understood (Dean, Kandel et al., 2008). In koalas, the situation is 
potentially complicated further by the possible co-infection by at least nine “Chlamydia-
like” bacteria (Devereaux, Polkinghorne et al., 2003) and their role in the pathogenesis of 
chlamydiosis is currently unknown. Chlamydophila pneumoniae has been demonstrated in 
a variety of lesions associated with chronic diseases in people (Jackson, Campbell et al., 
1997; Sriram, Stratton et al., 1999) but its exact role in the pathogenesis of disease can be 
difficult to interpret due to possible recruitment of chlamydially infected macrophages to 
sites of inflammation elicited by other causes (Gieffers, Pohl et al., 2001; Robinson, 
Dobson et al., 2004; Bagos, Nikolopoulos et al., 2006). Clearly much work is required to 
understand the syndemics of these pathogens in koalas. 
In this study, animals exhibiting signs of ocular chlamydiosis were also likely to have a 
urogenital tract infection, which was frequently subclinical (Table 8-9). Chlamydial 
species have spread systemically from inoculation sites in infection trials in other species 
(sheep and cats) (Wills, Gruffydd-Jones et al., 1987; TerWee, Sabara et al., 1998; Tsakos, 
  201 
Siarkou et al., 2001) and a proposed mechanism of systemic spread of C. pneumoniae in 
koalas and people is infection of, and circulation within, peripheral blood mononuclear 
cells (Bodetti & Timms, 2000). The likelihood of systemic or multi-site subclinical 
infection suggests that treatment of all chlamydial cases should be systemic. 
The lack of site preference for C. pneumoniae and urogenital site preference for C. 
pecorum contrasts with findings of other authors, who have reported an ocular bias of C. 
pneumoniae infections and lack of site bias for C. pecorum (Girjes, Hugall et al., 1993; 
Jackson, White et al., 1999). Further, the rate of mixed infectious found here is higher than 
other populations (Jackson, White et al., 1999; Devereaux, Polkinghorne et al., 2003). 
These findings may be related to regional differences in pathogen strain and prevalence 
between this study population and others previously examined (Jackson, White et al., 
1999), different methodologies influencing preferential DNA amplification (nested PCR 
versus species-specific qPCR), the result of stochastic error as study populations were 
small, or could indicate a difference in the likelihood of systemic spread between the 
species; a possible mechanism of systemic spread in peripheral blood mononuclear cells 
has been demonstrated for C. pneumoniae (Bodetti & Timms, 2000) but is yet to be 
demonstrated for koala strains of C. pecorum. 
The unsatisfactory nature of wet bottom score for monitoring response to treatment may 
have several explanations. Up to seven different operators scored animals throughout three 
field seasons, making consistent scoring difficult. The score has multiple factors within 
each category. This made classification of animals with clinical signs spanning several 
different categories challenging. The wet bottom score also places much emphasis on 
smell, which is highly subjective; some aspects may not be observed if intermittent (e.g. 
stranguria, teeth grinding); and some, such as rump pelage stain, do not change probably 
  202 
until complete hair regrowth (the period of which currently unknown). Most animals in 
advanced stages of wet bottom were excluded from this study for other reasons (e.g. poor 
body condition, renal insufficiency, ovarian bursal cysts), meaning most animals with a 
wet bottom score of > 0 were in the lowest grades of the wet bottom score and movement 
within these grades was difficult to assess. This score is used most frequently at the Koala 
Hospital to assess animals at admission for euthanasia or treatment, rather than as a 
monitoring tool (C. Flanagan, pers. comm.)
1
. Examination of its use as a tool for assessing 
response to treatment was included in this study, in part, to ease integration of researchers 
in an established hospital system. The difficulty encountered in its use here suggests that a 
useful addition to the monitoring of treatment of urogenital tract disease in koalas might be 
the development of a scoring system for urogenital tract clinical signs with multiple 
individually scored facets, such as the author developed in this work for eye disease. 
In this study, clinical scores associated with higher chlamydial load (proliferation, total eye 
scores, bladder wall thickness) may indicate active inflammation. In contrast, others, such 
as the wet bottom score, may best predict chronic inactive inflammation. In people and 
koalas, chlamydial loads in association with inactive chronic pathology (e.g. fibrosis) tend 
to be lower than in patients with more active inflammation (Solomon, Peeling et al., 2004; 
Higgins, Hemsley et al., 2005a; Gomes, Borrego et al., 2006). In this study, animals with 
clinical urogenital tract disease (wet bottom score > 0) had thicker bladder walls and 
smaller bladder lumens but did not have high pathogen loads. If the thicker bladder walls 
observed were due to inactive chronic pathology such as fibrosis, normal bladder function 
may have been altered in these animals contributing to incontinence and rump pelage 
soiling with urine and, thus, the observed elevated wet bottom scores. As the bladder wall 
                                                 
1
 Personal communication: C. Flanagan, Supervisor, Koala Hospital, Port Macquarie, NSW, January, 2010. 
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thickness did decrease during treatment in the high group, it is possible that the change in 
thickness of bladder wall observed in some animals was a result of resolving acute 
inflammation (e.g. oedema), comparable to the changes in chemosis observed during 
treatment in animals with conjunctivitis. As it was not possible to differentiate between 
oedema and fibrosis using ultrasound alone in this study, future work examining matched 
sonograms, bladder wall biopsy and urogenital pathogen load might be useful to better 
describe associations between wet bottom score, sonographic changes, pathogen load and 
pathological processes. A further potential limitation of ultrasonographic evaluation of the 
bladder wall is that the bladder wall thickness may vary depending on lumen volume 
(Geisse, Lowry et al., 1997). It is possible that animals with higher wet bottom scores were 
more likely to have an empty bladder and, consequently, thicker bladder walls at imaging. 
Dynamic bladder studies, in which elasticity is measured through instillation of increasing 
volumes of saline, might help differentiate whether bladder walls are thickened as a result 
of pathology or simply the result of urination prior to imaging.  
Absence of an association between ocular discharge and chlamydial load suggests that 
although discharge is a dramatic clinical sign, its presence should not necessarily be 
regarded as indicative of a high chlamydial load. As eyes were cleansed with saline daily 
on welfare grounds, it is possible that the constant removal of ocular discharge confounded 
this parameter, or that discharge was associated with secondary bacterial infections. A 
study in which discharge is not removed with saline and culture for secondary bacterial 
infections is performed might be useful.  
Although many of the structural changes detected in this study using ultrasonography were 
unlikely to improve during treatment, the results presented here indicate that monitoring of 
the genitourinary tract in animals under treatment is warranted to detect emerging 
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structural changes that might alter the prognosis for release. Although weekly monitoring 
of the urogenital tract indicated few changes in most animals, it detected changes in the 
renal medulla and ureter of one animal and the development of ovarian bursal cysts in two 
animals during treatment (see Chapter 5 and above). Structural reproductive tract changes 
such as ovarian bursal cysts have been associated with infertility (Brown, Carrick et al., 
1984; McLean, 2003) and significant renal disease may compromise long-term survival in 
the wild. Assessment of these structures prior to commencing treatment, and again prior to 
release, is important for successful rehabilitation.  
It is perhaps unsurprising that clear associations between different clinical signs and 
pathogen load were not always evident, as the interaction between host, environment and 
pathogen that manifests in clinical signs is frequently complex. Factors that have been 
proposed to change clinical expression of chlamydiosis in koalas and other species include 
the pathogenicity of the infective chlamydial strain (Morre, Rozendaal et al., 2000), 
environmental or nutritional stressors (Weigler, Girjes et al., 1988; Canfield, 1989), 
presence of other pathogens such as koala retrovirus (Tarlinton, Meers et al., 2005) or 
“Chlamydia-like organisms” (Devereaux, Polkinghorne et al., 2003), secondary infections 
(Canfield, 1989) and the immune response (Higgins, Hemsley et al., 2005a). Investigation 
of these would be useful in further characterising the expression of clinical chlamydiosis in 
koalas. 
Changes in haematological parameters and biochemistry analytes were minor and within 
reference ranges, which might indicate the need for better ranges, but when interpreted 
longitudinally they suggest a rising plane of health. Of all parameters measured, low 
albumin was the only parameter significantly associated with higher C. pecorum loads. 
Previous authors have also found hypoproteinaemia or hypoalbuminaemia to be a feature 
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of complicated cystitis (Obendorf, 1983; Canfield, O'Niell et al., 1989). Together with the 
observed increase in appetite and faecal output, these changes suggest improving health; 
however it is difficult to determine whether this occurred as a result of stress, positive 
energy balance (food supplied, exercise restricted) or habituation to captivity. The increase 
in ALT, AST and CK activity noted in animals receiving injections are likely to be related 
to local myopathy as a result of injection (Fry, Allen et al., 1994). Although ALT and AST 
could indicate hepatocellular damage, this is considered unlikely as other indicators of 
hepatopathy (bilirubin, bile acids, GGT activity) were not elevated and there was no 
evidence of hepatopathy in hepatic biopsies taken at post mortem. Alanine transaminase 
(ALT), AST and CK activity interpreted in concert may indicate myopathy more 
sensitively than CK activity alone (Fry, Allen et al., 1994) and thus it is likely the 
elevations of ALT and AST also indicated injection site myopathy.  
The rebound of C. pecorum load after removal of treatment strongly indicates a drug effect 
on chlamydial load, and the clinical impact of this is suggested by reduction in percentage 
bladder wall thickness and increase in percentage bladder lumen that occurred only in the 
high group. However, without a placebo group (precluded here by ethics and concern for 
animal welfare) it is impossible to accurately determine what degree of clinical 
improvement was attributable to drug treatment or supportive therapy, or if chlamydial 
infections resolved regardless of treatments. Clinical signs of ocular chlamydiosis in koalas 
may be self-limiting (Kempster, Hall et al., 1996), and the acute phase of ocular 
chlamydial infection in koalas (Kempster, Hall et al., 1996), cats (Dean, Harley et al., 
2005) and people (Thygeson, 1962) (six weeks), falls within the study period used in this 
work. Self-limiting disease could explain at least some of the improvement in clinical signs 
seen in many animals in this study and the reported historical success of fluoroquinolones 
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in treating koala chlamydiosis (Connolly, 1999; Blanshard & Bodley, 2008) (Chapter 3). 
That an antibiotic effect was observed during this study, despite plasma concentrations 
failing to reach a minimum inhibitory concentration (MIC) considered likely to be 
inhibitory to koala chlamydial species (Chapter 7), could be due to a number of reasons. 
The MIC of koala chlamydial species might be lower than expected, or plasma 
concentrations of fluoroquinolones may not accurately represent those to which pathogens 
are exposed. The MIC for marbofloxacin has not been determined for chlamydial species. 
The assumed MIC required to inhibit growth of chlamydial pathogens from koalas is based 
on studies of enrofloxacin in C. pneumoniae isolates from bandicoots (Kumar, Kutlin et 
al., 2007), which share 99.5% genetic homology with the koala biovar in a 16S rRNA gene 
signature segment (Kutlin, Roblin et al., 2007). This assumption seems likely to be valid, 
as the MICs of enrofloxacin for other chlamydial species of veterinary interest are in broad 
agreement (0.125 - 0.25 µg/mL) (Lindenstruth & Frost, 1993; Butaye, Ducatelle et al., 
1997; Failing, Theis et al., 2006). It appears more probable that plasma concentrations may 
not accurately represent those to which pathogens are exposed in vivo. Fluoroquinolones 
may accumulate at up to 63 times plasma concentrations within cells (Boeckh, Boothe et 
al., 1999; Boothe, Jones et al., 2005), tissues (Bayer Animal Health Australia, 2010; Pfizer 
Inc, 2010), and body fluids such as urine (Bayer Animal Health Australia, 2010). In 
addition, they may be transported to sites of active inflammation in white blood cells 
(Boothe, Boeckh et al., 2009). Investigation of the MIC of fluoroquinolones required to 
inhibit koala species of Chlamydiaceae and assay of fluoroquinolone concentration of 
chlamydially infected tissues would be helpful in investigating these hypotheses.  
The lack of elimination of chlamydial infections in this species following extended courses 
of fluoroquinolones is not completely new: treatment failure of koalas treated for up to 6 
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months with enrofloxacin or chloramphenicol have been described (Devereaux, 
Polkinghorne et al., 2003), although dose and route were not reported. Chlamydial 
antibiotic resistance would explain the failure to achieve microbial cure, but is rare (Yokoi, 
Yasuda et al., 2004). More likely hypotheses are the lack of effectiveness of the drug 
against koala chlamydial strains, and/or poor bioavailability (Chapter 7).  
Another intriguing explanation for treatment failure is that the low plasma concentrations 
of antibiotics in this study led to survival of small numbers of chlamydial organisms in an 
“intermediate form” allowing persistent infections. Stressors such as cytokines, phage 
infections, deficiency of essential nutrients and sub-inhibitory concentrations of antibiotics, 
including fluoroquinolones, may induce a quiescent “intermediate” form in which 
chlamydial organisms exhibit abnormal inclusion morphology and are metabolically 
inactive. Once stressors are removed, normal chlamydial lifecycle resumes (Hogan, 
Mathews et al., 2004; Mpiga & Ravaoarinoro, 2006). Although “intermediate” forms have 
DNA that is detectable using molecular techniques (Mpiga & Ravaoarinoro, 2006) during 
treatment cells infected with “intermediate” forms may be few in number (Dreses-
Werringloer, Padubrin et al., 2000; Kutlin, Roblin et al., 2002), or may be absent from the 
anatomical sites tested, leading to a false negative, as has been observed during treatment 
in studies of cats treated with pradofloxacin (Hartmann, Helps et al., 2008) and 
doxycycline (Dean, Harley et al., 2005). As many antibiotics are reliant on metabolic 
activity to be effective, such infections are difficult to resolve by antibiosis (Mpiga & 
Ravaoarinoro, 2006). The presence of this altered phase of development in vivo is difficult 
to demonstrate, but supportive evidence is provided by in vitro studies, and in vivo when 
other reasons for treatment failure (poor compliance, poor drug bioavailability, chlamydial 
resistance) are ruled out (Morrison, 2003; Mpiga & Ravaoarinoro, 2006).  
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Chlamydial load detected after treatment withdrawal remained low in comparison to 
starting load, and clinical signs did not return in most animals, illustrating that monitoring 
for the return of clinical signs for up to four weeks is not a sensitive indicator of microbial 
negativity. Clinical signs post-treatment might be more likely to recur in animals starting 
with high chlamydial load, as occurred in one case in this study.  
An important outcome of this study is the opportunity to re-evaluate the goals of treating 
infectious disease in the rehabilitation setting. Survival rates after treatment of 
chlamydiosis with fluoroquinolones appear to be acceptable, although the fertility of 
rehabilitated animals is unknown (Chapter 3). The fact that rehabilitated animals are 
released carrying chlamydial organisms is an important consideration for the epidemiology 
of this disease in the wild population. It is likely that most koalas treated for chlamydiosis 
have been released without achieving microbial cure in the Port Macquarie district for the 
history of the Koala Hospital (35 years). The impact of these animals is unknown, but 
appears to have been minimal, as there is no indication that probability of admission 
because of chlamydiosis has increased over time (Chapter 2). However, it is possible that 
release of animals post-rehabilitation has been deleterious, as the chlamydial prevalence in 
the population prior to the establishment of the Koala Hospital is unknown. Release of 
animals that are microbially positive may not, by itself, be detrimental to a population in 
which there is a high prevalence of chlamydial carriage but, should animals be infertile and 
habitat scarce, their survival may be detrimental to local populations. Infertile animals will 
continue to occupy scarce habitat, predate trees and act as effective reservoirs of 
Chlamydiaceae, especially if infertility increases their promiscuity. Recapture studies of 
treated animals after release, examining females for presence of pouch young, or larger 
studies examining medical records held at the Koala Hospital could provide valuable 
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information regarding the successful rehabilitation and breeding success of these animals 
within Port Macquarie. Animals being transferred into fauna parks or from Port Macquarie 
should not be assumed microbially negative based on lack of clinical signs, Clearview 
results (Chapter 5), or after treatment with enrofloxacin or marbofloxacin for clinical 
chlamydiosis. 
This study provides an evidence base for decisions relating to the treatment of koala 
chlamydiosis with fluoroquinolones. The poor sensitivity of commonly observed clinical 
signs for detecting chlamydial infection suggests a revision of commonly used diagnostic 
or case assessment practices. The improvement of clinical signs regardless of treatment 
modality provides strong support for the implementation of a blinded, placebo controlled 
study to determine the relative importance of husbandry and fluoroquinolones in changing 
pathogen load and resolution of clinical signs. The failure of most animals to achieve 
microbial cure using these drugs indicates that animals treated with doses and routes used 
in this study should not be regarded as microbially negative after treatment, and thus 
should not be transferred into microbially negative populations or those with different 
chlamydial strains. Assessment of the treatment goals of chlamydiosis in koalas should be 
re-evaluated. The prognosis and breeding success of these animals once released is a 
critical factor that requires examination, both for individuals and for appropriate resource 
allocation within the rehabilitation setting, and to allow accurate statistical modelling 
assessing the impact of treated animals on wild populations.
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CHAPTER 9 - OVERVIEW AND GENERAL IMPLICATIONS 
Despite wildlife rehabilitation in Australia involving many thousands of people and tens of 
thousands of animals annually, there is little formal research regarding how such 
rehabilitation is undertaken, whether it is successful and its impact on wild populations 
(Tribe & Brown, 2000). Although the direct contribution of wildlife rehabilitation to the 
conservation of species is debated, less quantifiable benefits, such as public education and 
public sympathy for the plight of wildlife, provide justification for wildlife rehabilitation as 
part of species conservation plans (Tribe & Brown, 2000). Studies of rehabilitation efforts 
are crucial to identify successful techniques on grounds of welfare and to advance 
knowledge of husbandry and diseases of wild animals. Research of wildlife rehabilitation 
techniques is further justified to minimise the risk of rehabilitated animals as a source of 
communicable disease to individuals (Barker, 1974; Griffin, Canfield et al., 1983; 
Menzano, Rambozzi et al., 2008) and wild populations (Jacobson, Gaskin et al., 1991; 
Chipman, Slate et al., 2008.) and of zoonotic disease to people (Allworth, Murray et al., 
1996). 
A study examining the records of the Koala Hospital over 30 years (Chapter 2) identified 
the most important potential threats to the local koala population as those involving 
traumatic injuries, principally motor vehicle strikes. The temporal and demographic 
patterns identified in this work suggest that a significant behavioural component is 
important in predisposing different cohorts to traumatic presentations and this must be 
taken into account when planning for threat mitigation. Although the total extinction of 
koalas may not be imminent, populations in south-east Queensland have declined sharply 
in recent years and populations in both New South Wales and Queensland may be 
vulnerable to local extinction should current trends continue (Department of Environment 
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and Climate Change - NSW, 2008; Department of Environment and Resource 
Management, 2009). 
Over-abundant populations of koalas in Victoria are often of poor genetic merit due to 
inbreeding (Houlden, England et al., 1996; Houlden, Costello et al., 1999), thus the 
preservation of populations in New South Wales and Queensland is important to maintain 
genetic diversity. Studies such as this one demonstrate the potential value of records kept 
at wildlife institutes and it is hoped this will provide impetus to improve and streamline 
record keeping at such organisations, which will in turn improve the rigour of future work. 
The studies of medical records of the Koala Hospital in Chapter 2 identified a common 
reason for presentation to be clinical signs associated with chlamydiosis. Effective 
treatments are yet to be identified for this disease and are required for treatment of 
individual animals, or where translocation between populations of different infective status 
is required. Despite the paucity of well-defined evidence-based studies of effective 
treatments for this disease, treatment has been attempted for decades and is anecdotally 
successful. This background prompted a study of medical records of animals treated for 
chlamydiosis over a10- year period at the Koala Hospital (Chapter 3) to identify commonly 
used medications, treatment regimes associated with successful return to the wild, and the 
long-term prognosis of animals returned to the wild. This work found the most commonly 
used treatments were not consistent with those recommended for treatment of chlamydiosis 
in other species, and diagnostic and treatment decisions were frequently based on clinical 
signs alone, despite past studies indicating these as poorly sensitive in predicting 
chlamydial carriage (Jackson, White et al., 1999; McLean, 2003). Despite theoretically 
inadequate treatments and insensitive diagnostics, clinical signs improved in approximately 
50% of treated cases, such that they were returned to the wild, and at least 50% of these 
animals survived for extended periods. The apparent contradictions between theoretically 
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inadequate treatment regimes and successful resolution of clinical signs and survival in the 
wild provided the basis for further studies examining treatments of chlamydiosis in koalas 
(Chapters 5-8).  
Chapters 4 and 5 describe the development of field diagnostics and clinical monitoring 
techniques used in later studies and detail a learning experience for the author regarding 
the types of studies possible within a wildlife rehabilitation setting. The difficulties 
encountered regarding these aspects were mainly logistical: an inadequate amount of 
appropriate housing and insensitive diagnostic techniques initially limited the numbers 
recruited. During the initial stages of the project, these obstacles were overcome through 
development of a field site diagnostic PCR for diagnosis of chlamydiosis in koalas and 
input into the building of koala housing that will be useful for future research.  
Chapter 5 describes a pilot study that found that drugs commonly used to treat 
chlamydiosis in other species were not safe to use in koalas. The cause of the severe side-
effects observed in most animals treated with azithromycin or doxycycline was not 
definitively determined, but may have been due to gut flora disturbance, as has been 
described by other researchers with previous generations of these drugs (Osawa, Bird et 
al., 1993). The current study also highlighted the difficulties of working with an iconic 
species within a wildlife rehabilitation setting. A somewhat unanticipated difficulty 
encountered was the complicated emotional involvement of lay carers with the 
experimental animals. The long courses of treatment administered to animals with poor 
prognosis for release were emotionally draining for lay workers and prompted a re-
evaluation of treatment goals. The author learnt much about what types of studies are 
appropriate within a rehabilitation setting and about communicating the scientific process 
to the general public. Concern for animal and staff welfare changed the initial focus of the 
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scientific investigation to one examining fluoroquinolones, in which side effects had not 
been observed in initial studies. 
Chapter 6 describes a pilot study using a modified agar diffusion method, which was found 
to be too insensitive to accurately detect antibiotic concentrations within plasma of koalas 
treated with fluoroquinolones. Working with wildlife often requires the adaption or 
modification of techniques used in other species and thus a more sensitive detection 
method (HPLC) was optimised and validated for use in Chapter 7. Difficulties were the 
limited time points at which blood was taken and, as animals were recruited 
opportunistically from diseased wild animals, lack of uniformity of experimental subjects 
with respect to signalment or disease status. Although the former decreased the ability to 
calculate some pharmacokinetic parameters, and the latter contributed to the wide inter-
animal variation observed, these limitations did not alter the major conclusions regarding 
poor absorption of fluoroquinolones administered by the oral route in diseased koalas. The 
results of this study offer a significant advancement in the treatment of koalas, as the oral 
route is frequently used for drug administration. This study, the first of its kind in koalas, 
provides a sound basis and justifies future research efforts in this area, both on 
pharmacokinetics of other therapeutic drugs, and the mechanisms by which koalas deal 
with xenobiotics of therapeutic and dietary origin. 
In Chapter 8, clinical signs of disease improved and C. pecorum loads decreased during 
treatment, but the pathogen load increased again after treatment withdrawal and most 
animals failed to achieve microbial cure. Clinical signs were poorly sensitive in predicting 
infection prior to and after treatment. The species-specific primers and qPCR method 
developed by the author in this section represent a novel method of diagnosing chlamydial 
infections in koalas and, as such a method was lacking prior to this work, will have 
application for future work examining pathogenesis and epidemiology of chlamydiosis in 
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koalas. The lack of inclusion of a placebo-controlled group means that the effect of 
treatment cannot be distinguished from other supportive measures, such as nursing care 
and nutritional improvements. In this respect, this study was a compromise between 
adhering to ideal scientific experimental design and conducting research within the wildlife 
rehabilitation setting. Despite being unable to distinguish which components of treatment 
and rehabilitation, if any, result in the resolution of clinical signs, the major finding of 
microbial positivity post-treatment is an important advance in the treatment of 
chlamydiosis in koalas and should prove to be useful information for veterinarians treating 
this disease, and provide rigour to decision-making regarding animal translocation. 
Identification of a treatment capable of achieving microbial cure is vital for animals 
entering into chlamydially negative populations (e.g. zoos), but the achievement of 
microbial cure is perhaps not a necessary goal where treated animals are released into areas 
with endemic chlamydiosis. Infectious disease in wildlife cannot be controlled without 
huge effort and has rarely been attempted (Artois, Delahay et al., 2001). Survival in the 
wild of treated animals appears reasonable and chlamydiosis as a reason for admission has 
not increased over the past 30 years at the Koala Hospital, possibly indicating a stable host-
pathogen relationship despite re-introduction of carriers back to the wild population. These 
results suggest the impact of these animals on the wild population may not be detrimental, 
although further research is required to confirm these observations. 
9.1 POSSIBILITIES FOR FUTURE RESEARCH 
Through this work, a number of methods were developed that are applicable to future 
studies of wildlife rehabilitation. Appetite and faecal monitoring, conjunctivitis scoring, 
ultrasonographic examination and the species-specific qPCR methods developed in this 
study will be applicable for future studies of chlamydiosis in koalas and may be applicable 
to other studies where diagnosis or monitoring of the general health of koalas is required. 
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The establishment of the Koala Hospital as an ongoing scientific research site has done 
much to cement the bond between the members of the Koala Preservation Society of NSW 
and scientific researchers and will ease future research in this setting. Further, it is hoped 
that this example of research in a wildlife rehabilitation setting will encourage future 
researchers to consider involving these institutions in the scientific process, as there is 
much to be gained in encouraging dialogue and understanding between scientists and the 
general public. 
9.1.1 Impact of rehabilitated animals on local populations 
An important question in the rehabilitation of wildlife is to determine whether efforts are 
advantageous or deleterious to local populations and individuals. Conclusions from the 
studies of wildlife records in this work suggested a number of threats to local populations. 
With information regarding the population demography of the wild koalas of Port 
Macquarie, statistical models could be used to examine the effect of these threats on the 
long-term viability of wild koala populations. The use of the Koala Hospital records to 
assess long-term survival and breeding success of animals returned to the wild could be 
expanded to assess the relative prognosis of animals admitted for other reasons (e.g. 
trauma), and might improve animal welfare, refine rehabilitation methods, better allocate 
resources and target the efforts of the Koala Preservation Society. The results of these 
latter studies might also be used in statistical models to predict the impact of returned 
animals, which might have otherwise died, on the wild population. 
9.1.2 Further examination of pharmacology in koalas 
As pharmacology in koalas is very much an unexplored field, the most practical 
investigations are to first describe pharmacokinetics of commonly used substances in 
koalas to formulate accurate dosing and to establish whether the poor bioavailability 
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observed in this study applies to other orally administered drugs. Potential barriers to 
bioavailability could be examined by catheterisation of mesenteric vessels after drug 
administration to identify the location of the major barriers to oral absorption; investigation 
of activation of the cytochrome P450 enzymes by examining gene expression using real-
time reverse transcriptase PCR; and demonstration of gut wall efflux pumps using 
inhibitors (Barthe, Bessouet et al., 1998). These studies may have applications outside of 
pharmacology, as they could contribute to understanding of the koala‟s ability to deal with 
secondary plant metabolites and survive on a diet of eucalypt leaves. However, studies 
involving terminal experiments may not be suitable within the wildlife rehabilitation 
setting. 
9.1.3 Further examination of treatments used to manage chlamydiosis in 
koalas 
This work did not identify a treatment resulting in microbial cure of chlamydiosis in 
koalas. Future work could examine other promising treatments (e.g. chloramphenicol) 
(Markey, Wan et al., 2007) to better explore whether such treatments effect a microbial 
cure, using methods of monitoring and pathogen detection developed in this study. Future 
work would also ideally include a placebo treated group to allow identification of which, if 
any, aspects of treatment (e.g. antibiosis, nutritional, nursing care) effect resolution of 
clinical signs. Such work would be best performed blinded, not only for scientific integrity, 
but also to mitigate carer concerns for individual animal welfare. 
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9.2 CONCLUSIONS 
This study examined the management, diagnosis and treatment of chlamydiosis in koalas 
in a rehabilitation setting, an area that has received little attention in the past. As part of 
this study, the pharmacokinetics of fluoroquinolones were examined and significant 
barriers to absorption of fluoroquinolones by the oral route were identified, opening the 
field of pharmacokinetics and xenobiotic metabolism in this species. The results of this 
study have implications for treatment of koalas with other medications and may prove 
useful in understanding how koalas absorb and metabolise dietary toxins. Although clinical 
signs resolved, animals failed to achieve microbial cure when treated with 
fluoroquinolones, a commonly used antibiotic in this species. Such a finding will better 
inform treatment decisions, particularly when koalas must be translocated between 
populations of differing chlamydial status. The review of the historical records in this 
thesis suggests animals thus treated have a good prognosis for survival, despite potentially 
having been returned to the wild still carrying chlamydial organisms. It is possible that 
release of such animals is not detrimental to wild populations, but this hypothesis requires 
further investigation of animal prognosis and the infectious status and demographics of the 
local wild population. Future studies of wildlife rehabilitation in other species are required 
in order to improve individual animal welfare, protect and contribute to the survival of 
wild populations and improve the scientific understanding of wild species. 
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APPENDIX I 
ADMISSION CODES FROM THE KOALA HOSPITAL: THEIR 
EXPLANATION AND RECLASSIFICATION FOR USE IN 
STATISTICAL ANALYSES 
Koala Hospital 
admission codes 
Explanation
1
 Reclassification n (%) 
DOG Dog attack Dog attack 272 (6.90) 
MVA Motor vehicle accident Motor vehicle accident 831 (21.09) 
BURN Burns Fire 31 (0.78) 
FIR Fire Fire 128 (3.25) 
EYE Eye disease Eye disease 370 (9.39) 
WEE Wet bottom and eye disease Wet bottom 58 (1.47) 
WET Wet bottom Wet bottom 387 (9.82) 
DEB Debilitated Debilitated 68 (1.73) 
DEH Dehydrated Debilitated 8 (0.20) 
ULD Underweight, lethargic, 
dehydrated 
Debilitated 194 (4.92) 
DGA Dangerous area Healthy 499 (12.66) 
HAB Habitat loss Healthy 91 (2.31) 
HEA Health check Healthy 404 (10.25) 
JOE Joey with mother Healthy 8 (0.20) 
KST Koala seeking territory Healthy 96 (2.44) 
REL Relocation Healthy 34 (0.86) 
ABN Abandoned Joey 9 (0.23) 
ORP Orphan Joey 54 (1.37) 
SEP Separated from mother Joey 3 (0.08) 
None None Unidentified 1 (0.03) 
UDI Unidentified cause of injury Unidentified 316 (8.02) 
                                                 
1
 E. Gabriel, Secretary, Koala Preservation Society of NSW, Port Macquarie, NSW, January 2010. 
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Appendix I cont.    
Koala Hospital 
admission` codes 
Explanation
2
 Reclassification n (%) 
BIC Unknown All other 1 (0.03) 
BTR Brain Trauma All other 1 (0.03) 
CAN Cancer All other 1 (0.03) 
CAT Cat attack All other 2 (0.051) 
CRO Crow attack All other 2 (0.051) 
DIA Diarrhoea All other 1 (0.03) 
DOA Dead on arrival All other 5 (0.13) 
DRO Drowned All other 13 (0.32) 
ELE Electrocuted All other 2 (0.05) 
FAL Fall All other 19 (0.48) 
FIT Fitting All other 10 (0.26) 
HYP Hyperkeratosis All other 1 (0.03) 
KFI Koala fight injury All other 7 (0.18) 
LAM Lame All other 6 (0.15) 
MAN Mange All other 2 (0.05) 
SCOL Scoliosis All other 1 (0.03) 
SHO Shot All other 1 (0.03) 
TEN Tendon damage All other 2 (0.05) 
TIC Ticks All other 1 (0.03) 
TUM Tumour All other 1 (0.03) 
Total   3941 (100) 
 
 
                                                 
2
 E. Gabriel, Secretary, Koala Preservation Society of NSW, Port Macquarie, NSW, January 2010. 
 
 220 
APPENDIX II  
POST MORTEM FINDINGS OF ANIMALS THAT WERE EUTHANASED OR DIED DURING THE PILOT STUDY 
Koala Drug Findings consistent with chlamydiosis Findings not consistent with chlamydiosis 
MO Chloramphenicol  
50 mg/kg p.o. BID 
Moderate diffuse chronic active urogenital sinusitis 
Severe diffuse chronic fibrosing cystitis 
Severe diffuse uterine fibrosis 
Moderate chronic active conjunctivitis 
None 
NK Chloramphenicol  
50 mg/kg p.o. BID 
Mild multifocal lymphocytic interstitial nephritis 
Severe diffuse acute haemorrhagic cystitis 
Moderate to severe diffuse chronic active prostatitis 
Severe diffuse chronic fibrosis of the bladder 
Thin 
Gastrointestinal tract relatively empty 
Severe acute diffuse oxalate diffuse leading to acute 
renal failure 
Multifocal severe acute fungal gastric 
ulceration/gastritis 
Mild chronic multifocal gliosis 
OC Doxycycline  
5 mg/kg p.o. SID  
Moderate chronic active pyometra 
Moderate diffuse chronic vaginitis 
Mild chronic ureteritis 
Sever chronic active bursitis and salpingitis 
Moderate chronic active diffuse cystitis 
Moderate diffuse chronic urogenital sinusitis 
 
Thin 
Liquid gastrointestinal contents 
CP Doxycycline  
2.5 mg/kg i.m. SIW 
Mild chronic diffuse ureteritis 
Severe diffuse chronic active cystitis 
Severe diffuse chronic active fibrosing prostatitis 
Thin 
Gastrointestinal tract relatively empty 
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Appendix  II cont.   
Koala Drug Findings consistent with chlamydiosis Findings not consistent with chlamydiosis 
TH Doxycycline  
0.25 mg/kg p.o. SID  
Left ovarian bursal cyst 
Diffuse moderate chronic vaginitis 
Diffuse moderate chronic cervicitis 
Moderate diffuse chronic active urogenital sinusitis 
Severe diffuse chronic active cystitis 
Mild diffuse chronic lymphocytic ureteritis 
Moderate chronic diffuse salpingitis (left) 
Moderate chronic diffuse plasmacytic lymphocytic conjunctivitis 
Thin 
Gastrointestinal tract relatively empty 
Left femoral fracture (old) with secondary chronic 
fibrosis and arthritis 
 
MM Azithromycin  
5 mg/kg p.o. SID 
Moderate diffuse chronic plasmacytic 
lymphocytic urogenital sinusitis 
Moderate diffuse chronic active vaginitis 
Moderate diffuse chronic active cervicitis 
Emaciated 
Gastrointestinal tract relatively empty  
Gingival recession lower incisors 
Left hip capital ligament is not intact 
OP Azithromycin  
2.5 mg/kg p.o. SID 
Chronic fibrotic ongoing urogenital tract disease Emaciated 
Lafora-like bodies in cerebrum 
WR Marbofloxacin  
3.34 mg/kg p.o. SID 
Mild chronic focal plasmacytic pyelonephritis 
Chronic diffuse severe plasmacytic cystitis 
Moderate chronic active diffuse vaginitis 
Ovarian bursal cysts with adhesions 
Fibrous adhesions between R uterus and ovarian bursal cyst 
obliterating normal tissue 
Hydrometron  
 
 
 
None 
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Appendix  II cont.   
Koala Drug Findings consistent with chlamydiosis Findings not consistent with chlamydiosis 
TM Marbofloxacin  
1.3 mg/kg p.o. SID 
Moderate diffuse plasmacytic lymphocytic pyometron 
Moderate diffuse chronic active salpingitis 
Chronic diffuse moderate plasmacytic lymphocytic pyometra 
Moderate diffuse chronic plasmacytic urogenital sinusitis 
Chronic diffuse moderate plasmacytic fibrous cystitis 
Mild chronic diffuse plasmacytic ureteritis 
Moderate chronic active vaginitis 
Caecal adhesion to left uterus 
Mild portal triad and centrilobular hepatic fibrosis 
Multifocal moderate pulmonary lipid granulomata 
 
RG Marbofloxacin 
 2.3 mg/kg p.o. SID 
Moderate diffuse neutrophilic interstitial pneumonia.  
Moderate diffuse chronic plasmacytic pyelonephritis 
Mild diffuse chronic plasmacytic pyelonephritis 
Severe chronic diffuse chronic active cystitis 
Bilateral moderate chronic diffuse chronic vaginitis 
Mild diffuse chronic active ureteritis 
Moderate to severe diffuse chronic active urogenital sinusitis 
Bilateral moderate to severe diffuse chronic active pyometron 
Mild diffuse neutrophilic salpingitis 
None 
CR Enrofloxacin  
5 mg/kg s.c. SID 
Bilateral severe chronic inactive uterine fibrosis  
Diffuse moderate chronic lymphocytic vaginitis 
Diffuse severe chronic active urogenital sinusitis 
Severe bilateral chronic-inactive cervical fibrosis  
Bilateral ovarian bursal cysts 
Diffuse moderate chronic cystitis with generalised oedema 
 
None 
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Appendix II cont.   
Koala Drug Findings consistent with chlamydiosis Findings not consistent with chlamydiosis 
SS Enrofloxacin  
5 mg/kg s.c. SID 
Chronic severe inactive uterine fibrosis 
Mild chronic diffuse plasmacytic lymphocytic vaginitis 
Moderate diffuse chronic active cervicitis and urethritis 
Mild diffuse acute urogenital sinusitis  
Moderate diffuse plasmacytic pyelonephritis 
Bilateral ovarian bursal cysts 
None 
KH Enrofloxacin  
5 mg/kg s.c. SID 
Mild diffuse lymphocytic plasmacytic pyelonephritis 
Severe diffuse chronic cystitis 
Moderate diffuse chronic active urogenital sinusitis 
Moderate diffuse chronic vaginitis 
Mild diffuse chronic plasmacytic lymphocytic metritis 
Bilateral ovarian bursal cysts  
None 
KS Enrofloxacin  
5 mg/kg s.c. SID 
Severe diffuse chronic inactive occlusive vaginal fibrosis 
Mild diffuse plasmacytic chronic conjunctivitis 
Bilateral diffuse severe chronic inactive salpingitis 
Bilateral ovarian bursal cysts 
Severe diffuse chronic inactive cervical occlusive fibrosis 
Severe diffuse chronic inactive uterine fibrosis 
Chronic inactive multifocal renal fibrosis 
Severe diffuse fibrotic chronic active cystitis  
Adhesion between liver and kidney 
 
LJ Enrofloxacin  
5 mg/kg p.o. SID 
Severe diffuse chronic active vaginitis & cystitis 
Moderate chronic active ureteritis  
Mild chronic diffuse pyometra 
Moderate diffuse chronic active pyelonephritis 
None 
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APPENDIX III 
LAST AVAILABLE BIOCHEMICAL AND HAEMATOLOGY ANALYSES IN 
ANIMALS FAILING TO COMPLETE TREATMENT IN THE PILOT STUDY 
 Reference 
intervals 
S.I. 
units 
MM OK OP NK OA AG OC TH CP 
Day   20 21 21 28 27 42 20 29 28 
Dose   mg/kg 5 10 2.5 50 10 5 5 0.25 2.5 
Route   p.o. p.o. p.o. p.o. i.m. i.m. p.o p.o i.m. 
Haemoglobin 88 - 140 g/L 102 88 133 128 111 92 100 96 101 
Red cell 
count 
2.7 - 4.2 x 10
^12/L 3.6 2.8 3.8 4.2 3.8 2.8 3 3.1 3.3 
Haematocrit 0.29 - 0.44 L/L 0.34 0.27 0.4 0.4 0.36 0.29 0.32 0.31 0.33 
Mean 
corpuscular 
volume 
94 - 117 fL 96 97 104 96 94 100 106 101 100 
Mean 
corpuscular 
haemoglobin 
33 - 35 pg/L 29 31 35 30 29 33 34 31 30 
Mean 
corpuscular 
haemoglobin 
concentration 
298 - 330 g/L 302 320 336 320 308 323 316 306 304 
Platelets 222 - 508 x 10
^9
/L 47 152
*
 208 273  388  170
*
 933 
Nucleated red 
blood cells 
 %WBC 79 21 37 5 22 15 197 9  
White blood 
cells 
2.8 - 11.2 x 10
^9
/L 1.5 8.3 3.9 14.2 4.7 5.8 7.7 4.5 7.2 
Neutrophils 0.5 - 6.3 x 10
^9
/L 0.9 6.6 2.5 12.1 2.6 4.2 4.8 3 4.7 
Lymphocytes 0.2 - 5.8 x 10
^9
/L 0.5 1.1 1.1 1.7 1.6 1.6 2.7 1.4 2.3 
Monocytes < 0.6 x 10
^9
/L 0.1 0.6 0.4 0.4 0.2 0.1 0.2 0 0.1 
Eosinophils < 1.1 x 10
^9
/L 0 0 0 0 0.3 0 0 0 0.1 
Basophils  < 0.1
† 
x 10
^9
/L 0 0 0 0 0 0 0 0 0 
Sodium  132 - 145 mmol/L 127 143 145 145 145 139 137 142 143 
Potassium  3.5 - 6.8 mmol/L 4.4 5.5 5.8 4.2 4.7 4.2 5.3 4.9 4.9 
Chloride  93 - 107 mmol/L 92 111 96 106 99 93 102 107 96 
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Appendix III  cont.           
 Reference 
intervals 
S.I. 
units 
MM OK OP NK OA AG OC TH CP 
Bicarbonate  12 - 30 mmol/L 17 16 27 15 29 23 17 18 23 
Anion Gap  11.3 - 32.3 mmol/L 22 22 28 28 22 27 23 22 29 
Urea  0.2 - 6.6 mmol/L 4.8 11.2 3.5 28.6 5.3 3.5 6.3 7 2.2 
Creatinine  80 - 150 µmol/L 70 110 85 230 110 70 115 125 70 
Glucose  2.7 - 7.2 mmol/L 3.8 1.4 4.8 3.5 1.8 5.1 3.7 2.8 6.3 
Bilirubin  < 8 mmol/L 5 1 2 0.5 2 1 0.5 2 1 
Aspartate 
transaminase  
1 - 134 U/L 45 61 18 86 27 23 6 23 18 
Alanine 
transaminase 
< 236 U/L 41 56 17 30 16 12 10 19 13 
Gamma 
glutamyl 
transferase 
< 16 U/L 7 6 10 16 9 10 11 10 7 
Alkaline 
phosphatase 
25 - 375 U/L 69 91 67 79 60 65 170 165 119 
Protein  53 - 83 g/L 53 50 63 56 69 53 70 61 61 
Albumin  34 - 50 g/L 26 29 35 33 41 29 42 34 33 
Globulin  13 - 39 g/L 27 21 28 23 28 24 28 27 28 
Albumin/ 
Globulin  
  1 1.4 1.2 1.4 1.5 1.2 1.5 1.3 1.2 
Calcium  2.28 - 2.97 mmol/L 1.92 2.16 2.63 2.82 2.6 2.26 2.65 2.45 2.67 
Phosphate  0.79 - 2.44 mmol/L 0.92 1.56 1.41 3.21 1.05 1.26 1.75 1.23 1.1 
Creatinine 
kinase  
100 - 300
†
 U/L 10483 8199 606 11959 1241 499 264 3512 290 
Cholesterol 1.15 - 3.09 mmol/L 3.9 2.6 3.8 3.2 3 2.2 3.5 3.4 2.3 
Triglyceride  0.5 - 3.02 mmol/L 1.4 0.2 2.1 1.8 2.8 3.7 1.8 0.9 4.6 
Urine specific 
gravity 
  NA NA NA 1.020 1.027 NA 1.037 1.052 NA 
*
platelets clumped  
† (Blanshard, 1994); all others (Canfield, O'Neill et al., 1989) 
Animals treated with azithromycin (MM, OK, OP); marbofloxacin then doxycycline (OA, AG); or 
doxycycline (OC, TH, CP). All animals were euthanased except OK, which died. Parameters outside 
reference range are highlighted in bold. NA: not available. 
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APPENDIX IV  
POST MORTEM FINDINGS OF ANIMALS THAT WERE EUTHANASED OR DIED OUTSIDE OF THE PILOT STUDY 
Koala ID  Drug (all once daily) Findings consistent with chlamydial disease Findings inconsistent with chlamydial disease 
BB
†
 Marbofloxacin  
10 mg/kg p.o.  
Severe focal medullary tubular nephrosis 
Severe diffuse chronic bladder oedema and fibrosis 
Right capital ligament rupture 
Moderate diffuse periodontal disease 
OJ
‡
 Enrofloxacin 
10 mg/kg s.c.  
Severe chronic active diffuse urogenital sinusitis 
Moderate diffuse chronic plasmacytic cystitis 
 
HL
*
 Enrofloxacin 
20 mg/kg p.o.  
Moderate chronic multifocal interstitial nephritis 
Diffuse moderate chronic plasmacytic cystitis 
Mild multifocal lymphocytic chronic active urogenital 
sinusitis 
Diffuse mild chronic active vaginitis 
Diffuse severe chronic fibrosis of the urinary bladder, vaginae, 
cervices, and uteri 
Diffuse severe chronic cystic salpingeal fibrosis 
Mild diffuse chronic active cholangitis 
Nodular hyperplasia of the adrenal medulla 
Diffuse moderate chronic splenic lymphoid hyperplasia 
Hyperplastic lymph node 
Focal chronic type II pneumocyte hyperplasia and mild focal 
chronic lymphocytic pneumonia 
Diffuse moderate chronic epicardial fibrosis 
Diffuse moderate chronic myocardial fibrosis and mild 
scattered myocardial necrosis 
Diffuse severe subacute cortical tubular oxalate nephrosis 
BP
*
 Enrofloxacin 
20 mg/kg p.o. 
Bilateral proliferative conjunctivitis with bilateral corneal 
oedema 
Mild chronic interstitial nephritis, cystitis and urethritis 
Severe peracute diffuse myocardial hyaline necrosis 
DA
§
 Enrofloxacin 
10 mg/kg  
Mild chronic diffuse vaginitis and ureteritis 
 
Cystic endometrial hyperplasia 
Bilateral ovarian bursal cysts 
*died; †euthanased due to non-resolution of clinical signs; ‡euthanased due to recurrence of clinical signs; §euthanased due to development of ovarian bursal cysts  
p.o: per os; s.c: subcutaneous injection; SID: once daily. 
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